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ABSTRACT 
 
Glioblastoma (GBM) is the most common, aggressive, and deadly form of primary brain 
tumor in adults, with a median survival time of only 14.6 months. GBM tumors present 
with chemo- and radio-resistance and rapid, diffuse invasion, making complete surgical 
resection impossible and resulting in nearly universal recurrence. While investigating the 
genomic landscape of GBM tumors has expanded understanding of brain tumor biology, 
targeted therapies against cellular pathways affected by the most common genetic 
aberrations have been largely ineffective at producing robust survival benefits. Currently, 
a major obstacle to more effective therapies is the impact of the surrounding tumor 
microenvironment on intracellular signaling, which has the potential to undermine 
targeted treatments and advance tumor malignancy, progression, and resistance to 
therapy. Additionally, mitochondria, generally regarded as putative energy sensors within 
cells, also play a central role as signaling organelles. Retrograde signaling occurring from 
mitochondria to the nucleus allows mitochondria to sense intracellular metabolic stress 
imposed by the extracellular tumor microenvironment and respond appropriately by 
relaying their status to the nucleus, thus inducing changes in gene expression and 
facilitating cellular adaptation. 
The focus of this work is on the mitochondrial protein coiled-coil-helix-coiled-coil-helix 
domain-containing protein 2 (CHCHD2) and its capacity to act in a signaling axis between 
mitochondria and the nucleus to facilitate cellular adaptation and plasticity as GBM cells 
navigate gradients in the tumor microenvironment. Chapters one, two, and three provide 
a general introduction of GBM, an analysis of mitochondrial biology in cancer and 
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retrograde signaling, and a review on the current state of the literature surrounding 
CHCHD2. Chapter four focuses on characterizing the functional capacity of CHCHD2 in 
GBM cells using CRISPR-Cas9 genome editing techniques. We hypothesized that 
CHCHD2 knockout would abrogate malignant characteristics such as cell proliferation, 
sensitivity to therapeutics, and mitochondrial respiration. CHCHD2 gene amplification 
was found to occur in 9% of GBM tumors, nearly always with EGFR, and was associated 
with decreased overall survival and progression-free survival. CHCHD2 mRNA levels 
were increased in grade IV glioma, IDH-wt GBM tumors, and in tumor versus non-tumor 
tissue. CRISPR-Cas9 derived GBM U87vIII CHCHD2 KO cells displayed decreased OCR 
and spare respiratory capacity compared to U87vIII CHCHD2 WT cells. The redox state 
of the glutathione (GSH) pool was more reduced within the mitochondrial matrix of 
CHCHD2 KO cells compared to WT cells, an effect independent of GSH synthesis, 
cystine import via xCT, or GPx-1, GPx-2, or GPx-4 levels. The cytosolic GSH pool was 
not perturbed by CHCHD2 KO. Furthermore, CHCHD2 KO abrogated the increased 
proliferation and invasion of U87vIII cells in hypoxia (1% O2) compared to standard 
normoxic culture conditions (20% O2). U87vIII CHCHD2 KO cells displayed increased 
sensitivity to sulfasalazine, erlotinib, and temozolomide, but not the procaspase activator 
Pac-1. CHCHD2 exhibited a heterogeneous protein expression pattern among patient-
derived cells investigated using western blot, with greater levels observed in more 
invasive samples. These results indicate that CHCHD2 mediates a variety of GBM cell 
hallmark characteristics, including cell proliferation, cell invasion in response to hypoxia, 
and cellular resistance to cytotoxic agents. 
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The C-terminus of CHCHD2 contains redox-sensitive cysteines in twin CX9C motifs 
that are amenable to thiol/disulfide formation, which in turn determines protein folding and 
import into mitochondria. Chapter five focuses on defining the relationship between 
hypoxia and redox stress, CHCHD2 protein folding, and subcellular redistribution of 
CHCHD2, in order to examine a mechanism by which CHCHD2 signals mitochondrial and 
cellular status back to the nucleus. We hypothesized that reduction of the C-terminal 
CHCH domain would induce mitochondrial export of CHCHD2. Total CHCHD2 protein 
levels were not significantly altered by decreasing oxygen tensions in U87 cells. U87vIII 
cells exhibited constant levels of total CHCHD2 protein at 20%, 7%, and 4% O2, while 
incubation in 1% O2 led to a significant decrease in total CHCHD2. Half-life of CHCHD2 
was determined to be approximately 3 h in both U87 and U87vIII cells. U87vIII cells 
constitutively displayed a greater amount of nuclear CHCHD2 compared to isogenic U87 
cells at 20% O2. Metabolic stress induced by incubation in 1% O2 for 48 h or serum-free 
media for 30 min both resulted in increased CHCHD2 detected in nuclei of U87 and 
U87vIII cells. Oxidative stress induced by the glutathione synthesis inhibitor BSO 
increased nuclear CHCHD2 in U87vIII cells, while the glutathione precursor NAC did not 
significantly affect nuclear CHCHD2 levels. Exposure to H2O2 in serum-free media 
abrogated the amount of nuclear CHCHD2 detected in nuclei of U87 and U87vIII cells. 
Reductive unfolding of CHCHD2 with the disulfide reductant DTT consistently resulted in 
the greatest and greatest degree of nuclear accumulation of CHCHD2 in both cell lines 
within 15-30 min. Ectopic expression of exogenous 3X-FLAG-tagged CHCHD2 in U87vIII 
cells did not result in increased expression of endogenous CHCHD2. These findings 
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indicate that reductive unfolding of CHCHD2 is responsible for mitochondrial export and 
nuclear translocation in response to hypoxia, serum deprivation, and redox stress. 
Finally, in addition to gradients in oxygen, nutrients, and biophysical cues, tumor-
associated microglia and macrophages represent a substantial portion of GBM tumors 
and play a critical role in cultivating a microenvironment that facilitates tumor expansion. 
Chapter six focuses on examination of the crosstalk between microglia and GBM cells 
that promotes angiogenesis, cell invasion, and remodeling of the tumor immune 
landscape. We hypothesized that GBM-microglia crosstalk would facilitate secretion of 
soluble factors that promote angiogenesis and extracellular matrix remodeling, as well as 
alter GBM cell glutathione redox balance. The expression of EGFRvIII on U87 cells 
resulted in an altered profile of secreted angiogenesis-related factors under basal culture 
conditions. Similarly, primary neonatal murine microglia, but not the human microglia cell 
line HMC3, exhibited differential angiogenesis-related secretomes when cultured in U87 
or U87vIII conditioned media. Primary murine microglia additionally displayed increased 
cell proliferation when cultured in U87 and U87vIII conditioned media, while HMC3 cells 
did not. Conditioned media from patient-derived, EGFRvIII-expressing xenograft GBM6 
cells led to a striking increase in HMC3 secretion of angiogenesis-related factors, inducing 
the greatest secretion of CCL2, IGFBP-2, TIMP-4, angiogenin, and IGFBP-3. HMC3 
conditioned media decreased expression of the system xc- antiporter and increased 
glutathione oxidation in mitochondria of U87 cells, while xCT expression and 
mitochondrial glutathione redox status in U87vIII cells remained stable. These findings 
indicate that GBM cells stimulate the secretion of cytokines, chemokines, and soluble 
factors by microglia to cultivate an immunosuppressive microenvironment promoting 
vi 
 
angiogenesis and cell invasion. Additionally, system xc- expression and, consequently, 
intracellular glutathione redox balance remained stable in U87vIII cells exposed to HMC3 
conditioned media. Together, the studies demonstrate a dynamic crosstalk between GBM 
cells and microglia that facilitates microenvironment remodeling and has the potential to 
influence GBM cell glutathione metabolism. 
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CHAPTER 1: A GENERAL INTRODUCTION TO GLIOBLASTOMA 
1.1. GLIOBLASTOMA 
Tumors of the brain and central nervous system (CNS) account for approximately 1% of 
newly diagnosed cancers and 2% of cancer deaths in the United States (Barnholtz-Sloan, 
Ostrom, & Cote, 2018). Unlike other cancer types, which are staged, brain and CNS 
tumors are broadly classified as nonmalignant (benign) and malignant, as determined by 
the World Health Organization (WHO) grading system, which ranges from grade I to 
grade IV (Barnholtz-Sloan et al., 2018). Grade I and II brain and CNS tumors are classified 
as low grade/nonmalignant, while grade III and IV are classified as high grade/malignant. 
Nonmalignant meningiomas represent the most common benign brain and CNS tumor, 
while malignant gliomas are the most commonly diagnosed malignant tumor, accounting 
for approximately 80% of all malignant brain tumors (Omuro & DeAngelis, 2013). Of 
gliomas, glioblastoma occurs at the greatest frequency, accounting for greater than 50% 
of diagnosed gliomas (Barnholtz-Sloan et al., 2018). 
Glioblastoma [GBM, WHO grade IV glioma] is the most common, aggressive, and 
deadly form of primary malignant brain tumor in adults (Omuro & DeAngelis, 2013; Stupp 
et al., 2005). In 2016, the WHO published an updated classification of tumors of the CNS, 
focusing on incorporation of both histological and molecular features to stratify diffuse 
gliomas (Louis et al., 2016). In this new classification system, GBMs are stratified into 
either: (1) GBM, isocitrate dehydrogenase 1/2 (IDH-1/2)-wild type; (2) GBM, IDH1/2-
mutant; or (3) GBM, not otherwise specified (NOS). IDH-1/2-wild type GBMs account for 
approximately 90% of cases, correspond with the clinically defined primary (or de novo) 
GBM, and predominate in patients over 55 years old (Louis et al., 2016). IDH-1/2-mutant 
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GBMs represent approximately 10% of cases, correspond to secondary GBM (i.e., tumors 
with history of prior lower grade glioma), and arise predominantly in younger patients 
(Louis et al., 2016). Tumors for which evaluation of IDH-1/2 status cannot be performed 
are designated GBM, NOS. Incidence of GBM is greater in male vs female patients 
(57.6% vs 42.4%), with 94.6% of GBMs diagnosed in patients aged ≥ 40 years (Barnholtz-
Sloan et al., 2018). Median survival of patients diagnosed with GBM is 14.6 months, with 
37.4% of patients surviving after 1 year and only 4.9% of patients surviving after 5 years 
(Barnholtz-Sloan et al., 2018). 
 
1.2. TREATMENT OF GBM 
The current standard-of-care for patients with GBM is a multimodal therapeutic regimen 
consisting of maximal safe surgical resection, radiotherapy (cumulative dose of 60 Gy, 30 
fractions over 6 weeks) with concomitant chemotherapy with the DNA alkylating agent 
temozolomide (TMZ), followed by six cycles of adjuvant maintenance chemotherapy with 
TMZ (150-200 mg/m2, 5 days of a 28-day cycle) (Stupp et al., 2005). This regimen was 
established following a seminal clinical trial in 2005 by Stupp et al., in which patients 
receiving TMZ concomitant with radiotherapy exhibited a median overall survival of 14.6 
months vs 12.1 months in patients receiving radiotherapy alone (Stupp et al., 2005). More 
recently, a multi-center randomized phase III clinical trial conducted by Stupp et al. 
assessed the effect of tumor-treating fields (TTFields) plus maintenance TMZ versus TMZ 
alone on progression-free and overall survival (Stupp et al., 2017). TTFields are an 
antimitotic treatment that delivers low-intensity, intermediate-frequency (200 kHz) 
alternating electric fields via transducer arrays applied directly to the scalp, subsequently 
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causing mitotic arrest and apoptosis of rapidly dividing cells (Giladi et al., 2015; Kirson et 
al., 2007; Stupp et al., 2017). Notably, patients receiving TTFields in conjunction with 
maintenance TMZ displayed progression-free and overall survival of 6.7 and 20.9 months, 
respectively, compared to 4.0 and 16.0 months in patients receiving maintenance TMZ 
alone (Stupp et al., 2017). The Food and Drug Administration approved the use of the 
TTFields device for treatment of recurrent GBM in 2011, and for newly diagnosed GBM 
in 2015 (Fabian et al., 2019). However, despite these recent advances, GBM tumors 
exhibit nearly universal recurrence and remain incurable. 
Several clinical trials aimed at a variety of promising therapeutic targets have sought 
to improve outcomes for patients with GBM, albeit with limited success. For instance, a 
phase III clinical trial evaluated the efficacy of a dose-dense TMZ regimen (75-100 mg/m2, 
21 days of a 28-day cycle), hypothesizing that prolonged TMZ exposure would deplete 
intracellular levels of the DNA repair enzyme O6-methylguanine DNA methyltransferase 
(MGMT) (Gilbert et al., 2013). Epigenetic silencing via methylation of the MGMT gene 
has been associated with increased overall survival in patients diagnosed with high-grade 
glioma, due to the inability to repair DNA damage induced by TMZ (Esteller et al., 2000; 
Gilbert et al., 2013). However, dose-dense TMZ did not increase overall survival or 
progression-free survival in a cohort of GBM patients (Gilbert et al., 2013). A separate 
randomized phase III clinical trial assessed the addition of bevacizumab, a monoclonal 
antibody against the angiogenesis-promoting vascular endothelial growth factor (VEGF), 
to standard-of-care therapy, but found no significant increase in overall survival in the 
bevacizumab group (Gilbert et al., 2014). More recent reports indicate that addition of the 
mechanistic target of rapamycin (mTOR) inhibitor everolimus to standard therapy led to 
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increased treatment-related toxicities and decreased overall survival in a randomized 
phase II study (Chinnaiyan et al., 2018). Moreover, while immunotherapy has continued 
to gain momentum and has proven an effective treatment strategy for some patients 
diagnosed with melanoma (Larkin et al., 2015), non-small cell lung (Scott J. Antonia et 
al., 2016), and renal malignancies (Motzer et al., 2015), high-grade glioma patients 
treated with immunotherapy have not demonstrated benefits in overall survival in any 
phase III clinical trials to date (Reardon et al., 2017a). 
 
1.3. GENETIC AND MOLECULAR STRATIFICATION OF GBM 
The advent of genomic profiling and the continual refining of nucleotide sequencing 
capabilities have provided powerful tools for the stratification of tumors in order to identify 
more personalized, rational, and targeted therapeutic strategies with tumor heterogeneity 
in mind. The Cancer Genome Atlas (TCGA) has provided a means with which to 
understand the comprehensive catalog of genomic aberrations driving tumorigenesis. 
Indeed, the recent WHO re-classification of GBM tumors to include molecular information 
(i.e., IDH-1/2 mutation status) acknowledges the strides taken in our understanding of the 
genomic landscapes observed across GBM tumors. 
 Utilizing TCGA data, seminal work by Verhaak et al. laid the foundation for the current 
understanding of genomic abnormalities driving GBM tumors by stratifying tumors into 
four different subtypes characterized by distinct genetic aberrations: classical, 
mesenchymal, proneural, and neural (Verhaak et al., 2010). The classical subtype is 
defined by chromosome 7 amplification paired with loss of chromosome 10 (observed in 
100% of the classical subtype) and high-level amplification of the epidermal growth factor 
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receptor gene (EGFR, observed in 97% of the classical subtype). Notably, regardless of 
subtype, EGFR amplification is observed in approximately 50% of all GBM tumors and is 
often accompanied by expression of the tumor-specific, constitutively active EGFR variant 
3 (EGFRvIII) mutant, which is characterized by loss of exons 2-7 and truncation of its 
extracellular ligand-binding domain (Gan, Kaye, & Luwor, 2009). EGFRvIII is expressed 
in approximately 50% of classical tumors and 25% of GBM tumors regardless of subtype. 
The mesenchymal subtype is characterized by a predilection for focal hemizygous 
deletions of a region on chromosome 17 containing the gene NF1. Proneural subtype 
tumors featured alterations in PDGFRA and point mutations in IDH1. Neural subtype 
tumors were unique in their expression of neuronal markers such as NEFL, GABRA1, 
SYT1, and SLC12A5. 
 Epigenetic analyses of GBM tumors has revealed that silencing via promoter 
methylation of the MGMT gene is a predictor of longer overall survival in patients treated 
with TMZ and radiotherapy (Brennan et al., 2013; Hegi et al., 2005). Expression of the 
DNA-repair enzyme MGMT confers tumor cell resistance by blunting the therapeutic 
efficacy of DNA-alkylating agents such as TMZ. Methylation of the MGMT promoter is 
often coupled with the glioma cytosine-phosphate-guanine (CpG) island methylator 
phenotype (G-CIMP), characterized by hypermethylation at a large number of foci 
(Noushmehr et al., 2010). Overall, MGMT promoter methylation, G-CIMP DNA 
methylation, IDH1 mutation, as well as patient age less than 50 years, are all independent 
positive prognostic factors (Brennan et al., 2013). 
 Advances in single-cell gene expression capabilities have recently provided higher 
resolution for understanding GBM tumor compositions, treatment-induced tumor 
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evolution, and the GBM tumor microenvironment. Single-cell RNA seq of primary GBM 
tumors has revealed striking inter-sample variability (Patel et al., 2014). Multivariate 
analysis consisting of hierarchical clustering and principal component analysis revealed 
four expression signatures enriched for genes related to cell cycle, hypoxia, immune 
response, and oligodendrocyte function (Patel et al., 2014). Additionally, all five tumors in 
this study exhibited a subpopulation of cells with a stem-like signature that correlated 
negatively to the cell cycle signature, indicating that subpopulations of glioma stem cells 
(GSCs) divide at lower overall rates (Patel et al., 2014). Intriguingly, all five tumors 
analyzed consisted of heterogeneous mixtures of individual cells corresponding to 
different GBM subtypes, as well as some “hybrid” cells exhibiting signatures reminiscent 
of two subtypes (Patel et al., 2014). Indeed, spatial intratumoral differences in mutational 
load and clonality of tumor cells have been described, with some mutations being 
regionally exclusive (R. V. Lukas et al., 2019). Altogether, these studies underscore the 
vast heterogeneity in intra- and intertumor gene expression landscapes in GBM. 
More recent analysis from the Verhaak group using single-cell gene expression 
analysis of IDH-wt GBMs and derivative neurospheres has revised the original subtype 
class system to include classical, mesenchymal, and proneural as the three primary 
subtypes comprising GBM tumors (Q. Wang et al., 2017). The previously observed neural 
subtype was likely an artifact of sample contamination with neurons related to the tumor 
margin (Q. Wang et al., 2017). In this analysis, median survival of mesenchymal tumor 
cases was 11.5 months, compared to 14.7 and 17.0 months for classical and proneural 
cases, respectively. This analysis provided a snapshot of the GBM immune 
microenvironment; illustrated the fluid nature of primary and recurrent GBMs, which were 
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demonstrated to be capable of switching molecular subtype upon recurrence; and 
demonstrated transitions in the microenvironmental immune landscape in response to 
treatment. 
 
1.4. PATHOLOGICAL CHARACTERISTICS OF GBM TUMORS 
As evidenced by studies including those discussed above, tumor heterogeneity and 
plasticity are major contributing factors to the limited success observed in achieving 
robust survival benefits in patients with GBM. Histologically, GBMs are distinguished from 
lower grade gliomas by virtue of a number of defining characteristics, most notably areas 
of necrosis and microvascular proliferation (Brat et al., 2004; Louis, 2006). Surrounding 
these necrotic foci are hypercellular zones called pseudopalisades comprised of 
neoplastic cells migrating away from the hypoxic core (Brat et al., 2004). Cells within 
pseudopalisades are characterized as less proliferative than adjacent tumor, show 
nuclear expression of HIF-1α, and exhibit enhanced gelatinase activity (Brat et al., 2004). 
The majority of pseudopalisades arise as a direct result of hypoxia arising from a vaso-
occlusive event, such as distorted, degenerated, or thrombosed blood vessels, indicating 
that pseudopalisading cells arise from a sequence of migration away from a hypoxic, 
necrotic foci suffering from inefficient, though hyperproliferative, neovascularization (Brat 
et al., 2004; Louis, 2006). 
The definitive cell of origin for malignant gliomas remains elusive. While mature glial 
cells could potentially undergo neoplastic events during reactive proliferation, a paucity 
of epidemiological evidence linking events evoking reactive proliferation, e.g. trauma, with 
the development of gliomas undermines this possibility (Louis, 2006). Instead, work in 
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both animal models and primary gliomas suggests that malignant gliomas likely arise from 
primitive pluripotent cells, including neural stem cells, glial precursor cells, and 
oligodendrocyte precursor cells (Holland et al., 2000; R. V. Lukas et al., 2019). 
Neuroectodermal stem cells have proliferative potential, are migratory, and can undergo 
diverse paths of differentiation (Louis, 2006). Additionally, malignant gliomas have been 
demonstrated to harbor cancer stem cell populations responsible for tumor propagation 
(Galli et al., 2004; Singh et al., 2004). Work using murine xenograft models has 
demonstrated that GBM tumors harbor a slow-cycling population of stem-like cells, which 
give rise to a rapidly dividing progenitor cell population, which in turn gives rise to 
terminally differentiated daughter cells, altogether supporting a hierarchical model of 
gliomagenesis and intratumor heterogeneity (Lan et al., 2017). Recent work by Lee et al. 
indicates that human GBM tumors arise from transformed neural stem cells (NSC) in the 
subventricular zone (SVZ) (J. H. Lee et al., 2018). Using deep sequencing of triple-
matched tissues from 28 patients (tumor tissue, normal SVZ away from tumor, normal 
cortical tissue), an average of 23.0 somatic mutations in tumor-free SVZ were observed 
compared to 80.7 in tumor specimens. Some of these somatic mutations were shared 
between tumor-free SVZ and tumor, an observation that occurred only in IDH-wt GBM 
(i.e., primary de novo GBM). Shared alterations included mutations in TERT promoter, 
EGFR, PTEN, and TP53. Notably, mouse models of p53/Pten/Egfr mutations targeted to 
NSCs in the SVZ generated cortical brain tumors, which developed after migration from 
the SVZ to distant cortical regions (J. H. Lee et al., 2018). 
Regardless of genetic heterogeneity, all malignant gliomas share a cardinal 
pathological characteristic in cell invasion. GBM tumors are highly invasive and rapidly 
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infiltrate surrounding brain parenchyma. Amplification of EGFR has been associated with 
fast migratory behavior of cells (Parker et al., 2018). Indeed, the highly invasive nature of 
GBM cells is a chief contributor to disease progression and recurrence (Alieva et al., 
2019). Invasion represents an early event in GBM progression, and infiltrating cells which 
lie beyond the definable margin for tumor resection give rise to inevitable tumor relapse, 
typically within 1-2 cm of the primary tumor border (Alieva et al., 2019; Louis, 2006). 
Similarly to adult stem cells in the mature brain, GBM cells tend to migrate along existing 
brain structures, such as white matter tracts and blood vessels (Cuddapah, Robel, 
Watkins, & Sontheimer, 2014). Additionally, a variety of invasion patterns have been 
described, including single cell invasion as well as group migration consisting of leading 
fronts and follower cells (Alieva et al., 2019). Despite being overly adept at infiltration 
throughout brain, GBM tumors rarely ever metastasize out of the brain (0.4-2%). This 
paucity of extracranial metastases originating from GBM or other primary brain tumors 
may be due in part to an inability of tumor cells to breach the blood-brain barrier (BBB) 
basement membrane and enter vasculature, an unfavorable microenvironment in 
extraneural tissues, a patient survival time too short to observe extracranial metastasis, 
or a combination of the aforementioned (Cuddapah et al., 2014). 
Migration of tumor cells in ex vivo culture GBM tissue culture slices was observed to 
be intermittent, characterized by stages of filopodia-mediated monitoring of the 
surrounding environment, followed by bursts of rapid movement, during which filopodia 
are retracted and nuclei deformed (Parker et al., 2018). Notably, this mode of migration 
has also been ascribed to neural progenitor cells (Parker et al., 2018). Other recent work 
by Alieva et al. utilizing high-resolution, time-lapse intravital imaging provided in-depth 
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characterization of invasive patterns of patient-derived orthotopic GBM tumors in SCID 
mice (Alieva et al., 2019). Analysis of patient-derived cells stably expressing H2B-
Dendra2 (a fluorescent marker of nuclei) revealed three invasion patterns: 1) “invasive 
margin,” characterized by protruding multicellular groups originating at the transition 
between tumor and parenchyma; 2) “well-defined tumor border,” characterized by 
margins with no protrusions; and 3) “diffuse cell infiltration,” characterized by individual 
cell migration into surrounding tissue (Alieva et al., 2019). In all patterns (as well as in the 
tumor core), movement was highly dynamic, and cells were observed moving both toward 
and away from the tumor. However, the “invasive margin” and diffusively invading cells 
exhibited the most persistent, directional movement of cohorts of cells or highly motile 
individual cells, respectively, contributing to tumor expansion. Additionally, perivascular 
migrating cells moved faster than parenchymal migrating cells. Collectively, this and other 
studies characterizing tumor invasion point to tumor microenvironmental triggers which 
influence GBM cell invasion. 
The GBM tumor microenvironment is characterized by a distinctive and 
heterogeneous population of cells, including endothelial cells, pericytes, and immune 
cells, as well as tissue specific astrocytes, neurons, and microglia (Figure 1.1). 
Additionally, gradients in nutrient and oxygen availability, as well as a milieu of biophysical 
cues, add to the complement of extracellular factors regulating GBM cell behavior, 
selecting for more invasive and therapeutically resistant cell populations, and supporting 
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tumor progression. The following sections will focus on two aspects of the GBM tumor 
microenvironment, namely hypoxia and tumor-associated microglia.  
 
1.5. HYPOXIA 
Hypoxia, defined as physiologically low levels of oxygen (O2), presents as a common 
microenvironmental feature in solid tumors, including GBM (Monteiro, Hill, Pilkington, & 
Madureira, 2017). Like other solid tumors, GBM is characterized by a heterogeneous 
pattern of oxygenation (Richards, Jenkinson, Haylock, & See, 2016). While normal 
oxygen levels in healthy human brain range from 5-8%, oxygen levels in GBM tumors 
range from 0.75-2.76% (Richards et al., 2016). Intra-tumor hypoxia occurs as a 
consequence of rapid cell proliferation and tumor growth coupled with aberrant and 
inefficient tumor neovascularization, which together result in poor oxygen diffusion 
throughout the tumor (Bar, Lin, Mahairaki, Matsui, & Eberhart, 2010; Monteiro et al., 
Figure 1.1. Characteristics of the GBM tumor microenvironment. The GBM tumor microenvironment is 
populated with a heterogeneous collection of cells participating in dynamic heterotypic cell-cell and cell-environment 
interactions. Rapid tumor growth, erratic neovascularization, and vaso-occlusive events result in tumor hypoxia, or 
physiologically low levels of oxygen, which selects for more malignant cell populations. Additionally, non-neoplastic 
cells, such as astrocytes, bone marrow-derived macrophages (BMDM), and microglia assist in tumor 
microenvironment remodeling and immunosuppression, mediated in part by Tregs. Additionally, mechanochemical 
cues from brain ECM, which contains high amounts of hyalyronic acid, glycosaminoglycans, and proteoglycans, 
influence cell behavior. 
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2017). Hypoxia increases GBM cell resistance to radiotherapy and chemotherapeutics 
and promotes cell invasion, presumably away from the hostile metabolic environment it 
creates (Monteiro et al., 2017; Richards et al., 2016). Hypoxia-induced migration of GBM 
cells results in the distinct GBM pathophysiological feature of necrotic foci containing 
microvascular proliferation surrounded by hyperproliferative cellular pseudopalisades, 
which form an invasive front (Monteiro et al., 2017). In line with these findings, greater 
volume of hypoxia and intensity in GBM tumors are both associated with decreased time-
to-progression and patient survival (Spence et al., 2008). 
 Hypoxia induces the activity of the hypoxia-inducible factor (HIF) transcription factors, 
HIF-1α and HIF-2α, which are the canonical master regulators of the hypoxia adaptive 
response (Monteiro et al., 2017). Under normoxic conditions (normal oxygen levels), HIFs 
are constitutively degraded via binding of the von Hippel-Linau (VHL) protein to prolyl 
residues within the HIF-α subunit that are hydroxylated by oxygen-dependent prolyl 
hydroxylases (PHDs) 1-3, subsequently recruiting E3 ubiquitin ligases that target HIF-α 
for proteasomal degradation (Monteiro et al., 2017; Schito & Rey, 2018). Conversely, 
hypoxia results in inhibition of PHDs, abrogated proteasomal degradation, and 
subsequent stabilization of HIF-α subunits. HIFs operate by binding to cis hypoxia 
responsive elements (HRE) within promoters of their target genes, which include a suite 
of genes involved in promoting angiogenesis, cell migration and invasion, survival and 
proliferation, and metabolic reprogramming (Monteiro et al., 2017; Schito & Rey, 2018; 
H. Xie & Simon, 2017). Notably, EGFR signaling results in canonical activation of the 
PI3K/AKT/mTOR signaling cascade, which itself can result in subsequent upregulation of 
HIF-1α (Monteiro et al., 2017). In GBM, amplification of EGFR, constitutive EGFR 
13 
 
signaling as a result of the EGFRvIII mutation, and/or phosphatase and tensin homolog 
(PTEN) deletion (observed in up to 60% of GBM cases) collectively exacerbate HIF-1 α 
upregulation. Thus, hypoxia and the molecular signature of GBM synergistically 
potentiate the progression of tumor growth and dissemination throughout surrounding 
brain parenchyma. 
 Indeed, the effect of hypoxia on tumor biology, including GBM, has received 
tantamount attention. Hierarchical clustering of single cell RNAseq (sc-RNAseq) data 
revealed a hypoxic gene expression signature within GBM tumors (Patel et al., 2014). 
Hypoxia has been demonstrated to result in GBM cell migration, necrosis, and the 
histopathological hallmark of pseudopalisades (Brat et al., 2004; J. E. Chen, Lumibao, 
Blazek, Gaskins, & Harley, 2018; W. Huang et al., 2018). Hypoxia additionally promotes 
chemoresistance by upregulation of the ATP-binding cassette subfamily B member 1 
(ABCB1) transporter, an ATP-dependent drug efflux pump conferring multidrug 
resistance (X. Zhang, Ding, Wang, Li, & Zhao, 2018). Additionally, hypoxia induces 
radioresistance of GBM cells (Benej et al., 2018), and recent efforts have targeted 
mitochondrial respiration and oxygen consumption as a strategy to induce tumor re-
oxygenation and sensitization to radiotherapy (Benej et al., 2018; Dewhirst, 2018). 
 One major consequence of intra-tumor hypoxia is the metabolic reprogramming 
conducted by cells to maintain cellular bioenergetics in the face of decreasing oxygen 
tensions. Indeed, HIF-1 activity leads to changes in gene expression that enhance 
glycolysis and attenuate oxidative phosphorylation and oxygen consumption (Loscalzo, 
2016). Accompanying this shift is increased expression of monocarboxylate transporters, 
including MCT-4, to enhance efflux of lactate and H+ produced as a result of increased 
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glycolytic flux (Schito & Rey, 2018). Notably, constitutive expression of MCT-1 on 
neighboring cells allows non-hypoxic cell populations to uptake secreted lactate, which is 
then converted to pyruvate via LDH-B, thus feeding the TCA cycle and oxidative 
phosphorylation in an elegant tumor microenvironmental metabolic symbiosis. 
Additionally, glycolytic and TCA cycle intermediates are diverted into anabolic reactions 
necessary for cell division and tumor growth. For example, hypoxia induces the entry of 
glucose-derived carbons to the pentose phosphate pathway to generate reducing power 
in the form of NADPH needed for antioxidant and biosynthesis reactions (Kathagen et al., 
2013). This shift toward glycolytic flux additionally serves to mitigate the generation of 
harmful reactive oxygen species (ROS) that are produced by the leakage of electrons 
from an inefficient mitochondrial electron transport chain (primarily from complexes I and 
III), which in turn react with oxygen to form superoxide anion (O2-) and, subsequently, 
hydrogen peroxide (H2O2) (Loscalzo, 2016; Schito & Rey, 2018). 
Excess production of ROS in hypoxia that exceeds endogenous antioxidant capacity 
(either through antioxidant enzymes or small molecule antioxidants) results in oxidative 
stress (Loscalzo, 2016). Complementary to this, reductive stress implies the presence of 
excess reducing equivalents that cannot be quenched by cellular oxidoreductases or 
oxygen tensions in the surrounding environment (e.g., limited oxygen in hypoxia) 
(Loscalzo, 2016). In both cases, resultant redox reactions have the ability to modulate 
biological phenotype. However, care must be taken to distinguish between “oxidative” and 
“reductive” stress in the biological context. For example, sustained hypoxia canonically 
leads to an increase in ROS production, implying oxidative stress. However, these ROS 
(e.g., superoxide anion, O2-) are partially reduced forms of oxygen, the consequences of 
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which change depending upon the redox reactions they are engaged in (Loscalzo, 2016). 
Redirecting metabolism in favor of increased glycolytic flux during hypoxia produces a 
mounting pool of reducing equivalents in the form of NADH and NADPH, implying 
reductive stress. Given the pleiotropic effects that arise from hypoxia-induced redox 
perturbations, “redox stress” arises as an appropriate term to describe the functional 
consequences of oxidative and reductive disturbances within cells (Loscalzo, 2016). The 
presence of structural and functional disulfides which respond to redox stress to modify 
protein function and influence cellular adaptation has gained increasing attention and is 
of particular interest to this work and is discussed further in later chapters. 
 
1.6. TUMOR-ASSOCIATED MICROGLIA 
Microglia are the primary resident immune cells of the CNS parenchyma and account for 
5-12% of cells in the brain (Alliot, Godin, & Pessac, 1999; Hickman et al., 2013; 
Nimmerjahn, Kirchhoff, & Helmchen, 2005). As mediators of baseline CNS immunity, 
microglial plasticity allows them to assume neurotoxic or neuroprotective states that 
determine their responses to changes in the surrounding microenvironment, invading 
pathogens and toxins, neurodegenerative diseases and traumatic brain injury, and 
cellular debris (Hickman et al., 2013; Nimmerjahn et al., 2005). Seminal work conducted 
by Nimmerjahn et al. (2005) revealed that, in the healthy brain, microglia continuously 
and dynamically surveil their surroundings via continuous cycles of de novo formation 
and withdrawal of cellular processes, which interact with cortical elements such as 
astrocytes, neurons, and blood vessels (Nimmerjahn et al., 2005). 
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 Brain resident microglia develop from embryonic yolk sac progenitor cells (Alliot et al., 
1999). In mouse brains, seeding of cells with myeloid features occurs as early as 
embryonic day 8.5-9, with the BBB beginning to form at embryonic day 13.5, thus isolating 
the developing brain from contributions of fetal liver hematopoiesis (Butovsky et al., 
2014). Development of microglia is dependent on TGF-β1, as mice with TGF-β1 
deficiency targeted to the CNS display loss of microglia (Butovsky et al., 2014). Stable 
microglia populations in adult brain are maintained primarily through prolonged cellular 
longevity and in situ proliferation, as adult microglia are not replenished postnatally via 
peripheral hematopoiesis (Ajami, Bennett, Krieger, Tetzlaff, & Rossi, 2007). 
 In adult brain and CNS, microglia mediate baseline immunity via constant physical 
surveillance of their surroundings (Nimmerjahn et al., 2005). As sentinels of CNS 
parenchyma, microglia require a complement of proteins for sensing extracellular 
perturbations, such as microbial invasion, neurodegenerative cell injury or death, 
chemokines and cytokines, or extracellular matrix changes. Some of these proteins, 
described collectively as the microglial sensome, are differentially expressed between 
microglia and bone marrow derived macrophages and consist primarily of 
transmembrane and cell surface receptors including pattern recognition receptors, 
chemoattractant and chemokine receptors (e.g. Cxcr4, Cxcr2), Fc receptors (e.g. Fcgr3, 
Fcer1g), toll-like receptors (e.g. Tlr2, Tlr7), cytokine receptors, purinergic receptors (e.g. 
P2ry12, P2rx7), receptors involved in cell-cell interaction, and receptors for extracellular 
matrix proteins (Hickman et al., 2013). 
 The BBB, which is composed of specialized capillary endothelial cells joined by 
complex tight junctions, establishes a barrier between the blood and CNS parenchyma 
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(Engelhardt, Vajkoczy, & Weller, 2017). Endothelial cells of the BBB are covered by a 
basement membrane formed by the fusion of endothelial and glia limitans basement 
membranes, which are further supported by astrocyte end-feet and in which pericytes are 
embedded. Given this tight barrier, the brain has conventionally been regarded as an 
“immune-privileged” organ, whose interaction with peripheral immunity is tightly regulated 
(Galea, Bechmann, & Perry, 2007). However, evidence that activated circulating T cells 
can cross the BBB in the absence of neuroinflammation and fact that cerebrospinal fluid 
drains into cervical lymph nodes have challenged this concept (Engelhardt & Ransohoff, 
2012; Louveau et al., 2015). Furthermore, disruption of the BBB as a result of rapid glioma 
outgrowth facilitates entry of tumor-infiltrating lymphocytes from the periphery (Louis, 
2006; Wainwright, Sengupta, Han, & Lesniak, 2011). Rather than complete immune cell 
exclusion, GBM tumors undermine anti-tumor immunity by cultivating a potently 
immunosuppressive microenviornment, via secretion of immunosuppressive cytokines 
(e.g. TGF-B, IL-10), expression of inhibitory molecules (e.g. PD-L1), and recruitment of 
immunosuppressive cells such as regulatory T cells, myeloid-derived suppressor cells, 
and tumor-associated microglia and macrophages (Binder, Davis, & Wainwright, 2016; 
Dutoit, Migliorini, Dietrich, & Walker, 2016; Wainwright & Lesniak, 2014). 
 The heterogeneity of the GBM immune landscape across tumors has been highlighted 
by previous efforts in single cell expression and next generation sequencing techniques, 
and data indicate that immune responses and cell populations vary among subtypes (Q. 
Wang et al., 2017). For instance, mesenchymal tumors were characterized by a greater 
frequency of IBA1+ tumor-infiltrating microglia and macrophages compared to non-
mesenchymal tumors (i.e. classical and proneural) (Q. Wang et al., 2017). An activated 
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natural killer cell gene signature was reduced in the mesenchymal subtype, and the 
resting memory CD4+ T cell gene signature was reduced in the proneural subtype, while 
classical subtype tumors displayed greater activated dendritic cell gene signatures (Q. 
Wang et al., 2017). These observations suggest that different immunotherapeutic 
modalities may exhibit differential efficacy against GBM tumors based on subtype. 
 Tumor-associated microglia (TAM) and bone marrow-derived macrophages (BMDM) 
can constitute as much as 30%-50% of GBM tumor bulk (Charles, Holland, Gilbertson, 
Glass, & Kettenmann, 2011; da Fonseca & Badie, 2013; Hambardzumyan, Gutmann, & 
Kettenmann, 2016; Quail & Joyce, 2017; Szulzewsky et al., 2015). Intra-tumor density of 
TAM and BMDM is highest in malignant high-grade gliomas compared to lower grade 
gliomas and is inversely correlated with patient survival (Choi, Stradmann-Bellinghausen, 
Yakubov, Savaskan, & Regnier-Vigouroux, 2015; Gieryng, Pszczolkowska, 
Walentynowicz, Rajan, & Kaminska, 2017). Originating either from peripheral circulation 
as BMDMs or representing brain-intrinsic TAM, they are actively recruited to GBM tumors 
via tumor secretion of chemokines, cytokines, and soluble matrix proteins (da Fonseca & 
Badie, 2013; Hambardzumyan et al., 2016). In turn, paracrine signaling networks among 
GBM cells, TAM, and BMDMs propagate the survival and proliferation of the tumor, 
making TAM and BMDMs an increasingly investigated aspect of the GBM tumor 
microenvironment. TAM commonly produce pro- as well as anti-inflammatory molecules 
and matrix remodeling proteins (VEGF, MMP-2, MMP-9, MT1-MMP), thus promoting 
tumor growth and invasion and local immunosuppression (Hambardzumyan et al., 2016). 
 Accurate identification of TAM versus BMDMs in gliomas has largely been precluded 
by a lack of definitive markers capable of distinguishing the two very closely related cell 
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populations. Most studies use CD45 expression levels to differentiate between microglia 
(CD45low) and peripherally-derived macrophages (CD45high). Other microglia-specific 
markers have been introduced recently, including Tmem119, P2ry12, Cx3cr1, and Siglec-
H (Bennett et al., 2016; Butovsky et al., 2014). The ability to discriminate between TAMs 
and BMDMs will enable investigation of relative contributions from each cell type to tumor 
progression. 
 The impact TAM and BMDMs have on tumor progression has inspired therapeutic 
strategies aimed at depleting them from the GBM tumor microenvironment. These efforts 
have focused primarily on inhibition of the colony-stimulating factor 1 receptor (CSF-1R) 
signaling axis, the inhibition of which depletes TAM (Coniglio et al., 2012). GL261 glioma 
cells exhibited significantly reduced invasion in a Matrigel invasion assay when co-
cultured with microglia pre-treated with PLX3397 (Coniglio et al., 2012). Preclinical 
studies in orthotopic xenograft GBM mouse models have demonstrated that ionizing 
radiation upregulates CSF-1R expression and increases Iba1+ BMDMs in tumors 
(Stafford et al., 2016). Administration of PLX3397 depleted Iba1+ BMDMs in developing 
tumors, sensitized tumors to ionizing radiation, and increased median survival time 
(Stafford et al., 2016). However, a phase II multicenter study demonstrated limited 
efficacy of PLX3397 as a single agent in increasing progression-free survival of patients 
with recurrent GBM (Butowski et al., 2016). Intriguingly, the only two patients who 
exhibited improved PFS in this study both displayed tumors similar to a mesenchymal 
subtype, which have since been demonstrated to harbor a greater frequency of TAM and 
BMDM (Q. Wang et al., 2017). More recent preclinical investigations demonstrate robust 
survival benefits in mice bearing intracranial gliomas treated with trimodal combination 
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therapy consisting of dendritic cell vaccination, anti-PD-1 checkpoint inhibitor, and 
PLX3397, underscoring the significance of combination therapies (Antonios et al., 2017). 
 While therapies such as PLX3397 and BLZ945 (another CSF-1R inhibitor) targeting 
the TAM and BMDM compartments of the GBM tumor microenvironment show promising 
preclinical results, long-term regression remains a challenge as a subset of tumors 
invariably acquires resistance to CSF-1R inhibition in a manner that is dependent upon 
the tumor microenvironment itself (Quail et al., 2016). Enhanced understanding of the 
complex milieu of signals tumor cells receive from neighboring malignant, cancer-
associated, and co-opted endothelial and tissue-resident cells, as well as how they sense 
and respond to gradients in extracellular metabolic and biophysical cues, may reveal new 
approaches to managing tumor burden and improving patient care. 
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CHAPTER 2: RETROGRADE SIGNALING BETWEEN MITOCHONDRIA AND 
NUCLEI 
2.1. MITOCHONDRIA 
The evolution of mitochondria within modern eukaryotic cells is firmly established as 
having arisen from the endosymbiotic engulfment of a prokaryotic organism (α-
proteobacterium) approximately 2 billion years ago (Archibald, 2015; Muller et al., 2012; 
Yang, Oyaizu, Oyaizu, Olsen, & Woese, 1985). It remains to be definitively determined 
whether this initial endosymbiotic event occurred between a complex Archezoa and 
prokaryote (“mitochondrion-late” hypothesis) or between two prokaryotes evolving in 
concert (“mitochondrion-early” hypothesis; hydrogen hypothesis) (Archibald, 2015; Martin 
& Muller, 1998). Nevertheless, the horizontal transfer of genes from an α-proteobacterium 
to host consolidated the symbiotic relationship, and mitochondria have since evolved as 
organelles critical for proper metabolic functioning and bioenergetics within most 
eukaryotic cells. 
 Mitochondria are comprised of two membranes: an outer mitochondrial membrane 
(OMM) and inner mitochondrial membrane (IMM), with the IMM housing respiratory 
complexes I, II, III, IV of the electron transport chain (ETC) and ATP synthase. The 
surface area of the IMM is increased by virtue of membrane folds called cristae, the 
structural integrity of which are maintained by multiprotein complexes at cristae junctions 
called MICOS (mitochondrial contact site and cristae organizing system) (Wollweber, von 
der Malsburg, & van der Laan, 2017). Seven mammalian MICOS subunits have been 
identified which comprise the large MICOS multiprotein complex: Mitofilin, CHCHD3, 
CHCHD6, APOO, APOOL, QIL1, and MINOS1 (Wollweber et al., 2017), with Mitofilin and 
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MINOS1 acting as key core components. The space created between the OMM and IMM 
is termed the inter-membrane space (IMS), while the compartment encapsulated by the 
IMM is the mitochondrial matrix, in which a variety of metabolic activities are conducted, 
including fatty acid oxidation and the tricarboxylic acid (TCA) cycle, which produce 
reducing equivalents for the electron transport chain.  
 Within cells, mitochondria are critically responsible for a plethora of functions, 
including regulation of the intrinsic pathway of apoptosis, calcium signaling, generation of 
heme and iron-sulfur clusters, carbohydrate and fatty acid metabolism, redox 
homeostasis, and generation of ROS as signaling molecules (Connolly et al., 2018). 
Arguably, the most widely recognized function of mitochondria is the oxygen-dependent 
generation of energy in the form of ATP, driven by an electrochemical gradient of H+ 
across the IMM. This gradient of protons is generated by the actions of the ETC, 
comprised of Complex I (NADH:ubiquinone oxidoreductase/NADH dehydrogenase), 
Complex II (succinate-ubiquinone oxidoreductase/succinate dehydrogenase), Complex 
III (ubiquinol-cytochrome c oxidoreductase), and the oxygen consuming Complex IV 
(cytochrome c oxidase). Electrons are donated initially to Complexes I and II via NADH 
and FADH2, respectively. The movement of electrons through the electron transport chain 
is coupled to the pumping of hydrogen ions (H+) against their concentration gradient from 
the mitochondrial matrix into the IMS. In turn, a chemiosmotic gradient is produced across 
the IMS, and H+ can only move down its electrochemical gradient and back into the matrix 
through ATP synthase. This proton motive force drives ATP synthase and is coupled with 
the production of ATP from ADP. 
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2.2. A GENERAL OVERVIEW OF MITOCHONDRIA IN CANCER 
An emerging hallmark of cancer is cellular reprogramming of bioenergetics in order to 
provide the biomass and anabolic precursors for rapid cell proliferation and the 
bioenergetics to participate in cellular events such as migration, invasion, and metastasis 
(Hanahan & Weinberg, 2011). The first observation of striking increases in glucose 
consumption by tumors compared to non-malignant tissue was described by the German 
physiologist Otto Warburg (Warburg, 1956; Warburg, Wind, & Negelein, 1927). Since, 
this phenomenon has been observed in a variety of tumor contexts and has been 
leveraged successfully in the clinic via positron emission tomography (PET)-based 
imaging of tumor uptake of a radioactive fluorine-labeled glucose analog [18F-
fluorodeoxyglucose (18F-FDG)], allowing for tumor diagnosis, staging, and monitoring of 
treatment responses (P. J. Song, Lu, Li, Li, & Shen, 2016). Cancer metabolism has since 
greatly evolved into a burgeoning field of research, with six hallmarks of cancer 
metabolism described to date, including: 1) deregulated uptake of glucose and amino 
acids; 2) use of opportunistic modes of nutrient acquisition; 3) use of glycolysis and TCA 
cycle intermediates for biosynthesis and NADPH production; 4) increased nitrogen 
demand; 5) alterations in metabolite-driven gene regulation; and 6) metabolic interactions 
with the microenvironment (Pavlova & Thompson, 2016). 
The “carbon economy” of a proliferating tumor cell is focused primarily on biosynthesis 
of biomolecules including fatty acids and cholesterol, nucleotides, pentose and hexose 
sugar derivatives, non-essential amino acids, reducing power in the form of NADPH, and 
others (Pavlova & Thompson, 2016). However, assuming that glucose was primarily used 
to generate ATP in ex vivo tumor slices, Warburg and others concluded, albeit incorrectly, 
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that increased glucose fermentation and tumorigenesis itself was a direct result of 
mitochondrial respiratory dysfunction (Warburg, 1956). Although this misinterpretation 
was recognized by some at the time (Weinhouse, 1956), it has nevertheless fueled 
contemporary investigations into cancer metabolism. 
It is now established that mitochondria and respiration are not entirely “deficient” or 
“damaged” in cancer, but continue to be critical for maintenance of malignant cell 
bioenergetics, protection against induction of apoptosis, and generation of ROS as 
second messengers (Galluzzi et al., 2010). The close interplay between mitochondrial 
function and hallmarks of cancer have been elegantly reviewed by others (Galluzzi et al., 
2010). Depletion of mitochondrial DNA has been shown to diminish tumorigenic potential 
of glioblastoma and breast cancer cell lines (Cavalli, Varella-Garcia, & Liang, 1997; A. S. 
Tan et al., 2015). Intriguingly, using in vivo mouse models, Tan et al. demonstrated that, 
breast tumor cells depleted of mitochondrial DNA (mtDNA) and devoid of mitochondrial 
respiration horizontally acquired mtDNA of host stromal origin in a stepwise recovery of 
mitochondrial respiration, with primary tumor cells, circulating tumor cells, and metastatic 
cells showing progressive increases in respiratory capacity (A. S. Tan et al., 2015). In 
vivo isotope tracing analysis of human brain and lung tumor patients has revealed that 
these tumors possess an oxidative phenotype, in which glucose is fully oxidized through 
the TCA cycle, as opposed to primarily converted into lactate (Courtney et al., 2018). 
Glioma stem cells have been demonstrated to be less glycolytic than proliferative, 
differentiated glioma cells (Vlashi et al., 2011). Additionally, mitochondrial spare 
respiratory capacity has been associated with glioma stem cell resistance to radiotherapy 
(Vlashi et al., 2011). Therefore, the Warburg effect represents a regulated state of 
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metabolic reprogramming in which glycolysis is decoupled from TCA cycle flux and 
oxidative phosphorylation, rather than a consequence of mitochondrial dysfunction. 
Mitochondrial function has been highlighted in priming states of invasive tumor cells 
navigating tumor microenvironments. Existing as tubular, reticular networks, mitochondria 
constantly undergo dynamic reorganization, i.e. fusion and fission, which controls 
subcellular compartmentalization of ATP production based on local need. Indeed, 
formation of lamellipodia by migrating cells is dependent upon reorganization of the actin 
cytoskeleton and requires an abundance of local energy production at the leading edge, 
which can be achieved by mitochondrial fission. Metastatic breast cancer cells have been 
demonstrated to display more fragmented mitochondria coincident with higher levels of 
the mitochondrial fission protein dynamin-related protein 1 (Drp1) and lower levels of 
mitochondrial fusion protein 1 (Mfn1) (Zhao et al., 2013). Selection for highly invasive 
tumor cell populations is accompanied by increased mitochondrial oxygen consumption 
in SiHA human cervix squamous cell carcinoma cells (Porporato et al., 2014). In this 
study, mitochondrial production of ROS in the form of H2O2 induced cell migration in a 
Src-SMAD-Pyk2-mediated mechanism (Porporato et al., 2014). 
Cancer stem cells represent a minority population of tumor cells which are capable of 
propagating and repopulating tumors (W. S. Song et al., 2016). GBM has been described 
as following the cancer stem cell hierarchy, with highly plastic brain tumor initiating cells 
(BTICs)/glioma stem cells (GSCs) residing at the apex. This population of cells has been 
characterized as resistant to conventional therapies, elusive of the antitumor immune 
response, and highly invasive (Fidoamore et al., 2016; W. S. Song et al., 2016). 
Therefore, defining qualities that differentiate GSCs from the bulk tumor population has 
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received significant attention. Compared to their non-stem counterparts, GSCs have been 
described as more respiratory and less glycolytic, a phenotype associated with resistance 
to radiotherapy (Vlashi et al., 2011). Mitochondria in BTICs from patient-derived 
xenografts display a more fragmented phenotype, in line with greater expression of 
activated phosphorylated fission protein Drp1, compared to mitochondria in matched non-
BTIC populations (Q. Xie et al., 2015). shRNA-mediated Drp1 knockdown, as well as 
pharmacologic inhibition of Drp1-mediated mitochondrial fission with Mdivi-1, significantly 
decreased BTIC growth (Q. Xie et al., 2015). Notably, increased expression of activated 
Drp1, observed in greater levels in tumor vs non-tumor tissue, was associated with poorer 
GBM patient survival (Q. Xie et al., 2015). 
 
2.3. RETROGRADE SIGNALING 
Mitochondria are semi-autonomous organelles which harbor multiple copies of mtDNA, 
ranging from 100-1000 copies per cell, depending on cell and tissue type (Guha & 
Avadhani, 2013). Approximately 16.5 kb of circular DNA, mtDNA encodes only 13 
essential structural subunits out of the 90 protein subunits that comprise the respiratory 
complexes of the ETC, while the majority of respiratory subunits and mitochondrial 
proteome are encoded by the nuclear genome (Baughman et al., 2009; Guha & Avadhani, 
2013). It is estimated that 1500-2000 nuclear encoded, cytoplasmically translated 
proteins are imported into mitochondria (Guha & Avadhani, 2013). Therefore, tight 
coordination between mitochondrial and nuclear gene expression is crucial for the 
maintenance of appropriate mitochondrial function.  
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 Communication between mitochondria and the nucleus is bidirectional, and can be 
described by either (1) anterograde or (2) retrograde signaling (Guha & Avadhani, 2013). 
Anterograde signaling refers to activation of nuclear transcription and cytoplasmic 
translation which directly regulates mitochondrial biogenesis. Complementary to this, 
retrograde signaling originates in mitochondria. Perturbations in mitochondrial function 
initiate signaling back to the nucleus, resulting in altered expression of nuclear genes 
(Eisenberg-Bord & Schuldiner, 2017). This signaling axis thus facilitates a mechanism by 
which mitochondria communicate with the nuclear genetic compartment to relay 
metabolic, respiratory, and redox conditions in order to maintain cellular homeostasis 
(Guha & Avadhani, 2013). 
Three main routes of 
retrograde signaling have 
been described by which 
intracellular proteins 
mediate communication 
between mitochondria 
and the nucleus (Figure 
2.1). These include: 1) the classical retrograde signaling pathway, in which resident 
cytosolic proteins sense disruptions in mitochondrial output and translocate to the nucleus 
from the cytosol; 2) “moonlighting” proteins that are located in both mitochondria and the 
nucleus, but are differentially shuttled between these compartments based on need; and 
3) direct translocation from mitochondria to the nucleus (da Cunha, Torelli, & 
Kowaltowski, 2015; Liao & Butow, 1993; Monaghan & Whitmarsh, 2015). 
Figure 2.1. Routes of mitonuclear retrograde signaling. Proteins that 
participate in mitonuclear communication accomplish their function via three 
main routes: as participants in the classical retrograde signaling pathway 
(Protein 1), residing as dually localized “moonlighting” echoforms in both 
subcellular compartments (Protein 2), or directly translocating from 
mitochondria to the nucleus (Protein 3). 
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The classical retrograde signaling pathway was first described by Liao and Butow in 
Saccharomyces cerevisiae (Liao & Butow, 1993). This pathway is controlled by the 
ReTroGrade regulation proteins Rtg1, Rtg2, and Rtg3. Rtg1 and Rtg3 are basic helix-
loop-helix/leucine zipper transcription factors that translocate from the cytosol to the 
nucleus upon activation, which occurs as a result of Rtg2 inhibiting phosphorylation 
inhibition of Rtg3 by Mks1 (Eisenberg-Bord & Schuldiner, 2017). Activation of the 
retrograde pathway (e.g. by loss of mtDNA, sudden drops in ATP levels, or spikes in ROS 
production), leads to genetic reprogramming affecting amino acid metabolism, redox 
homeostasis, and other metabolic adaptations (Hashim, Mukai, Bamba, & Fukusaki, 
2014; Torelli, Ferreira-Junior, Kowaltowski, & da Cunha, 2015). A well-characterized 
mechanism responsible for maintaining intracellular redox status that could potentially be 
classified as classical retrograde signaling involves the NRF2-KEAP1 axis (transcription 
factor NF-E2 p45-related factor 2/Kelch-like ECH-associated protein 1). Under 
unstressed conditions, KEAP1 sequesters NRF2 to the cytosol and targets it for 
proteasomal degradation. However, upon redox stress, KEAP1 loses this ability by virtue 
of cysteine residue oxidation, allowing Nrf2 to localize to the nucleus and regulate the 
expression of a suite of genes harboring antioxidant response elements (ARE) to bolster 
defense against redox stress (Cuadrado et al., 2019). 
Moonlighting proteins, also known as echoforms, are capable of dual localization in 
both mitochondria and the nucleus. These are distinct from proteins with multiple isoforms 
that localize in different compartments, such as the IDH isoforms. Proteins with echoforms 
across various subcellular compartments include aconitase (mitochondria and the 
cytosol), Nfs1 (mitochondria and the nucleus), fumarase (mitochondria and the nucleus), 
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and the telomerase component telomerase reverse transcriptase (TERT, mitochondria 
and the nucleus) (Monaghan & Whitmarsh, 2015; Yogev, Naamati, & Pines, 2011). 
Mitochondrial fumarase catalyzes the conversion of fumarate to malate in the TCA cycle, 
while enhanced localization of fumarase in the nucleus has been observed as a DNA 
damage response (Yogev et al., 2011). While it has been demonstrated that the 
enzymatic activity of fumarase is required for its defensive capabilities against DNA 
damage, how its primary metabolites affect the DNA damage response remains unknown, 
although it is possible that nuclear fumarate inhibits histone demethylation (Jiang et al., 
2015). TERT has also been demonstrated to localize in both mitochondria and the 
nucleus to maintain integrity of both nuclear and mitochondrial genomes by protecting 
against telomere shortening in the nucleus and ROS-induced mtDNA damage in 
mitochondria (Monaghan & Whitmarsh, 2015). 
A third paradigm of mitonuclear communication involves the direct translocation of 
mitochondrial proteins to the nucleus. A number of proteins have been implicated in 
retrotranslocation out of mitochondria and import into the nucleus in response to 
mitochondrial perturbations. Recent work in HEK293 cells has ascribed this ability to 
MOTS-c, a 16 amino acid peptide encoded by mtDNA that can regulate cellular 
metabolism in an AMPK-dependent manner (C. Lee et al., 2015). In HEK293 cells, 
MOTS-c translocated from mitochondria to the nucleus in response to metabolic stress 
imposed by glucose restriction, serum deprivation, and oxidative stress induced by tert-
butyl hydrogen peroxide (Kim, Son, Benayoun, & Lee, 2018). In the nucleus, MOTS-c 
interacts with Nrf2 to regulate expression of a complement of genes involved in a 
metabolic and oxidative stress response. Similarly to MOTS-c, in differentiating 
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adipocytes and brown adipose tissue, G-Protein Pathway Suppressor 2 (GPS2) 
translocates from mitochondria to the nucleus in response to mitochondrial depolarization 
to activate the transcription of nuclear encoded mitochondrial genes coding for the 
electron transport chain, fatty acid oxidation, and mitochondrial structure (Cardamone et 
al., 2018). Quite notably, the pyruvate dehydrogenase complex (PDC) has also been 
suggested to be able to directly translocate from mitochondria to the nucleus during S 
phase, as well as in response to treatment with epidermal growth factor, complex I 
inhibition with rotenone, and serum stimulation in A549 cells (Sutendra et al., 2014). 
Canonically, mitochondrial PDC catalyzes the irreversible conversion of pyruvate to 
acetyl-CoA, which can then feed into the TCA cycle. Sutendra et al. concluded that 
accumulation of nuclear PDC was required for increasing the pool of nuclear acetyl-CoA 
used for acetylation of key histones important for the progression into S phase of the cell 
cycle. However, a mechanism describing the export of PDC, a multienzyme complex on 
the order of thousands of kDa, out of the mitochondrial matrix, across the IMM and OMM, 
and into the nucleus remains elusive. 
The mitochondrial unfolded protein response (UPRmt) is another avenue by which 
mitochondrial structure, integrity, and function are maintained. Although it is considered 
distinct from the mitochondrial retrograde stress response heretofore discussed, the two 
pathways share some overlap with regard to signaling pathways involved. The canonical 
UPRmt is driven by the release of unfolded and/or misfolded peptides from mitochondria 
via the HAF-1 transporter and detection of those peptides in the cytosol, as well as nuclear 
accumulation and transcriptional activity of activating transcription factor 4 (ATF-4), 
C/EBP homologous protein (CHOP), and the dually-localized activating transcription 
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factor associated with stress-1 (ATFS-1), whose import into mitochondria is inhibited upon 
UPRmt (Munch, 2018). Ultimately, this results in increased folding capacity either through 
the induction of chaperones, the reduction of protein uptake into mitochondria, or reduced 
translation, all in an effort to reduce the load of unfolded proteins. Notably, the UPRIMS is 
distinct from the canonical UPRmt and is dependent upon estrogen receptor α (ERα) and 
ROS-dependent phosphorylation and activation of ERα by AKT (Munch, 2018). 
Subsequently, activated ERα induces expression of nuclear respiratory factor 1 (NRF1) 
and the IMS protease OMI, as well as increased proteasome activity, to maintain 
mitochondrial IMS proteostasis (Munch, 2018). To what extent classical retrograde 
signaling pathways involve mitochondrial protein misfolding is an intriguing avenue of 
future research. 
Maintenance of mitochondrial integrity, biogenesis, and respiration has been 
demonstrated to mediate neoplastic characteristics in a variety of cancer contexts, some 
described above. The transcription coactivator peroxisome proliferator-activated receptor 
γ, coactivator 1 alpha (PGC-1α) is responsive to extracellular stimuli such as nutrient 
supply and oxygen tension and is regarded as a master regulator of mitochondrial 
biogenesis and oxidative phosphorylation in mammals (Wu et al., 1999). Although itself 
possessing no DNA-binding activity, PGC-1α acts in concert with other transcription 
factors including NRFs and estrogen-related receptors (ERR) to mediate nuclear 
expression of mitochondrial genes, and is associated with predictive prognosis in a variety 
of neoplasms including breast, ovarian, prostate, endometrial, and colorectal cancer, 
among others (Deblois, St-Pierre, & Giguere, 2013). Strong correlations between PGC-
1α expression in invasive breast cancer cells and formation of distant metastases have 
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been observed (LeBleu et al., 2014). Knockdown of PGC-1α abrogated migratory and 
invasive phenotypes of breast cancer and GBM cells (Bruns et al., 2019; LeBleu et al., 
2014). Thus, mitochondrial functions, as well as their regulation, have deep implications 
in maintaining and promoting cancer malignancy. 
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CHAPTER 3: COILED-COIL-HELIX-COILED-COIL-HELIX DOMAIN-CONTAINING 
PROTEIN 2 
3.1. INTRODUCTION TO CHCH DOMAIN-CONTAINING PROTEINS 
Coiled-coil-helix-coiled-coil-helix (CHCH) domain-containing proteins are a family of 
nucleus-encoded, small mitochondrial proteins with functions in maintenance of 
mitochondrial structure and function (Modjtahedi, Tokatlidis, Dessen, & Kroemer, 2016; 
Z. D. Zhou, Saw, & Tan, 2017). To date, nine members of this protein family have been 
described (CHCHD1, CHCHD2, CHCHD3, CHCHD4, CHCHD5, CHCHD6, CHCHD7, 
CHCHD8, CHCHD10), each of 
which contains one CHCH 
domain (with the exception of 
CHCHD5, which harbors two) (Z. 
D. Zhou et al., 2017). The CHCH 
domain, in turn, consists of two 
CX9C motifs, with each motif 
defined by two cysteines (Cys) 
separated by 9 amino acids. The 
pair of CX9C motifs engages in 
disulfide bond formation, which is 
necessary for proper oxidative 
protein folding as well as import 
into the mitochondrion.  
Figure 3.1. Import of CX3C and CX9C motif-containing proteins 
is regulated by the Mia40/Erv1 disulfide relay system 
(CHCHD4/ALR in humans). After translation in the cytosol, 
CHCHD2 permeates the OMM via TOM40 in a reduced form. The 
oxidoreductase CHCHD4, tethered to the IMM via interaction with 
AIF, catalyzes covalent intermolecular bond disulfide formation, 
ultimately resulting in oxidative disulfide bond formation within 
incoming substrate. CHCHD4 is then re-oxidized by the ALR, with 
electrons ultimately transferring to complex IV and H2O. 
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 Each member of the CHCH domain-containing protein family, along with other 
cysteine motif-containing proteins (such as CX3C proteins), is imported into mitochondria 
via the redox-regulated Mia40/Erv1 (human equivalents: CHCHD4/ALR) disulfide relay 
system (Modjtahedi et al., 2016), which features oxidation-driven folding into the IMS 
(Figure 3.1). Nucleus-encoded (CX9C)2 proteins are first translated by cytosolic 
ribosomes, then imported in their reduced form into the IMS through the translocase of 
the outer membrane (TOM) complex. Central to the relay system is the CHCHD4 
oxidoreductase, which is bound to the IMM via its interaction with apoptosis-inducing 
factor (AIF). CHCHD4 first binds to the MISS motif (mitochondrial IMS-sorting signal) 
present on incoming protein substrates, followed by covalent intermolecular disulfide 
bond donation, ultimately resulting in the catalyzed oxidative folding and entrapment of 
substrate proteins in the IMS (Modjtahedi et al., 2016). The re-oxidation of 
Mia40/CHCHD4 is facilitated by the FAD-linked sulfhydryl oxidase Erv1/ALR, with 
electrons subsequently transferring to FAD, cytochrome c, complex IV of the electron 
transport chain, and, finally, water. 
 
3.2. CHCHD2 
Coiled-coil-helix-coiled-coil-helix domain-containing protein 2 (CHCHD2) is a 16 kDa 
protein and member of the evolutionarily conserved CHCH domain-containing protein 
family. The CHCHD2 gene is located on chromosome 7p11.2 and encodes the 151 amino 
acid CHCHD2 protein, defined by its C-terminal CHCH domain encompassing amino 
acids 107-147. The CHCH domain itself is defined by two cysteine-X9-cysteine motifs 
(twin CX9C), each consisting of two cysteines (Cys) separated by 9 amino acids. Cys114 
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and Cys124 define the first CX9C motif, and Cys134 and Cys144 define the second. Two 
disulfide bonds, formed between Cys114-Cys144 and Cys124-Cys134, stabilize the helix-turn-
helix fold of the CHCH domain. These Cys residues are indispensable for proper protein 
folding and import of CHCHD2 into the mitochondrial inter-membrane space via 
interaction with CHCHD4 (Aras et al., 2015). In addition, Cys144 is the terminal amino acid 
in the MISS motif, which interacts with CHCHD4 and is required for CHCHD4-mediated 
protein import into the IMS via disulfide relay. Furthermore, the N-terminus of CHCHD2 
harbors a putative mitochondrial localization sequence defined by amino acid residues 1-
53 (Aras et al., 2015). The sequence of CHCHD2 is highly conserved among human, 
mouse, and rat, suggesting a critical intracellular function (Funayama et al., 2015). 
CHCHD2 was first identified during a computational screen as a protein required for 
optimal mitochondrial respiration (Baughman et al., 2009). The tight transcriptional 
regulation of electron transport chain subunits offered a strategy for identifying non-
structural regulators based on shared patterns of co-expression in micro-array 
experiments (Baughman et al., 2009). In a large-scale computational screen, Baughman 
et al. surveyed 1,427 independent microarray data sets to identify genes that consistently 
co-expressed with canonical electron transport chain subunits across different biological 
contexts, and identified CHCHD2 as among these highly co-expressed genes. shRNA-
mediated gene silencing of CHCHD2 resulted in reduced oxygen consumption rate of 
MCH58 fibroblasts by 40%, decreased levels of the complex IV subunit COX2, and 
decreased complex IV activity by 40-60% (Baughman et al., 2009). Similar regulation of 
oxygen consumption by CHCHD2 has since been demonstrated in HEK293 cells (Aras 
et al., 2017; Aras et al., 2015), non-small cell lung carcinoma (NSCLC) HCC827 cells and 
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xenograft-derived LPC43 lung primary cells (Wei et al., 2015), as well as Drosophila 
embryonic cells (Meng et al., 2017). This regulation of oxygen consumption has been 
attributed to physical binding of CHCHD2 with complex IV and positive transcriptional 
regulation of the tissue specific complex IV subunit 4 isoform 2 (COX4I2) (Aras et al., 
2015). However, other reports indicate a lack of this physical interaction, instead 
suggesting that CHCHD2 maintains proper electron flow rate through the electron 
transport chain between complexes III and IV (Meng et al., 2017). Collectively, these 
studies establish a canonical role for CHCHD2 in mediating efficient electron transport 
chain function, oxygen consumption, and cellular respiration. However, the precise 
mechanism by which this is accomplished remains to be fully elucidated. 
Functions of CHCHD2 within mitochondria extend beyond regulation of cellular 
respiration to include maintenance of baseline cellular ROS levels. shRNA-mediated 
CHCHD2 knockdown resulted in decreased abundance of ROS scavenging enzymes 
glutathione peroxidase (GPx), manganese superoxide dismutase (Mn-SOD), and 
copper/zinc superoxide dismutase (Cu/Zn-SOD), as well as increased total cellular ROS 
in HEK293 cells (Aras et al., 2015). CHCHD2 knockdown cells also displayed decreased 
abundance of complex I subunits NDUFB6 and NDUFS3 (Aras et al., 2015). Loss of 
CHCHD2 in Drosophila embryonic cells resulted in elevated total ROS production, 
however without changes in the level of Cu/Zn-SOD (Meng et al., 2017). 
More recently, CHCHD2 has been demonstrated to function in the maintenance of 
inner mitochondrial membrane cristae integrity in HEK293 cells via formation of a tertiary 
complex with MICS1, a protein associated with maintenance of cristae structure (Oka et 
al., 2008), and cytochrome c (Meng et al., 2017). Indirect flight muscles of CHCHD2-/- 
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Drosophila displayed disordered cristae and dilated matrices (Meng et al., 2017). Ectopic 
overexpression of mutant CHCHD2 protein, as well as siRNA-mediated transient 
CHCHD2 knockdown, significantly altered cristae ultrastructure in neural progenitor cells 
(NPCs) derived from isogenic human embryonic stem cells (W. Zhou et al., 2018). 
Accompanying cristae deformation and loss were decreased levels of MICOS core 
components Mitofilin and MINOS1, as well as MICOS-associated protein CHCHD10, the 
latter of which CHCHD2 binds to in a C-terminus-dependent fashion (W. Zhou et al., 
2018). Together, these results provide evidence for a structural role for CHCHD2 in 
mediating mitochondrial cristae integrity. 
CHCHD2 also participates in the negative regulation of the intrinsic pathway of 
apoptosis that originates at the level of mitochondria. In mouse embryonic fibroblasts, 
ectopically expressed WT CHCHD2 repressed cytochrome c release and caspase 
activation, while Parkinson’s disease-associated CHCHD2 mutant isoforms (T61I and 
R145Q) failed to do so (Meng et al., 2017). Another study in U2OS osteosarcoma cells 
demonstrated that CHCHD2 constitutively interacts with the pro-survival B-cell lymphoma 
2 (Bcl-2) protein Bcl-xL under unstressed conditions to prevent the oligomerization of pro-
apoptotic Bcl-2-associated X protein (Bax) and subsequent mitochondrial outer 
membrane permeabilization (MOMP), the putative “point of no return” during the intrinsic 
pathway of apoptosis (Kalkavan & Green, 2018).  
Moreove, CHCHD2 mediates extra-mitochondrial cellular functions, such as acting as 
a hypoxia-sensitive nuclear transcription factor. Early studies focusing on the lung- and 
trachea-specific isoform of complex IV COX4I2 demonstrated its oxygen-responsive 
transcriptional regulation, induced maximally at 4% O2 under the control of a HIF-
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independent cis oxygen responsive element (ORE) (Huttemann, Lee, Liu, & Grossman, 
2007). Later work from the same group identified CHCHD2, in concert with recombination 
signal sequence-binding protein J κ (RBPJ), as transcription factors positively regulating 
COX4I2 gene expression in HEK293 and primary pulmonary arterial smooth muscle cells 
(Aras et al., 2013).  
A subset of literature across diverse biological contexts describes regulatory 
mechanisms for CHCHD2 at the transcriptional and post-translational levels. Additional 
work by Aras et al. further demonstrates the ability of CHCHD2 to act as a transcription 
factor increasing the expression of itself in hypoxia, maximally at 4% O2 (Aras et al., 
2013). Other work has demonstrated cAMP regulatory element binding protein (CREB) 
as a positive regulator of CHCHD2 gene expression in hepatocellular carcinoma (R. Song 
et al., 2015). Notably, Zhu et al. demonstrated that CHCHD2 expression in human 
induced pluripotent stem cells was positively regulated by pluripotency proteins OCT4 
and SOX2 (Zhu et al., 2016). One study has provided evidence for post-translational 
modification of CHCHD2, demonstrating phosphorylation of CHCHD2 at Tyr99 by Abl 
kinase promoting mitochondrial complex IV activity (Aras et al., 2017). 
 Additional studies have reported CHCHD2 as a mediator of cell migration. Using a 
functional genetic screen, Seo et al. identified CHCHD2 as a novel regulator of NIH3T3 
cell migration (Seo, Lee, & Suk, 2010). shRNA-mediated knockdown of endogenous 
CHCHD2 decreased motility in a Transwell migration assay, while ectopic overexpression 
increased cell migration in an Akt-dependent manner (Seo et al., 2010). Notably, the 
physical interaction of CHCHD2 with hyaluronic acid-binding protein 1 
(HABP1/C1QBP/p32) suppressed cell migration (Seo et al., 2010). Similar results were 
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observed in 786-O and ACHN renal cell carcinoma (RCC) cells, in which CHCHD2 
knockdown led to downregulated cell migration and decreased matrix metalloproteinase 
2 (MMP-2) expression (Cheng, Qu, Lu, & Zhang, 2019). Additionally, conditioned media 
from CHCHD2 knockdown 786-O and ACHN cells failed to stimulate tube formation by 
HUVECs, coincident with decreased VEGF secretion (Cheng et al., 2019). A separate 
study also demonstrated an interaction between CHCHD2 and HABP1, and that 
knockdown and overexpression of CHCHD2 in lung carcinoma LPC43 cells also reduced 
and increased cell migration, respectively (Wei et al., 2015). Shimojima et al. 
demonstrated significantly decreased CHCHD2 expression in induced pluripotent stem 
cells (iPSCs) from two patients with distinct genetic backgrounds of lissencephaly, one of 
the most severe forms of cortical migration disorders that occurs from defects in neuronal 
migration during development (Shimojima et al., 2015). During neuronal differentiation 
from iPSCs, normal control iPSCs exhibited step-wise increases in CHCHD2 expression 
over 16 and 48 days, a phenomenon not observed in iPSCs derived from patients with 
lissencephaly (Shimojima et al., 2015). 
 In line with results from Shimojima et al., Zhu et al. demonstrated a positive correlation 
between expression of CHCHD2 in human embryonic stem cells (hESC) and induced 
pluripotent stem cells (iPSCs) and their ability to efficiently differentiate specifically into 
neuroectodermal lineages (Zhu et al., 2016). This function was attributed to CHCHD2 
binding and sequestering SMAD4 away from the nucleus and in mitochondria. This 
sequestration in turn suppressed the activity of the TGF-β signaling pathway, which 
negatively impacted hESC and iPSC neuroectoderm differentiation capability (Sakaki-
Yumoto, Katsuno, & Derynck, 2013). Human iPSCs, which exhibited reduced 
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neuroectodermal differentiation compared to hESCs, also displayed significantly lower 
levels of CHCHD2 gene expression compared to hESCs (Zhu et al., 2016). Notably, 
neural stem cells (NSCs) derived from iPSCs exhibited decreased migration capabilities 
compared to NSCs derived from hESCs, indicating the involvement of CHCHD2 in 
migration as well as differentiation of pluripotent stem cells (Zhu et al., 2016). 
 Due to the pleiotropic functions ascribed to CHCHD2 across a variety of biological 
contexts, the pathological relationship of CHCHD2 with neurodegenerative diseases has 
gained increasing attention. Indeed, various mutations and polymorphisms within the 
CHCHD2 gene have been associated with Parkinson’s disease (PD). A genome-wide 
linkage analysis on individuals with autosomal dominant PD identified putative pathogenic 
missense mutations including Thr61Ile and Arg145Gln, as well as one splice-site mutation 
in a Japanese population (Funayama et al., 2015). Notably, Thr61 and Arg145 are 
conserved residues among vertebrates (Funayama et al., 2015), suggesting their 
functional importance. Indeed, Arg145 lies C-terminal adjacent to the CHCH domain. A 
separate study failed to identify these causal variants in a separate analysis of PD cases 
of European ancestry, instead noting three separate novel putative pathogenic variants 
(Ala32Thr, Pro34Leu, Ile80Val) in 4 cases (Jansen et al., 2015). Foo et al. identified a 
Pro2Leu mutation as significantly associated with PD in a Chinese population of sporadic 
disease (Foo, Liu, & Tan, 2015). A nonsense mutation (Gln126X) was identified in a 
German individual with Parkinson’s disease (Koschmidder et al., 2016). However, 
separate studies in other familial PD cohorts from Arkansas, Sweden, China, and Canada 
have not identified putative pathogenic variants, or other mutations, in the CHCHD2 gene 
(Z. Liu et al., 2015; Puschmann, Dickson, Englund, Wszolek, & Ross, 2015; M. Zhang et 
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al., 2016). The rarity of CHCHD2 variants and their heterogeneity across various 
populations suggests that mutations in CHCHD2 may contribute to, but do not fully 
account for, the underlying genetic risk for Parkinson’s disease. 
 Collectively, these studies highlight the functional relevance of CHCHD2 across a 
variety of biological contexts. A canonical mediator of mitochondrial function, CHCHD2 
has also been ascribed to other functions including regulation of apoptosis, cell migration, 
stem cell differentiation into neuroectodermal lineages and neural stem cells, and 
retrograde signaling in hypoxia. Continuing to study and interrogate CHCHD2 in the 
context of human health and disease is thus an exciting and promising avenue of 
research. 
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CHAPTER 4: CRISPR-CAS9-MEDIATED CHCHD2 KNOCKOUT COMPROMISES 
MALIGNANT CHARACTERISTICS OF GLIOBLASTOMA CELLS EXPRESSING 
EGFRvIII 
ABSTRACT 
INTRODUCTION 
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults 
and remains incurable. Although amplification of the epidermal growth factor receptor 
(EGFR) is prevalent across GBM tumors, therapies targeting EGFR have failed to 
robustly increase patient overall survival. Inter-organelle communication between 
mitochondria and the nucleus may be a potential compensatory signaling route 
undermining molecular subtype therapies. Previous reports have demonstrated the 
mitochondrial protein coiled-coil-helix-coiled-coil-helix domain-containing protein 2 
(CHCHD2) to mediate nuclear gene expression, cell migration, and apoptosis, but 
evidence of these capabilities in GBM is lacking. The hypothesis motivating this study 
was that CHCHD2 served a functional role in mediating GBM malignant phenotype. The 
objective of the present study was to characterize the functional capacity of CHCHD2 in 
mitochondrial respiration and glutathione redox homeostasis, cell proliferation and 
invasion, and therapeutic sensitivity in U87 GBM cells expressing the constitutively active 
EGFRvIII mutation (U87vIII). 
METHODS 
Analysis of CHCHD2 gene amplification patterns and patient survival were conducted on 
the glioblastoma TCGA Provisional database using cBioPortal. Analysis of CHCHD2 
mRNA expression levels was compared among GBM tumors using Gliovis. U87vIII 
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CHCHD2 knockout (KO) cells were derived using CRISPR-Cas9 genome editing 
techniques. Oxygen consumption rate (OCR) was measured using a Seahorse XFp 
Extracellular Flux Analyzer. Compartmentalized glutathione (GSH) redox state was 
assessed using genetically encoded fluorescent redox biosensors targeted to the cytosol 
and mitochondrial matrix. Protein levels of xCT, GPx-1/2, GPx-4, and MMP-2 were 
analyzed using western blot. The sulforhodamine B assay was used to determine cell 
proliferation (in normoxia and hypoxia), as well as cell sensitivity to sulfasalazine, 
erlotinib, temozolomide, and Pac-1. Methacrylated gelatin (GelMA) hydrogels were 
employed as a biophysical model of the GBM microenvironment to analyze cell invasion 
in normoxia and hypoxia. CHCHD2 protein levels were analyzed in a panel of GBM 
patient-derived cells via western blot.  
RESULTS 
CHCHD2 gene amplification occurred in 9% of GBM tumors, nearly always with EGFR, 
and was associated with decreased overall survival and progression-free survival. 
CHCHD2 mRNA levels were increased in grade IV glioma, IDH-wt GBM tumors, and in 
tumor versus non-tumor tissue. U87vIII CHCHD2 KO cells displayed decreased OCR and 
spare respiratory capacity compared to U87vIII CHCHD2 WT cells. The redox state of the 
GSH pool was more reduced within the mitochondrial matrix of CHCHD2 KO cells 
compared to WT cells, an effect independent of GSH synthesis, cystine import via xCT, 
or GPx-1, GPx-2, or GPx-4 levels. The cytosolic GSH pool was not perturbed by CHCHD2 
KO. Furthermore, CHCHD2 KO abrogated the increased proliferation and invasion of 
U87vIII cells in hypoxia (1% O2) compared to standard normoxic culture conditions (20% 
O2), coupled with decreased expression of MMP-2. U87vIII CHCHD2 KO cells displayed 
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increased sensitivity to sulfasalazine, erlotinib, and temozolomide, but not Pac-1. 
CHCHD2 exhibited a heterogeneous protein expression pattern among patient-derived 
cells investigated, with greater levels observed in more invasive samples. 
CONCLUSIONS 
CHCHD2 mediates a variety of GBM cell hallmark characteristics, including cell 
proliferation, cell invasion in response to hypoxia, and cellular resistance to cytotoxic 
agents. 
 
4.1. INTRODUCTION 
Glioblastoma (GBM, WHO grade IV glioma) is the most common, malignant, and 
aggressive form of primary brain tumor in adults, accounting for approximately 50% of 
diagnosed gliomas each year (Barnholtz-Sloan et al., 2018). Patients with GBM present 
with a median survival time of only 15-20 months, with only 5-10% of patients surviving 
after 5 years (Stupp et al., 2017). Despite the current multimodal standard of care, which 
consists of maximal surgical resection followed by radiotherapy and chemotherapy with 
the DNA alkylating agent temozolomide (TMZ), overall prognosis remains poor, 
underscoring the need for a deeper understanding of tumor biology to inspire new 
therapeutic targets. Contributing to tumor aggressiveness and virtually universal 
recurrence are GBM hallmarks, including but not limited to: rapid, diffuse invasion into 
surrounding brain parenchyma, substantial chemo- and radioresistance, and rapid 
adaptation to microenvironmental stressors such as hypoxia (Ceccarelli et al., 2016; 
Omuro & DeAngelis, 2013).  
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Genetic aberrations resulting in dysregulated cell signaling perpetuate malignant cell 
phenotypes. Amplification of the epidermal growth factor receptor (EGFR) is the most 
common genetic abnormality observed in GBM tumors (Michael Weller et al., 2017). 
Increased signaling downstream of EGFR contributes to proliferative and anti-apoptotic 
signaling, as well as invasive behavior (Gan et al., 2009). Indeed, amplification of EGFR 
has been associated with fast migratory behavior of GBM cells (Parker et al., 2018). 
Tumors that exhibit EGFR amplification also frequently present with the constitutively 
active EGFR variant 3 (EGFRvIII) mutant (Michael Weller et al., 2017). The EGFRvIII 
mutant arises from deletion of exons 2-7 of the EGFR gene, leading to deletion of 267 
amino acids in the extracellular domain, and resulting in a truncated, yet constitutively 
active, EGFR protein (Gan et al., 2009). The resultant increased signaling downstream 
confers enhanced glioma malignancy through multiple mechanisms, and, importantly, the 
EGFRvIII mutant is not present on non-malignant tissues (Gan et al., 2009). However, 
although targeting EGFRvIII is a rational strategy to combat GBM, phase II clinical trials 
with the EGFR receptor tyrosine kinase inhibitor erlotinib and phase III clinical trials with 
the EGFRvIII vaccine rindopepimut have failed to robustly increase patient overall 
survival, highlighting the immense plasticity of GBM cell populations, which dampens 
treatment efficacies and hinders tumor management (Raizer et al., 2010; Raizer et al., 
2016; Michael Weller et al., 2017). 
 Mitochondria, in addition to regulating cellular energy conservation, also serve as 
signaling organelles. Mitochondria participate in retrograde signaling to the nucleus to 
induce changes in nuclear gene expression in response to intracellular metabolic 
perturbations in order to maintain metabolic homeostasis (Eisenberg-Bord & Schuldiner, 
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2017). Several proteins have been demonstrated to participate in inter-organelle signaling 
between mitochondria and the nucleus, including p53, fumarase, the pyruvate 
dehydrogenase complex, and coiled-coil-helix-coiled-coil-helix domain-containing protein 
2 (CHCHD2) (Aras et al., 2015; Sutendra et al., 2014; Yogev et al., 2011; Zhuang et al., 
2013). 
 The CHCHD2 gene is located proximal to EGFR on chromosome 7; as such, 
CHCHD2 and EGFR are frequently co-amplified in non-small cell lung carcinoma 
(NSCLC) (Wei et al., 2015). CHCHD2 belongs to a family of 9 evolutionarily conserved 
small mitochondrial proteins, all containing at least one CHCH domain (Modjtahedi et al., 
2016; Z. D. Zhou et al., 2017). The CHCH domain, characterized by two CX9C motifs (two 
cysteines separated by 9 amino acids), is necessary for simultaneous oxidative folding 
and protein import into the mitochondrial intermembrane space (IMS), where CHCHD2 
canonically functions in mediating mitochondrial respiration (Aras et al., 2015; Meng et 
al., 2017; Modjtahedi et al., 2016). In addition, CHCHD2 has been demonstrated in a 
variety of biological contexts to regulate other cellular functions, including cell migration 
and regulation of apoptosis (Y. Liu et al., 2015; Seo et al., 2010). The objective of this 
study was to characterize the functional capacity of CHCHD2 in GBM cells expressing 
EGFRvIII. Our results indicate that CHCHD2 participates in a number of GBM cell 
functions representing disease hallmarks and may inspire therapeutic strategies which 
undermine mitochondrial biology to potentially improve GBM tumor management. 
 
4.2. METHODS 
CHCHD2 gene amplification and mRNA expression analysis 
47 
 
Analysis of CHCHD2 gene amplification patterns across GBM tumors was performed on 
The Cancer Genome Atlas (TCGA) Provisional GBM database using cBioPortal 
(www.cbioportal.org) (Cerami et al., 2012; Gao et al., 2013). Analysis was limited to tumor 
samples with available copy number alteration (CNA) data (n = 577). Analysis of CHCHD2 
mRNA expression levels (HG-U133A Array) was compared among GBM tumors using 
publicly available data via Gliovis (http://gliovis.bioinfo.cnio.es/) (Bowman, Wang, Carro, 
Verhaak, & Squatrito, 2017). Tumors were stratified by variables including tumor grade, 
tumor vs non-tumor tissue, GBM subtype, G-CIMP status, IDH1 mutational status, and 
MGMT mutational status. 
 
Cell culture 
Human U87 GBM cells transduced to stably express the constitutively active EGFRvIII 
mutant (U87vIII) were generously provided by Dr. Nathan Price (Institute for Systems 
Biology, Seattle, WA). Cells were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 1 mM sodium pyruvate, 15 mM HEPES, non-essential amino acids 
(NEAA), 10% fetal bovine serum, and 1% penicillin/streptomycin. For hypoxic 
experiments, media was pre-equilibrated overnight at designated hypoxic oxygen 
conditions in order to account for time required for oxygen-saturated culture media to 
equilibrate with the gas atmosphere (Huttemann et al., 2007). Cells were then incubated 
in a BiospherixTM hypoxic incubator (BiospherixTM, Parish, NY). All cells were maintained 
at 37 °C and 5% CO2. 
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Generation of CHCHD2 knockout cells 
U87vIII CHCHD2 KO cells were derived using CRISPR-Cas9 genome engineering 
following published protocols (Ran et al., 2013). Suitable target sites within exons of the 
coding sequence for CHCHD2 were identified using the online WU-CRISPR design tool 
(Wong, Liu, & Wang, 2015). Potential guide RNA (gRNA) oligonucleotides were obtained 
from Integrated DNA Technologies (IDT, Coralville, IA). Each gRNA sequence was 20 
nucleotides in length and directly upstream of the protospacer adjacent motif (PAM) 5’-
NGG-3’. Three separate gRNA expression constructs were generated by cloning 
phosphorylated and annealed gRNA oligos into the BbsI (NEB, Ipswich, MA) site of the 
pSpCas9(BB)-2A-Puro expression vector (Addgene, Watertown, MA) for co-expression 
of each sgRNA with the Cas9 endonuclease. The integrity of constructs was confirmed 
by plasmid sequencing (University of Illinois Urbana-Champaign Roy J. Carver 
Biotechnology Center).  
U87vIII cells were transfected with Cas9-CHCHD2gRNA expression constructs using 
Lipofectamine 2000 Reagent according to the manufacturer’s protocol (ThermoFisher, 
Waltham, MA). Stably transfected cells were selected with puromycin (10 µg/mL). 
Successful CHCHD2 protein knockout was confirmed by western blot as described below. 
Assessment of genomic mutational status was conducted via nested PCR of the region 
containing the induced double-strand break using two primer sets. The PCR product was 
cloned into the pCR2.1-TOPO vector (TOPO TA Cloning Kit, ThermoFisher, Waltham, 
MA) and confirmed by sequencing (UIUC Roy J. Carver Biotechnology Center). 
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Western blot 
Total protein levels of CHCHD2 (1:500, NBP1-94106, Novus Biologicals, Centennial, 
CO), the glutamate-cystine antiporter xCT (1:500, ab37185, Abcam, Cambridge, UK), 
GPx-1/2 (1:100, sc-133160, Santa Cruz Biotechnology, Dallas, TX), GPx-4 (1:100, NBP2-
75511, Novus Biologicals, Centennial, CO), and matrix metalloproteinase 2 (MMP-2) 
(1:500, 10373-2-AP, Proteintech Group, Rosemont, IL) were compared in U87vIII 
CHCHD2 WT and KO cells using western blot. β-actin (1:1000, #4967, Cell Signaling 
Technology, Danvers, MA) was used as loading control. Total protein concentrations 
were determined using the Pierce BCA assay (Thermo Fisher, Waltham, MA). Protein 
lysates were mixed 1:1 with 2X Laemmli Sample Buffer (Bio-Rad, Hercules, CA) (5% β-
mercaptoethanol) and heated at 95 °C for 5-10 min. Denatured lysates were loaded into 
4-20% Mini-Protean ® TGXTM electrophoresis gels (Bio-Rad), and SDS-PAGE was run 
at 150 V for 1-1.5 h. Proteins were transferred to a nitrocellulose membrane (Amersham, 
Little Chalfont, UK) at 300 mA for 2 h at 4⁰ C. Membranes were then blocked with either 
5% BSA or 5% non-fat dry milk for 1 h at RT, then incubated in primary antibody at 
designated concentrations overnight at 4⁰ C. Membranes were washed in TBS-T for 5 
min 3x, then incubated in HRP-linked goat anti-rabbit secondary antibody (1:2500, #7074, 
Cell Signaling Technology, Danvers, MA) at RT for 1.5 h. Following TBS-T washes (3x 5 
min each), membranes were imaged using the SuperSignalTM West Femto Maximum 
Sensitivity Substrate (Thermo Fisher, Waltham, MA) in an ImageQuant LAS 4010 (GE 
Life Sciences, Pittsburgh, PA). Band densitometry analysis was performed using ImageJ. 
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Measurement of oxygen consumption rate 
Mitochondrial respiration of U87vIII CHCHD2 WT and KO cells was compared using the 
Seahorse XFp Extracellular Flux Analyzer. Cells were seeded at 1 × 104 cells/well five 
hours prior to conducting the mitochondrial stress test, according to the manufacturer’s 
protocol (Agilent, Santa Clara, CA). Serial applications of oligomycin (ATP synthase 
inhibitor, 1 µM), FCCP (protonophore, 0.5 µM), and rotenone and antimycin A (respiratory 
complex I and III inhibitor, respectively, 0.5 µM) over time enabled calculation of various 
parameters of mitochondrial respiration in both cell lines. 
 
Measurement of compartmentalized glutathione redox poise 
U87vIII CHCHD2 WT and KO cells were transfected with genetically encoded, fluorescent 
redox biosensors targeted to the cytosol (cyto-Grx1-roGFP2) or mitochondrial matrix 
(mito-Grx1-roGFP2), previously described by our lab (Kolossov et al., 2015). Cells 
expressing cytosolic or mitochondrial Grx1-roGFP2 were seeded at equal densities in 
standard culture medium without phenol red in µ-Slide eight-well ibiTreat microscopy 
chambers (Ibidi, Munich, Germany). Time-lapse images were collected with a 
fluorescence-enabled inverted microscope (Axiovert 200 M, Carl Zeiss, Feldbach, 
Switzerland). Dual-excitation imaging of live cells used 395 and 494 nm excitation cubes, 
and an emission filter at 527 nm was used for both cubes. Exposure times were set to 
100-200 ms, and images were taken every 15 s. To assess the effect of GSH synthesis 
inhibition on GSH:GSSG status, cells were pre-treated with buthionine sulfoximine (BSO, 
100 µM) for 24, 48, and 72 h before time-lapse image acquisition. Acquired images were 
processed with Zeiss Axiovision SE64 Rel6.8 software, via manual selection of three to 
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five individual cells to obtain multiple regions of interest in each time lapse. The means of 
emission intensities at 527 nm were exported to Excel files and corrected by background 
subtraction. 
 
Cell proliferation 
Proliferation of U87vIII CHCHD2 WT and KO cells was compared over 72 h in normoxic 
culture conditions (20% O2) and hypoxia (1% O2) using the sulforhodamine B assay 
according to published protocols (Vichai & Kirtikara, 2006). Briefly, cells were seeded at 
equal densities in a 96-well plate, followed by fixation with 10% trichloroacetic acid for 1 
h at 4⁰ C at 0 h and 72 h timepoints. After washing 4x with water and air-drying at RT, 
0.057% sulforhodamine B (SRB) solution (wt/vol in 1% acetic acid) was applied to each 
well and incubated for 30 min at RT, followed by washing 4x in 1% acetic acid. After 
drying, bound SRB was solubilized in 10 mM Tris base solution (pH 10.5), and plates 
were shaken for 30 min at RT. The optical density (OD) of each well was measured at 
510 using a BioTek SynergyTM HT microplate reader (BioTek, Winooski, VT). OD values 
at 72 h were corrected by 0 h OD subtraction to account for possible variations in initial 
seeding densities. 
 
Hydrogel preparation and measurement of cell invasion 
The invasive behavior of U87vIII CHCHD2 WT and KO cells was examined in normoxic 
culture conditions (20% O2) and hypoxia (1% O2). Invasion was quantified within 
methacrylamide-gelatin (GelMA) hydrogels via a bead invasion assay described 
previously (J.-W. E. Chen et al., 2018; J. E. Chen et al., 2018; J. E. Chen, Pedron, & 
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Harley, 2017). Hydrogels used in this study were made using 5% wt GelMA, ~53% degree 
of methacrylamide functionalization determined via H1-NMR (data not shown), and 
photopolymerized under UV light (AccuCure LED 365 nm, 7.1 mW cm-2 for 30 s) in the 
presence of a lithium acylphophinate photoinitiator. The compressive modulus of 5% wt 
GelMA hydrogels was measured using a Instron 5943 mechanical tester with the Young’s 
modulus obtained from the linear region of the stress-strain curve (0-10% strain) (J.-W. 
E. Chen et al., 2018). 
 To examine invasive behavior, U87vIII CHCHD2 WT and KO cells were seeded onto 
collagen-coated dextran beads (~200 µm diameter, GE Life Sciences, Pittsburgh, PA) at 
a density of 2 × 106 cells per 5 × 103 beads in 5 mL DMEM. Cell-bead suspensions were 
lightly shaken for one min, every 30 min, for 5 h to facilitate cell adhesion to beads. Cell-
coated beads were then encapsulated in pre-polymerized GelMA hydrogel solution, and 
bead-containing hydrogels were cultured in standard DMEM in either normoxic culture 
conditions (20% O2) or hypoxia (1% O2) for 7 days. Cell invasion distance was measured 
from the bead surface using ImageJ from images acquired via fluorescent microscopy 
after fixing and staining cells with DAPI (Invitrogen, Carlsbad, CA) (10 µg/mL in 1X PBS). 
Cell invasion is reported as the mean invasion of all cells from the surface of the bead (J. 
E. Chen et al., 2018). 
 
Cell cytotoxicity assays 
Sensitivity of U87vIII CHCHD2 WT and KO cells to a panel of cytotoxic agents was 
determined using the sulforhodamine B assay according to published protocols as 
described above (Vichai & Kirtikara, 2006). The cytotoxicity of sulfasalazine (SSZ, xCT 
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cystine-glutamate antiporter inhibitor), erlotinib (Erl, EGFR receptor tyrosine kinase 
inhibitor), temozolomide (TMZ, DNA alkylating agent), and Pac-1 (procaspase-3 
activator) (Joshi et al., 2017) were assessed using dosages derived from the literature. 
 
CHCHD2 protein levels in patient-derived cells cultured in GelMA hydrogels 
Total protein levels of CHCHD2 were analyzed in a panel of GBM patient-derived cells 
(PDCs) with disparate EGFR/PTEN status, MGMT methylation state, molecular subtype, 
invasive characteristics in mouse orthotopic xenografts (0: low, 7: hi), and sensitivity to 
erlotinib (0: not sensitive, 100: sensitive) (Figure 4.7A). PDCs were cultured in GelMA 
hydrogels without hyaluronic acid (HA) (7% wt GelMA) or with HA (6% wt GelMA, 1% wt 
HA). 
 
Statistical analysis 
Differences among means were tested for using Student’s t-test or one-way ANOVA, 
followed by post-hoc Student-Newman-Keuls analysis where appropriate. Statistical 
significance was set at p < 0.05. Variance is reported as standard error of the mean. Odds 
ratios for CHCHD2 co-amplification with EGFR and log-rank tests for overall and 
progression-free survival were conducted in cBioPortal (www.cbioportal.org). Tukey’s 
Honest Sigificant Difference or pairwise t-tests were conducted to compare mRNA 
expression levels in GlioVis (http://gliovis.bioinfo.cnio.es/). 
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4.3. RESULTS 
CHCHD2 is amplified in a subset of GBM tumors and is associated with decreased patient 
survival 
Analysis of CHCHD2 amplification patterns across GBM tumors was performed on The 
Cancer Genome Atlas (TCGA) Provisional GBM database using cBioPortal 
(www.cbioportal.org) (Cerami et al., 2012; Gao et al., 2013). Analysis was performed on 
tumor samples with available copy number alteration (CNA) data (n = 577). Amplification 
of CHCHD2 was observed in 9% of GBM tumors (Figure 4.1A). Of tumors with EGFR 
amplification, the most common genetic aberration across GBM tumors, CHCHD2 was 
co-amplified in 20% of cases, with a significant tendency to co-occur (log2 odds ratio > 3, 
p < 0.001) (Figure 4.1A). Of the 9 proteins in the CHCH domain-containing protein family, 
only CHCHD2 was amplified at an appreciable frequency, with the next most frequently 
Figure 4.1. cBioPortal analysis of CHCHD2 gene amplification patterns across GBM tumors. (A) Oncoprint 
from cBioPortal (www.cbioportal.org) representing tumors with amplification (red), deep deletion (blue), or no 
alteration (grey) of query genes. Percentages represent percentage of samples analyzed (tumor samples with 
available copy number alteration data, n = 577) with alteration in given gene. COA4 encodes CHCHD8. (B) Overall 
survival of patients with (red) and without (blue) CHCHD2 amplification. (C) Progression-free survival of patients 
with (red) and without (blue) CHCHD2 amplification. * p < 0.05, log-rank test conducted in cBioPortal. 
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amplified CHCH protein being CHCHD3 (1.2%) (Figure 4.1A). Additionally, patients with 
CHCHD2 amplified tumors had decreased overall survival (OS, 12.48 mo vs 14.45 mo, 
log-rank p = 0.0223) (Figure 4.1B) and progression-free survival (PFS, 4.86 mo vs 7.82 
mo, log-rank p = 0.0420) (Figure 4.1C). While this effect could potentially be explained 
by the propensity for EGFR to co-amplify with CHCHD2, amplification of EGFR was not 
solely associated with decreased patient survival (not shown). These data indicate that 
amplification of the CHCHD2 gene occurs in a subset of GBM tumors, is associated with 
decreased OS and PFS, and is nearly always accompanied by EGFR amplification.  
 Expression of CHCHD2 across brain tumors was further explored using the GlioVis 
data portal (http://gliovis.bioinfo.cnio.es/) (Bowman et al., 2017). CHCHD2 mRNA 
Figure 4.2. GlioVis analysis of CHCHD2 mRNA expression patterns across GBM tumors. CHCHD2 mRNA 
expression determined using Human Genome U133A Microarray was compared across (A) glioma grade (II, III, 
and IV), as well as GBM (B) IDH1 mutational status, (C) non-tumor vs tumor tissue, (D) GBM subtype (classical, 
mesenchymal, and proneural), (E) G-CIMP status, and (F) MGMT methylation status. Data were analyzed using 
Tukey’s Honest significance difference or pairwise t-test directly in GlioVis. * p < 0.001. 
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expression was observed to be increased in grade IV gliomas (GBM) relative to grade II 
and III (Figure 4.2A), as well as in IHD1-wt tumors compared to IDH1-mutant (Figure 
4.2B). CHCHD2 expression was also increased in GBM tumor compared to non-tumor 
tissue (Figure 4.2C). Additionally, CHCHD2 expression was increased in classical 
subtype tumors (Figure 4.2D), which are defined by chromosome 10 loss paired with 
chromosome 7 amplification and focused predilection for EGFR amplification. Tumors 
exhibiting genome-wide promoter hypermethylation, i.e. glioma-CpG island methylator 
phenotype (G-CIMP), displayed decreased CHCHD2 mRNA expression (Figure 4.2E). 
No differences in CHCHD2 expression were observed between MGMT methylated vs 
non-methylated tumors (Figure 4.2F).  
 
Knockout of CHCHD2 alters mitochondrial respiration in U87vIII cells 
U87vIII CHCHD2 KO cells were 
derived using CRISPR-Cas9 following 
published protocols, and protein 
knockout validated using western blot 
(Figure 4.3A) (Ran et al., 2013; Wong 
et al., 2015). To determine if CHCHD2 
KO impacted mitochondrial respiration 
in GBM cells, a mitochondrial stress 
test was conducted on U87vIII 
CHCHD2 WT and CHCHD2 KO cells 
using a Seahorse XFp Extracellular Flux Analyzer (Figure 4.3B) (Divakaruni, Paradyse, 
Figure 4.3. Mitochondrial respiration in U87vIII CHCHD2 
WT and KO cells. (A) Western blot of U87vIII and U87vIII 
CHCHD2 KO cells. (B) Oxygen consumption rate (OCR) 
traces of U87vIII CHCHD2 WT and KO cells during 
mitochondrial stress test. (C) Basal OCR, (D) maximal 
respiration, (E) spare respiratory capacity, and (F) OCR 
coupled to ATP production in U87vIII CHCHD2 WT and KO 
cells. Data presented as mean ± SE, n = 2 * p < 0.05. 
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Ferrick, Murphy, & Jastroch, 2014). CHCHD2 KO cells displayed decreased basal and 
maximal oxygen consumption rate (OCR) (Figure 4.3C-D). Spare respiratory capacity 
was also significantly lower in CHCHD2 KO cells (Figure 4.3E), indicating a decreased 
ability of U87vIII CHCHD2 KO cells to respond to increased energy demand. Additionally, 
the amount of oxygen consumed coupled to ATP production by ATP synthase was 
significantly lower in CHCHD2 KO cells (Figure 4.3F). Collectively, these data indicate 
that CHCHD2 is required for efficient mitochondrial respiration in U87 GBM cells 
expressing EGFRvIII.  
 
Knockout of CHCHD2 leads to a more reduced glutathione redox potential in the 
mitochondrial matrix 
It was further hypothesized that perturbed mitochondrial respiration and deficient electron 
transport chain function would result in a more oxidized intracellular redox environment. 
Glutathione (GSH), an enzymatically produced tripeptide of cysteine, glycine, and 
glutamate, is the main intracellular redox buffer, which, along with thioredoxins and 
glutaredoxins, maintains thiol redox status (Hanschmann, Godoy, Berndt, Hudemann, & 
Lillig, 2013). The glutathione redox couple (reduced and oxidized glutathione, GSH and 
GSSG respectively), along with glutathione peroxidase (GPx) and glutathione reductase 
(GR), comprises the glutathione system, which maintains thiol redox homeostasis and 
functions in antioxidant defense (Estrela, Ortega, & Obrador, 2006). The balance of 
reduced to oxidized glutathione (GSH:GSSG) thus represents intracellular redox status, 
and can be interrogated within live cells using genetically encoded, fluorescent redox 
biosensors (Grx1-roGFP2) (Figure 4.4A). Additionally, such probes can be targeted to 
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various subcellular compartments, including cytosol (cyto-Grx1-roGFP2) or mitochondrial 
matrix (mito-Grx1-roGFP2) to measure compartmentalized GSH redox status in live cells 
in real time via ratiometric fluorescence intensity measurements (Figure 4.4B) (Kolossov 
et al., 2015). 
 The percent of oxidized mito-Grx1-roGFP2 in U87vIII CHCHD2 KO cells was 
decreased by 15.8% compared to that measured in CHCHD2 WT cells, indicating that 
the pool of glutathione in the mitochondrial matrix of KO cells is more reduced than WT 
counterparts (Figure 4.4C). This effect was confined to the mitochondrial matrix, as the 
Figure 4.4. Glutathione redox status in U87vIII CHCHD2 WT and KO cells. (A) Schematic of the molecular 
mechanism of the Grx1-roGFP2 sensor and redox response of the compartmentalized probe to exogenous oxidant 
and reductant. Superoxide (•O2−) is rapidly converted by superoxide dismutase (SOD) into H2O2, which is then 
reduced by glutathione peroxidase (GPx) to water. Glutaredoxin (Grx) fused to roGFP2 efficiently and rapidly 
equilibrates the probe with alterations in the local GSH:GSSG ratio. Additionally, thiol-disulfide equilibration is 
reversible, as GSH reductase (GR) catalyzes reduction of GSSG to GSH. (B) Representative fluorescence images 
demonstrate the sensor targeted to mitochondria of U87vIII CHCHD2 WT (left) and KO cells (right). (B’) 
Corresponding time-lapse responses of the 395/494 nm ratio to treatment with 1 mM diamide (vertical solid line) to 
the fully oxidized state and 10 mM DTT (vertical dashed line) to the fully reduced state. Each trace designates a 
separate cell. Arrows represent basal oxidation level of probe. (C) Percent oxidized mito-Grx1-roGFP2 and (D) 
cyto-Grx1-roGFP2 in U87vIII CHCHD2 WT and KO cells. (E) Percent oxidized mito-Grx1-roGFP2 in U87vIII 
CHCHD2 WT and KO cells at baseline and after treatment with GSH synthesis inhibitor BSO for 24, 48, and 72 h. 
(F) Western blot of xCT, GPx-1/2, and GPx-4 in U87vIII CHCHD2 WT and KO cells. Data are presented as mean 
± SE, n = 3 *, differing superscript: p < 0.05. 
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cytosolic glutathione pool was not affected by CHCHD2 KO (Figure 4.4D). Treatment 
with buthionine sulfoximine (BSO), an inhibitor of glutamate-cysteine ligase (GCL, the 
rate-limiting enzyme in GSH synthesis), led to similar oxidation of the glutathione pool 
over time in the mitochondrial matrix of both U87vIII CHCHD2 WT and KO cells (Figure 
4.4E). Additionally, levels of components of the glutathione system, including the 
glutamate-cystine antiporter xCT, GPx-1/2, and GPx-4, were all unaltered in CHCHD2 
KO cells (Figure 4.4F). These data demonstrate a role for CHCHD2 in mediating 
glutathione redox balance specifically in the mitochondrial matrix, albeit through a 
mechanism not involving GSH synthesis, cystine import through xCT, or reduced GSH 
flux through glutathione peroxidases 1, 2, or 4.  
 
U87vIII cell growth and invasion are negatively impacted by CHCHD2 KO in both 
normoxia and hypoxia 
The observed deficiencies in mitochondrial respiration led to the hypothesis that U87vIII 
GBM cell growth would be negatively impacted by CHCHD2 KO. To test this hypothesis, 
U87vIII CHCHD2 WT and KO cells were incubated in either standard oxygen culture 
conditions (normoxia, 20% O2) or pathophysiologically relevant hypoxia (1% O2). Utilizing 
the sulforhodamine B (SRB) colorimetric assay (Vichai & Kirtikara, 2006) to assess cell 
growth over 72 h, CHCHD2 WT cell growth was observed to be significantly increased in 
hypoxia (Figure 4.5A). CHCHD2 KO cell growth was decreased compared to normoxic 
control (Figure 4.5A). Additionally, the growth-inducing effect of hypoxia on U87vIII cells 
was abrogated upon CHCHD2 KO (Figure 4.5A). These results demonstrate that 
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CHCHD2 is involved in not only mediating U87vIII cell growth in normoxia, but also plays 
a role in the initial increased cell proliferation observed in hypoxic cells. 
 Rapid, diffuse invasion of GBM cells into tumor margins and into surrounding brain 
parenchyma represents a major obstacle impeding effective tumor treatment. To 
determine whether CHCHD2 knockout impacted GBM cell invasion, a bead invasion 
assay in methacrylated gelatin (GelMA) hydrogels (Young’s modulus 2.9 ± 0.45 kPa) was 
used as a three-dimensional culture platform to model biophysical aspects of the brain 
parenchyma and GBM cell invasion (J.-W. E. Chen et al., 2018; J. E. Chen et al., 2018; 
J. E. Chen et al., 2017). This technique enables monitoring of cell invasion from a defined 
starting point in a spatiotemporal manner in normal as well as hypoxic three-dimensional 
culture conditions (Figure 4.5B). Hypoxia (1% O2) stimulated U87vIII cell invasion over 
Figure 4.5. Growth and invasion of U87vIII CHCHD2 WT and KO cells in normoxia and hypoxia. (A) Cell 
growth of U87vIII CHCHD2 WT and KO cells over 72 h in standard oxygen conditions (21% O2) and hypoxia (1% 
O2) determined using the SRB assay. (B) Representative images of U87vIII CHCHD2 WT and KO cells stained for 
DAPI after incubation in 21% or 1% O2 for 7 days during bead invasion assay. Associated ImageJ-derived images 
for average invasion distance analysis are displayed below corresponding fluorescence images. (C) Quantification 
of U87vIII CHCHD2 WT and KO invasion as determined by the bead invasion assay. (D) Western blot of pro-MMP-
2 levels in U87vIII CHCHD2 WT and KO cells and fold-change normalized to β-actin loading control. Data are 
presented as mean ± SE, n = 3. Differing superscript, *: p < 0.05. 
61 
 
long-term culture (7 d) (Figure 4.5C). In contrast, U87vIII CHCHD2 KO cells displayed 
minimal cell invasion in both normoxia and hypoxia, with the hypoxia-induced invasion 
observed in CHCHD2 WT cells abrogated (Figure 4.5C). Furthermore, CHCHD2 KO cells 
displayed decreased levels of pro-MMP-2 (matrix metalloproteinase 2) (Figure 4.5D), a 
key protein involved in the breakdown of extracellular matrix. These data demonstrate a 
role for CHCHD2 in mediating U87vIII cell invasion, particularly in response to hypoxia.  
 
CHCHD2 knockout increases U87vIII sensitivity to a variety of cytotoxic drugs 
To determine the effect 
of CHCHD2 KO on 
cellular resistance to 
various drugs, cells were 
treated with increasing 
concentrations of a 
panel of agents, and 
cytotoxicity was 
assessed using the SRB 
assay (Vichai & Kirtikara, 
2006). Included in this 
panel were: 
temozolomide (TMZ), a DNA-alkylating agent and the standard-of-care chemotherapy 
administered to patients with GBM (Stupp et al., 2005); erlotinib (Erl), a receptor tyrosine 
kinase inhibitor that inhibits EGFR and EGFRvIII tyrosine kinase activity (Raizer et al., 
Figure 4.6. Sensitivity of U87vIII CHCHD2 WT and KO cells to various 
cytotoxic agents. Sensitivity of U87vIII and CHCHD2 KO cells to (A) 
sulfasalazine, (B) erlotinib, (C) temozolomide, and (D) Pac-1 determined using 
the SRB assay. Data are presented as percent of untreated control, mean ± 
SE, n = 3. Differing superscript: p < 0.05. 
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2010); sulfasalazine (SSZ), an inhibitor of the cell membrane xCT antiporter, which 
couples the export of the amino acid glutamate with the import of cystine, thus depriving 
cells of the rate-limiting substrate to synthesize reduced GSH (L. Chen et al., 2015; 
Huberfeld & Vecht, 2016); and Pac-1, a novel activator of apoptosis which acts on 
procaspase-3 (Joshi et al., 2017). Results, shown in Figure 4.6, demonstrate that 
CHCHD2 KO cells were more susceptible to treatment with TMZ, Erl, and most 
significantly, SSZ. However, CHCHD2 KO had no effect on cellular sensitivity to treatment 
with Pac-1 (Figure 4.6D), consistent with previous work demonstrating that CHCHD2 
regulates apoptosis upstream of procaspase-3 activity in the apoptotic cascade (Y. Liu et 
al., 2015). These results demonstrate a role for CHCHD2 in mediating cell sensitivity to 
various drugs relevant to GBM treatment, highlighting CHCHD2 as a promising avenue 
for future investigation.  
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CHCHD2 protein levels vary across GBM patient-derived cell samples 
Total protein levels of CHCHD2 were analyzed in a panel of GBM patient-derived cells 
(PDCs) cultured in GelMA hydrogels with extracellular HA (6% wt gelatin, 1% wt HA) or 
without HA (7% wt gelatin). PDCs were characterized by disparate EGFR/PTEN status, 
MGMT methylation state, molecular subtype, invasive characteristics in mouse orthotopic 
xenografts (0: low, 7: hi), and sensitivity to erlotinib (0: not sensitive, 100: sensitive) 
(Figure 4.7A). Included in this panel were: GBM10 (EGFR-/PTEN-), GBM44 (EGFR-
/PTEN-), GBM12 (EGFR+/PTENwt), GBM39 (EGFRvIII/PTENwt), and GBM6 
(EGFRvIII/PTENwt). When PDCs were cultured in GelMA hydrogels without HA, GBM6 
expressed the greatest amount of CHCHD2, followed by GBM44 and GBM12, and 
GBM10 and GBM39 (Figure 4.7B). When HA was included in the hydrogel matrix, GBM6 
Figure 4.7. CHCHD2 protein levels in GBM patient-derived cells. (A) Patient-derived xenograft (PDX) subset 
analyzed in the current study, with descriptors including EGFR/PTEN status, patient status, invasion in mouse 
orthotopic xenografts, erlotinib sensitivity, MGMT methylation status, and subtype. (B) CHCHD2 total protein levels 
in patient-derived cell (PDC) samples from each PDX cultured in GelMA hydrogels without hyaluronic acid (HA) 
(7% wt GelMA). (C) CHCHD2 total protein levels in PDC samples from each PDX cultured in GelMA hydrogels 
containing matrix-immobilized HA (6% wt GelMA, 1% wt HA). (D) Effect of matrix-immobilized HA on CHCHD2 total 
protein levels in each PDC. Data are presented as mean ± SE, n = 3 samples. Differing superscript: p < 0.05. * 
denotes significant effect of HA, p < 0.05 
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and GBM12 expressed the greatest amount of CHCHD2 (Figure 4.7C). GBM39 
responded most strikingly to the presence of HA in the extracellular matrix (Figure 4.7D). 
These data demonstrate heterogeneity in CHCHD2 expression among tumor samples, 
as well as in response to the presence of extracellular HA.  
 
4.4 DISCUSSION 
The current work investigated the functional capacity of CHCHD2, a dually-localized 
protein implicated in mitochondria-to-nucleus retrograde signaling (Aras et al., 2015), in 
the context of GBM. The challenges associated with achieving robust survival benefits in 
patients with GBM has prompted the need for a deeper understanding of intracellular 
events mediating cellular plasticity, tumor malignancy, and recurrence. CHCHD2 
presented as a promising avenue to pursue, given: 1) its proximity to and frequency of 
co-amplification with EGFR in NSCLC and GBM (Figure 4.1A) (Wei et al., 2015), both of 
which have recently been characterized as relatively oxidative versus fermentative tumors 
(Courtney et al., 2018); 2) its mRNA expression patterns across glioma grade and tumor 
vs non-tumor tissue (Figure 4.2A, C); 3) its reported oxygen-sensitive transcription factor 
activity (Aras et al., 2013); and 4) its pleiotropic roles mediating cellular functions 
reminiscent of cancer hallmarks, including cell proliferation, migration and invasion, and 
inhibition of apoptosis (Aras et al., 2015; Y. Liu et al., 2015; Seo et al., 2010). Here, we 
demonstrate that CHCHD2 is involved in mediating cell growth and invasion in response 
to hypoxia, as well as therapeutic sensitivity, in GBM cells expressing mutant EGFRvIII. 
 Knockout of CHCHD2 in U87vIII GBM cells resulted in decreased baseline respiration 
as well as spare respiratory capacity (Figure 4.3), an effect corroborated by multiple 
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studies which have characterized CHCHD2 as a canonical regulator of mitochondrial 
respiration (Aras et al., 2015; Baughman et al., 2009; Meng et al., 2017; Wei et al., 2015). 
While metabolic reprogramming towards increased glycolytic flux to favor increased cell 
proliferation is an emerging and increasingly recognized hallmark of cancer (Hanahan & 
Weinberg, 2011), functional mitochondria remain essential in maintaining malignant cell 
bioenergetics in particular tumors, including those of lung and brain (Courtney et al., 2018; 
Marin-Valencia et al., 2012; Pavlova & Thompson, 2016). Notably, mitochondrial spare 
respiratory capacity has been positively associated with glioma stem cell resistance to 
radiotherapy (Vlashi et al., 2011). Thus, the decreased spare respiratory capacity 
measured in U87vIII CHCHD2 KO cells (Figure 4.3E) may partially contribute to their 
increased sensitivity to treatment with TMZ, Erl, and SSZ (Figure 4.6A-C).  
 Additionally, CHCHD2 has been demonstrated by others to mediate mitochondrial 
outer membrane permeabilization (MOMP) (Y. Liu et al., 2015), the “point of no return” 
during the intrinsic pathway of apoptosis. Indeed, U87vIII CHCHD2 KO cells exhibited 
increased sensitivity to TMZ, Erl, and SSZ. The observation that no increase in 
cytotoxicity was seen in CHCHD2 KO cells treated with Pac-1, an activator of procaspase-
3 which acts downstream of MOMP in the apoptotic cascade (Joshi et al., 2017), further 
corroborates the demonstrated role of CHCHD2 early in apoptosis regulation. 
 Notably, as evidenced by the use of mito-Grx1-roGFP2, the mitochondrial GSH pool 
was more reduced in response to CHCHD2 KO compared to WT, an effect independent 
of GSH biosynthesis (Figure 4.4E). It should be noted that roGFP2 itself is not directly 
oxidized by ROS species, and rather equilibrates with the local GSH redox potential, 
which is influenced by the GSH:GSSG ratio, and in turn is influenced by activity of various 
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ROS-scavenging enzymes that use GSH as a cofactor (Figure 4.4A). In HEK293 cells, 
CHCHD2 knockdown was accompanied by decreased expression of superoxide 
dismutase 2 (SOD2/Mn-SOD) and loss of glutathione peroxidase (GPx) expression (Aras 
et al., 2015). However, we did not observe changes in protein levels of GPx-1/2, GPx-4, 
nor the glutamate-cystine antiporter xCT (Figure 4.4F). 
 In the current work, incubation in hypoxia increased U87vIII CHCHD2 WT cell 
proliferation over 3 days, and increased invasion over 7 days (Figure 4.5A-C). Using the 
GelMA hydrogel platforms described here, previous work from our demonstrated that 
hypoxic U87vIII cells exhibited increased cell proliferation until day 5, at which point cell 
proliferation stalled, while invasion continued to increase up to day 7 (J. E. Chen et al., 
2018). Notably, CHCHD2 KO abrogated the increased cell growth and invasion in hypoxia 
exhibited by WT cells (Figure 4.5A-C). The observed decrease in U87vIII CHCHD2 KO 
cell growth is not likely due to an increase in apoptosis, as evidence has indicated that 
shRNA-mediated CHCHD2 knockdown does not alter cellular levels of poly (ADP-ribose) 
polymerase (PARP) (Aras et al., 2015), the cleavage of which by caspases is a 
characteristic of apoptosis (Chaitanya, Steven, & Babu, 2010). Deficiencies in 
mitochondrial respiration and ATP production are likely responsible for hampering cell 
proliferative capacity, and may also be implicated in the repression of cell invasion, as 
migration and invasion throughout parenchyma is an energy-expensive process, 
particularly when moving through dense extracellular matrices (Zanotelli et al., 2018). The 
observed decrease in pro-MMP-2 expression in CHCHD2 KO cells provides further 
explanation for their decrease in invasive capacity (Figure 4.5D). Other work has 
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highlighted CHCHD2 as an activator of NIH3T3 fibroblast migration via the AKT-
RhoA/ROCK-JNK cascade (Seo et al., 2010). 
 Analysis of CHCHD2 gene amplification, mRNA expression, and protein levels in a 
subset of clinical patient-derived samples further revealed intriguing patterns indicating 
an involvement of CHCHD2 in supporting GBM malignant characteristics. Of note, 
CHCHD2 mRNA expression was increased in GBM vs grade II and III gliomas, as well as 
in GBM tumor compared to non-tumor tissue (Figure 4.2A, C). Additionally, among GBM 
subtypes, CHCHD2 expression was greatest in the classical subtype (Figure 4.2D), an 
observation consistent with GBM6 (classical subtype) exhibiting greater levels than all 
other PDCs analyzed in this study (which were classified as mesenchymal subtype) 
(Figure 4.7A, B). Notably, GBM6 also expresses mutant EGFRvIII, is relatively resistant 
to erlotinib, and is the most invasive PDC sample analyzed (Figure 4.7A, B). 
 Functional outcomes investigated here relate primarily to mitochondrial functions of 
CHCHD2. As a protein implicated in mitonuclear communication in response to hypoxia, 
the nuclear functions of CHCHD2 in GBM cells and the panel of nuclear genes it regulates 
are of equal importance and areas of future work. Evidence in the literature indicates that 
CHCHD2 acts as a nuclear transcription factor in hypoxia, maximally active at 4% O2, to 
increase gene expression of cytochrome c oxidase subunit 4 isoform 2 (COX4I2) and 
itself (Aras et al., 2013), an effect we did not observe in U87vIII cells, as COX4I2 is a 
tissue-specific isoform highly expressed in lung and trachea (data not shown). It is 
tempting to speculate that the abrogated proliferative and invasive responses of CHCHD2 
KO cells are due to a disturbance of a CHCHD2-mediated mitonuclear communication 
network. The nuclear function of CHCHD2 was demonstrated to act in concert with other 
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transcription factors, namely recombining binding protein suppressor of hairless (RBPJ) 
(Aras et al., 2013), the main downstream effector protein of the Notch signaling pathway, 
which has been implicated in the maintenance of glioma stem cell maintenance and 
viability (Q. Xie et al., 2016). Future work should seek to identify the complement of genes 
regulated by CHCHD2 in both normal oxygen conditions as well as hypoxia to provide a 
deeper understanding of CHCHD2 function in GBM. 
 
4.5. CONCLUSIONS 
This study is the first to describe the functional relevance of CHCHD2 in GBM. These 
data indicate that CHCHD2 is essential for mitochondrial respiration and maintenance of 
mitochondrial GSH status in U87vIII cells. Additionally, these studies demonstrate a 
critical role for CHCHD2 in mediating cell growth and invasion in normoxia and hypoxia 
and resistance to various cytotoxic agents in U87 GBM cells expressing the mutant 
EGFRvIII, underscoring CHCHD2 as a mediator of GBM cell malignant phenotype. 
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CHAPTER 5: DEFINING THE RELATIONSHIP BETWEEN HYPOXIA, REDOX 
STATUS, AND SUBCELLULAR LOCALIZATION OF CHCHD2 IN GLIOBLASTOMA 
CELLS 
ABSTRACT 
INTRODUCTION 
Glioblastoma (GBM) is the most common and malignant form of primary brain tumor in 
adults and remains incurable. Inter-organelle communication between mitochondria and 
the nucleus represents a potential compensatory signaling pathway that may allow cells 
to sense and respond to external stress and fluctuations in intracellular conditions, and 
consequently contribute to therapeutic resistance and cellular plasticity in a hypoxic tumor 
microenvironment. Coiled-coil-helix-coiled-coil-helix domain-containing protein 2 
(CHCHD2) is a protein that colocalizes to the mitochondrial inter-membrane space and 
the nucleus, the latter wherein it exhibits hypoxia-sensitive transcription factor capabilities 
(Aras et al., 2013). The C-terminus of CHCHD2 contains redox-sensitive cysteines in twin 
CX9C motifs that are amenable to thiol/disulfide formation, which in turn determines 
protein folding and import into mitochondria. The objective of this study was to 
characterize the effects of hypoxia and cellular redox status on CHCHD2 subcellular 
localization. The hypothesis was that reducing the C-terminal CHCH domain would 
induce mitochondrial export of CHCHD2. 
METHODS 
U87 and U87vIII GBM cells (the latter of which are transduced to stably express the 
constitutively active EGFRvIII mutant) were incubated for 48 h either in standard culture 
oxygen conditions (20% O2), 7% O2, 4% O2, or 1% O2. Total protein levels of CHCHD2 
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in response to decreasing oxygen tension were analyzed via western blot. Protein 
turnover of CHCHD2 was determined by incubation of cells in cycloheximide (CHX, 10 
µg/mL) followed by total protein lysis at designated time points. Subcellular localization of 
CHCHD2 was observed in U87 and U87vIII cells expressing the pDsRed2-Mito 
fluorescent mitochondrial marker incubated in 20% and 1% O2 for 48 h, buthionine 
sulfoximine (BSO) or N-acetylcysteine (NAC) for 48 h, or in serum-free media for 30 min. 
Acute chemical oxidation and reduction of cells was achieved using hydrogen peroxide 
(H2O2) and dithiothreitol (DTT), respectively, at designated concentrations and time 
courses. The ability of CHCHD2 to induce expression of itself in U87vIII cells was 
assessed by ectopic expression of 3X-FLAG-tagged CHCHD2, followed by western blot 
analysis of endogenous CHCHD2 band intensity. 
RESULTS 
Total CHCHD2 protein levels were not significantly altered by decreasing oxygen tensions 
in U87 cells. U87vIII cells exhibited constant levels of total CHCHD2 protein at 20%, 7%, 
and 4% O2; however, incubation in 1% O2 led to a significant decrease in total CHCHD2. 
Half-life of CHCHD2 was determined to be approximately 3 h in both U87 and U87vIII 
cells. U87vIII cells constitutively displayed a greater amount of nuclear CHCHD2 
compared to isogenic U87 cells at 20% O2. Metabolic stress induced by incubation in 1% 
O2 for 48 h or serum-free media for 30 min both resulted in increased CHCHD2 detected 
in nuclei of U87 and U87vIII cells. Oxidative stress induced by the glutathione synthesis 
inhibitor BSO increased nuclear CHCHD2 in U87vIII cells, while the glutathione precursor 
NAC did not affect nuclear CHCHD2 levels. Including H2O2 in serum-free media 
abrogated the amount of nuclear CHCHD2 detected in nuclei of U87 and U87vIII cells. 
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Reductive unfolding of CHCHD2 with the disulfide reductant DTT consistently resulted in 
the greatest and most drastic nuclear accumulation of CHCHD2 in both cell lines within 
15-30 min. Ectopic expression of exogenous 3X-FLAG-tagged CHCHD2 in U87vIII cells 
did not result in increased expression of endogenous CHCHD2. 
CONCLUSIONS 
Collectively, these data demonstrate subcellular redistribution via translocation of 
CHCHD2 from mitochondria to the nucleus in response to metabolic stress induced by 
hypoxia and serum deprivation. Furthermore, the data indicate that reductive unfolding of 
CHCHD2 is responsible for mitochondrial export and nuclear translocation. However, the 
functional relevance of nuclear CHCHD2 remains to be determined, as introduction of 
exogenous 3x-FLAG-tagged CHCHD2 did not induce expression of endogenous 
CHCHD2 in U87vIII cells. 
 
5.1. INTRODUCTION 
Mitochondria are critical for a variety of cellular functions, including regulation of the 
intrinsic pathway of apoptosis, calcium signaling, generation of heme and iron-sulfur 
clusters, carbohydrate and fatty acid metabolism, redox homeostasis, and generation of 
reactive oxygen species (ROS) as signaling molecules (Connolly et al., 2018; Guha & 
Avadhani, 2013). Arguably, the most widely recognized function of mitochondria is the 
oxygen-dependent generation of energy in the form of ATP, driven by chemiosmosis of 
protons down their electrochemical gradient across the inner mitochondrial membrane 
through ATP synthase, which couples this movement with the phosphorylation of ADP. 
This gradient of protons is generated by the actions of the electron transport chain (ETC), 
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comprised of Complex I (NADH:ubiquinone oxidoreductase/NADH dehydrogenase), 
Complex II (succinate-ubiquinone oxidoreductase/succinate dehydrogenase), Complex 
III (ubiquinol-cytochrome c oxidoreductase), and the oxygen consuming Complex IV 
(cytochrome c oxidase). 
 In addition to regulating cellular energy conservation, mitochondria also serve as 
crucial signaling organelles. The vast majority of mitochondrial proteins are encoded by 
nuclear genes, necessitating the ability for mitochondria to communicate their status to 
the nucleus in response to metabolic perturbations. Indeed, only 13 of the 90 protein 
subunits that comprise the respiratory complexes that constitute the electron transport 
chain are encoded by mitochondrial DNA, while the majority of respiratory subunits and 
mitochondrial proteome are encoded by the nuclear genome (Baughman et al., 2009; 
Guha & Avadhani, 2013) Disturbances in ATP and ROS production, damage to 
mitochondrial DNA, and aberrations in mitochondrial protein folding induce a retrograde 
signaling pathway by which mitochondria can communicate with the nucleus to induce 
changes in nuclear gene expression in order to maintain metabolic homeostasis and 
mitochondrial biogenesis (Eisenberg-Bord & Schuldiner, 2017). Several proteins have 
been demonstrated to participate in inter-organelle signaling between mitochondria and 
the nucleus, including p53, fumarase, the pyruvate dehydrogenase complex, and coiled-
coil-helix-coiled-coil-helix domain-containing protein 2 (CHCHD2) (Aras et al., 2015; 
Sutendra et al., 2014; Yogev et al., 2011; Zhuang et al., 2013). 
CHCHD2 is a 16 kDa protein and member of the evolutionarily conserved, 
mitochondrial CHCH domain-containing protein family. The CHCHD2 gene is located on 
chromosome 7p11.2 and encodes the 151 amino acid CHCHD2 protein, characterized 
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by its C-terminal CHCH domain. This domain is defined by two cysteine-X9-cysteine 
motifs (twin CX9C), each consisting of two cysteines (Cys) separated by 9 amino acids. 
Two disulfide bonds, formed between Cys114-Cys144 and Cys124-Cys134, stabilize the helix-
turn-helix fold of the CHCH domain. These Cys residues are indispensable for proper 
protein folding and import of CHCHD2 into the mitochondrial inter-membrane space (IMS) 
via the CHCHD4-mediated disulfide relay system (Aras et al., 2015). Furthermore, the N-
terminus of CHCHD2 harbors a putative mitochondrial localization sequence defined by 
amino acid residues 1-53 (Aras et al., 2015). Moreover, the amino acid sequence of 
CHCHD2 is highly conserved among human, chimpanzee, mouse, rat, zebrafish, and 
other metazoan species, as well as yeast, suggesting a critical function across species 
(Modjtahedi et al., 2016). 
Previous studies implicate CHCHD2 as a protein involved in mitonuclear 
communication with the ability to act as a nuclear transcription factor in response to 
hypoxia, inducing expression of complex IV subunit 4 isoform 2 (COX4I2) and itself 
maximally at 4% O2 (Aras et al., 2013). Notably, hypoxia is a key component of the 
glioblastoma (GBM) tumor microenvironment, inducing intracellular signaling, canonically 
via hypoxia inducible factors (HIFs), which in turn promotes malignant characteristics 
such as cell invasion and therapeutic resistance (J. E. Chen et al., 2018; W. L. Chen, 
Wang, Lin, Wu, & Hsieh, 2015; Monteiro et al., 2017). However, the subcellular 
localization, distribution, and dynamics of CHCHD2 in GBM cells in response to hypoxia 
has not been described. Additionally, a mechanism governing its mitochondrial export 
and subcellular redistribution remains elusive. 
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Mitochondria-to-nucleus retrograde signaling is a signaling axis that can potentially be 
undermined to combat progression and malignancy of cancers, including GBM, the 
plasticity of which has undermined attempts at successful therapies. The objective of this 
study was to interrogate the intracellular dynamics of CHCHD2 in response to metabolic 
stressors in U87 and U87vIII GBM cells. The hypothesis was that the cysteines defining 
the CHCH domain acted as redox-sensitive “switches,” governing CHCHD2 protein 
folding and subcellular localization in response to metabolic and/or redox stress. Hypoxia 
and serum deprivation were used to model metabolic stressors imposed by the tumor 
microenvironment. Treatment with the glutathione synthesis inhibitor buthionine 
sulfoximine (BSO), as well as with the glutathione precursor N-acetylcysteine (NAC), 
were used to model oxidative and reductive stress, respectively. Acute chemical oxidation 
and reduction with H2O2 and the disulfide reductant dithiothreitol (DTT), respectively, were 
used to investigate the relationship between CHCHD2 protein folding and subcellular 
localization. 
 
5.2. METHODS 
Cell culture 
The human U87 parental GBM cell line, as well as U87 GBM cells transduced to stably 
express the constitutively active EGFRvIII mutant (U87vIII) were generously provided by 
Dr. Nathan Price (Institute for Systems Biology, Seattle, WA). U87 and U87vIII cells 
transfected to express the pDsRed2-Mito fluorescent mitochondrial marker were used for 
a subset of immunofluorescence experiments. Cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 1 mM sodium pyruvate, 15 mM HEPES, non-
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essential amino acids, 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin. 
Media devoid of FBS was used for serum deprivation experiments. Media without phenol 
red was used for immunofluorescence experiments. 
 
Hypoxic cell culture 
For hypoxic experiments, media was pre-equilibrated overnight in a BioSpherixTM hypoxic 
incubator (BioSpherix, Parish, NY) at designated oxygen concentrations (7%, 4%, and 
1%) to account for time required for oxygen-saturated media to equilibrate with the gas 
atmosphere (Huttemann et al., 2007). Standard culture conditions are designated as 
normoxia (20% O2). All cells were maintained at 37 °C and 5% CO2. 
 
Chemically-induced oxidation and reduction 
To model the relationship between CHCHD2 protein folding and subcellular localization, 
chemically induced oxidation and reduction of U87 and U87vIII cells was achieved by 
incubation in hydrogen peroxide (H2O2) or dithiothreitol (DTT) at designated 
concentrations (1, 5, 10 mM) for 15 or 30 min. Additionally, treatment with the glutamate-
cysteine ligase inhibitor L-buthionine sulfoximine (BSO, 100 µM, 48 h), as well as with the 
glutathione precursor N-acetyl-L-cysteine (NAC, 1 mM, 48 h), were employed as 
alternative oxidant and reductant, respectively. 
 
Western blot 
Total protein levels of CHCHD2 (1:500, NBP1-94106, Novus Biologicals, Centennial, CO) 
were compared in U87 and U87vIII cells exposed to decreasing oxygen tensions using 
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western blot. β-actin (1:1000, #4967, Cell Signaling Technology, Danvers, MA) was used 
as loading control. Total protein concentrations were determined using the Pierce BCA 
assay (Thermo Fisher, Waltham, MA). Protein lysates were mixed 1:1 with 2X Laemmli 
Sample Buffer (Bio-Rad, Hercules, CA) (5% β-mercaptoethanol) and heated at 95 °C for 
5-10 min. Denatured lysates were loaded into 4-20% Mini-Protean ® TGXTM 
electrophoresis gels (Bio-Rad, Hercules, CA), and SDS-PAGE was run at 150 V for 1-1.5 
h. Proteins were transferred to a nitrocellulose membrane (Amersham, Little Chalfont, 
UK) at 300 mA for 2 h at 4⁰ C. Membranes were then blocked with either 5% BSA or 5% 
non-fat dry milk for 1 h at RT, then incubated in primary antibody at designated 
concentrations overnight at 4⁰ C. Membranes were washed in TBS-T for 5 min 3x, then 
incubated in HRP-linked goat anti-rabbit secondary antibody (1:2500, #7074, Cell 
Signaling Technology, Danvers, MA) at RT for 1.5 h. Following TBS-T washes (3x 5 min 
each), membranes were imaged using the SuperSignalTM West Femto Maximum 
Sensitivity Substrate (Thermo Fisher, Waltham, MA) in an ImageQuant LAS 4010 (GE 
Life Sciences, Pittsburgh, PA). Analysis of bands was conducted using ImageJ. 
 
RT-qPCR 
Gene expression of CHCHD2 in hypoxic (1% O2) or physiological (7% O2) oxygen levels 
was measured in U87 and U87vIII cells using TaqMan gene expression probes 
(Hs00853326_g1, Thermo Fisher). Total cellular RNA was isolated from cells using the 
RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 
Complementary DNA (cDNA) was generated by reverse transcriptase polymerase chain 
reaction using the High Capacity cDNA Reverse Transcription Kit (Applied BiosystemsTM, 
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Foster City, CA). Transcript levels were measured by real-time PCR using an Applied 
Biosystems 7900HT Fast Real-Time PCR System. Analysis was performed using the 
ΔΔCt method. Gene expression was normalized to GUSB (Hs02786624_g1). 
 
Cycloheximide time-course 
Half-life of CHCHD2 in U87 and U87vIII cells was determined using the cycloheximide 
(CHX) pulse-chase method (Kao et al., 2015). Cells were seeded at equal densities and 
treated with CHX (10 µg/mL), and total protein lysates collected at 3, 6, 9, and 12 h post-
treatment. CHCHD2 levels over time were analyzed using western blot, as described 
above. Resultant bands were quantified using ImageJ to determine the time at which 50% 
of total CHCHD2 protein was degraded following translation inhibition with CHX. β-actin 
was used as loading control. 
 
Immunofluorescence 
U87 and U87vIII, as well as cells expressing the pDsRed2-mito fluorescent marker 
targeted to mitochondria were seeded at equal densities on sterile coverslips. Cells were 
fixed with 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) in PBS at 
RT for 30 min. After washing 3 x 5 min in PBS, cells were permeabilized in 0.5% Triton 
X-100 in PBS at RT for 15 min, followed by incubation in ultracold methanol at –20 ⁰C for 
15 min, then incubation in PBS at RT for 30 min. Samples were blocked using Image-iT® 
FX Signal Enhancer ReadyProbes® Reagent (Thermo Fisher) at RT for 30 min. Samples 
were then incubated with primary antibody against CHCHD2 (1:100, NBP1-94106, Novus 
Biologicals, Centennial, CO) at RT overnight. After washing 3 x 5 min in PBS, samples 
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were incubated with Goat anti-Rabbit IgG (H+L) Secondary Antibody conjugated with 
Alexa Fluor 488 (1:200, Thermo Fisher) at 37 °C for 2 h. After washing 3 x 5 min in PBS, 
coverslips were mounted in ProLong® Gold Antifade Mountant with DAPI (Thermo 
Fisher). Samples were imaged using a Zeiss LSM 700 confocal fluorescence-enabled 
microscope (Carl Zeiss, Oberkochen, Germany). 
 Amounts of nuclear CHCHD2 detected were analyzed using Axiovision SE.64 and an 
automated image analysis pipeline therein. Quantities of nuclear CHCHD2 are expressed 
as fluorescent area detected within nuclei of individual cells normalized to nuclear area, 
in order to account for varying surface areas of nuclei imaged among cells.  
 
CHCHD2 ectopic expression 
Expression vectors for CHCHD2 were generously provided by Dr. Siddhesh Aras (Wayne 
State University, Detroit, MI). pCI-Neo CHCHD2 3x-FLAG expression vectors and pCI-
Neo empty vectors were transfected into U87vIII cells using Lipofectamine 3000 Reagent 
according to manufacturer’s protocols. Successfully transfected cells were selected for 
with G418 (640 µg/mL). Determination of exogenous (3x-FLAG) and endogenous 
CHCHD2 levels was conducted by western blot, relying on the increased molecular 
weight of exogenous CHCHD2 harboring a 3x-FLAG epitope. 
 
Statistical analysis 
Differences among means were tested for using Student’s t-test or one-way ANOVA, 
followed by post-hoc Student-Newman-Keuls analysis where appropriate. Statistical 
significance was set at p < 0.05. Variance is reported as standard error of the mean. 
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5.3. RESULTS 
Nuclear CHCHD2 is increased in hypoxic, serum-deprived, and oxidatively stressed GBM 
cells 
U87 and U87vIII cells 
expressing the 
fluorescent 
mitochondrial marker 
pDsRed2-Mito were 
incubated in 20% and 
1% O2 for 48 h, 
followed by CHCHD2 
immunofluorescence 
analysis. Under 
standard culture 
conditions (20% O2), 
U87vIII cells consistently exhibited a greater quantity of nuclear CHCHD2 compared to 
isogenic, EGFRvIII-lacking U87 counterparts (p < 0.0001) (Figure 5.1A, C), indicating a 
greater propensity for CHCHD2 to reside in nuclei of GBM cells expressing the mutant 
EGFRvIII. Upon incubation in 1% O2, the amount of nuclear CHCHD2 detected 
significantly increased in both U87 and U87vIII cells (Figure 5.1A-B), indicative of a 
hypoxia-sensitive redistribution of CHCHD2 to nuclei of GBM cells. Notably, incubation of 
U87 and U87vIII cells in 7% O2 (representative of average physiological oxygen levels in 
Figure 5.1. Subcellular distribution of CHCHD2 in U87 and U87vIII cells in 
hypoxic and serum-deprived conditions. (A) Representative 
immunofluorescence images of U87 (left column) and U87vIII cells (right column) 
expressing the pDsRed2-mito fluorescent mitochondrial marker. Cells were 
incubated in 21% O2 (top row) or 1% O2 (middle row) for 48 h, or serum-free 
media for 30 min (bottom row). (B) Quantification of nuclear CHCHD2 as a ratio 
of nucleus area occupied in U87 and U87vIII cells expressing pDsRed2-mito 
incubated in 20% or 1% O2 for 48 h, serum-free media for 30 min, or BSO (100 
µM) or NAC (1 mM) for 48 h. Differing superscript indicates statistically significant 
effect of treatment on nuclear CHCHD2 levels detected compared to 20% O2 
control condition for each cell line. (C) Quantification of nuclear CHCHD2 as a 
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normal brain) did not result in increased accumulation of nuclear CHCHD2 compared to 
20% O2 (Figure 5.1C). 
 Hypoxia represents a common metabolic stressor imposed by the GBM tumor 
microenvironment resulting from rapid tumor growth coupled with aberrant and inefficient 
neovascularization (Louis, 2006). In addition to oxygen constraints, gradients in various 
nutrients, metabolites, and growth factors commonly occur across solid tumors, along 
with chronic intracellular redox stress. To mimic the metabolic stress imposed by 
decreasing nutrient and/or growth factor gradients, U87 and U87vIII pDsRed2-Mito cells 
were incubated in serum-free media for 30 min. Similarly to chronic hypoxia, acute serum 
deprivation resulted in a marked increase in nuclear CHCHD2 detected in U87 and 
U87vIII cells (Figure 5.1A-B). Additionally, incubation in the pro-oxidant L-buthionine 
sulfoximine (BSO, 100 µM, 48 h), an inhibitor of glutathione (GSH) synthesis, induced an 
increase in nuclear CHCHD2 that was only statistically significant in U87vIII cells (Figure 
5.1B). Application of the GSH precursor N-acetyl-L-cysteine (NAC, 1 mM, 48 h) did not 
increase nuclear CHCHD2 (Figure 5.1B). Altogether, these data demonstrate subcellular 
redistribution of CHCHD2 to nuclei in U87 and U87vIII cells in response to chronic 
hypoxia, acute serum deprivation, and chronic oxidative stress. 
 
 
 
 
 
 
81 
 
Total CHCHD2 protein levels do not increase in hypoxic GBM cells 
A potential explanation for the increased nuclear CHCHD2 detected in hypoxic U87 and 
U87vIII cells is an increase in total CHCHD2 protein levels in response to hypoxia. 
Previous work has demonstrated that, in hypoxia, CHCHD2 transactivates gene 
expression of itself (Aras et al., 2015; Aras et al., 2013). Incubation of U87 and U87vIII 
cells in 1% O2 for 24 h led to increased gene expression of CHCHD2 only in U87, but not 
U87vIII cells, compared to 7% O2 incubation (Figure 5.2A). To determine if increased 
total CHCHD2 protein levels accounted for increased nuclear CHCHD2 in hypoxic GBM 
cells, U87 and U87vIII cells were incubated for 48 h in 21% O2, 7% O2 (average 
physiological oxygen level in brain), 4% O2 (level demonstrated to induce maximal 
CHCHD2 expression) (Aras et al., 2015), and 1% O2. A slight, though non-statistically 
significant increase in U87 CHCHD2 protein levels was observed at 4% O2 (Figure 5.2B-
C). Overall, U87 CHCHD2 protein levels did not change with decreasing oxygen tensions 
(Figure 5.2B-C). On the other hand, CHCHD2 protein levels in U87vIII cells decreased 
when cells were incubated in 1% O2 (Figure 5.2B-C). Together, these data indicate that 
Figure 5.2. CHCHD2 expression in hypoxia. (A) RT-qPCR of CHCHD2 in U87 and U87vIII cells in 1% O2 
compared to 7% O2. (B) Representative western blot of CHCHD2 in U87 and U87vIII cells incubated in decreasing 
O2 levels. U87 and U87vIII cells were incubated in standard culture conditions (20% O2), 7% O2, 4% O2, and 1% 
O2 for 48 h. (C) Quantification of relative band intensity. β-actin was used as loading control. Data are presented 
as mean ± SE. n = 2. Differing superscript: p < 0.05. 
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the increase in nuclear CHCHD2 observed under hypoxia is not due to an increase in 
total cellular CHCHD2 expression.  
 
CHCHD2 exhibits relatively rapid turnover in GBM cells 
A second possible explanation for 
increased CHCHD2 in nuclei of 
hypoxic U87 and U87vIII cells is that, 
in hypoxia, newly translated 
CHCHD2 is preferentially shuttled to 
the nucleus versus to mitochondria. 
To begin to address this hypothesis, 
the turnover rate of CHCHD2 in U87 
and U87vIII cells was first 
determined in a time-course 
experiment with the translation inhibitor cycloheximide (CHX), followed by western 
blotting of total protein lysates collected over time after CHX administration. CHX inhibits 
total intracellular protein translation machinery, thus allowing for the tracking of 
degradation rate for proteins of interest and determination of protein half-life, 
representative of protein turnover in cells at rest. Total protein lysates were collected at 
3, 6, 9, and 12 h after administration of CHX (10 µg/mL) to U87 and U87vIII cells. The 
half-life of CHCHD2 was approximately 3 h (U87: 2.79 h; U87vIII: 3.41 h) (Figure 5.3). 
Extrapolating these data, an entire pool of CHCHD2 would be recycled in approximately 
15 h. Levels of β-actin remained relatively stable throughout the 12 h time-course. These 
Figure 5.3. CHCHD2 turnover analyzed using 
cycloheximide chase. (A) Representative western blot of 
CHCHD2 levels in U87 and U87vIII cells treated with CHX (10 
µg/mL) for 0, 3, 6, 9, and 12 h. Top band is CHCHD2. (B) 
Quantification of CHCHD2 band intensity following CHX 
treatment in U87 cells. Data are presented as percentage of 
the band intensity at 0 h. (C) Quantification of CHCHD2 band 
intensity following CHX treatment in U87vIII cells. Data are 
presented as percentage of the band intensity at 0 h. 
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results suggest a regulatory (versus structural) role for CHCHD2, as well as establish a 
time frame in which to interpret subcellular redistribution of CHCHD2 under various 
conditions. 
 
Disulfide reduction induces rapid nuclear accumulation of CHCHD2 
Import of CHCHD2 into the mitochondrial IMS requires disulfide relay-mediated import 
via interactions with CHCHD4, which result in oxidative formation of CHCH disulfide 
bonds, protein folding, and trapping in the IMS (Modjtahedi et al., 2016). Additionally, 
mounting pools of reducing intermediates produced by increased glycolytic flux as a result 
of hypoxia and/or malignant transformation can result in reductive stress, i.e. the 
presence of excess reducing equivalents that cannot be quenched by cellular 
oxidoreductases or oxygen tensions in the surrounding environment (e.g., limited oxygen 
Figure 5.4. Subcellular distribution of CHCHD2 in U87 and U87vIII cells acutely reduced with DTT. (A) 
Representative images of U87 (left column) and U87vIII cells (right column). Cells were treated with 10 mM DTT 
for 15 min (middle row) or 30 min (bottom row). (B) Quantification of nuclear CHCHD2 as a ratio of nucleus area 
occupied in U87 and U87vIII cells incubated in 10 mM DTT for 15 and 30 min. Data are presented as mean ± SE, 
n ≥ 10 cells. Differing superscript: p < 0.05. 
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in hypoxia) (Loscalzo, 2016). It was hypothesized that reductive unfolding of CHCHD2 
was the primary driver for its export out of mitochondria and nuclear translocation. To test 
this hypothesis, U87 and U87vIII cells were treated with the disulfide-reducing agent 
dithiothreitol (DTT) under a variety of conditions. Incubation of cells in 10 mM DTT 
resulted in a striking increase of nuclear CHCHD2 within 15 min (Figure 5.4). By 30 min, 
CHCHD2 could only be detected in the nuclei of both cell lines (Figure 5.4). This 
observation was not due to malformations in cellular shape, as evidenced by differential 
interference contrast (DIC) images in which cell shape was still intact (Figure 5.5A-C). 
Treatment with lower concentrations of DTT (1 mM) was sufficient to induce nuclear 
accumulation of CHCHD2 in both cell lines within 15 min (Figure 5.5A).  
Figure 5.5. Subcellular distribution of CHCHD2 in U87 and U87vIII cells acutely reduced with DTT is not a 
result of cell shape deformation. Representative images of U87 (top row) and U87vIII cells (bottom row) treated 
with (A) 1 mM DTT for 15 min, (B) 10 mM DTT for 15 min, and (C) 10 mM DTT for 30 min. DIC images are included 
for qualitative assessment of cell morphology. 
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Additional treatments in serum-free media were conducted which mirrored oxidized 
and reduced redox western blot conditions reported in the literature (Go & Jones, 2009). 
Treatment of U87 and U87vIII cells expressing the pDsRed2-Mito fluorescent 
mitochondrial marker with 5 mM DTT in serum free media for 30 min again resulted in 
rapid nuclear accumulation of CHCHD2 (Figure 5.6). Notably, addition of the oxidant 
H2O2 (5 mM) abrogated the increase in nuclear CHCHD2 observed with serum 
deprivation (Figure 5.6). Collectively, these data are consistent with reductive unfolding 
of CHCHD2 being a primary driver of its rapid accumulation in nuclei.  
 
 
Figure 5.6. Subcellular distribution of CHCHD2 in U87 and U87vIII cells treated with H2O2 or DTT in serum-
free media. (A) Representative images of U87 (left column) and U87vIII cells (right column). Cells were treated 
with 5 mM H2O2 for 30 min (middle row) or 5 mm DTT for 30 min (bottom row). (B) Quantification of nuclear CHCHD2 
as a ratio of nucleus area occupied in U87 and U87vIII cells incubated in 5 mM H2O2 or DTT for 30 min. Data are 
presented as mean ± SE, n ≥ 10 cells. Differing superscript: p < 0.05. 
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Ectopic expression of CHCHD2 does not result in increased levels of endogenous 
CHCHD2 
Previous work demonstrated that CHCHD2 acts as a transcription factor to transactivate 
gene expression of itself via physical interaction with recombination signal binding protein 
for immunoglobulin κ J (RBPJ), the main downstream effector of the Notch signaling 
pathway, which has been implicated in maintenance of brain tumor initiating cells (Aras 
et al., 2015; Aras et al., 2013; Q. Xie et al., 2016). To determine if CHCHD2 transactivates 
expression of itself in GBM cells expressing EGFRvIII, U87vIII cells were transiently 
transfected with a CHCHD2 3x-FLAG expression vector (pCI-Neo CHCHD2 3x-FLAG), 
and protein levels of CHCHD2 were analyzed using western blot. Notably, presence of 
the 3x-FLAG epitope allows for the distinction between endogenous and exogenously 
expressed CHCHD2 by virtue of increased molecular weight of exogenous CHCHD2 
(approximately 3 kDa) (Figure 5.7). No increase in endogenous CHCHD2 levels were 
detected in U87vIII cells expressing the pCI-Neo CHCHD2 3x-FLAG vector (Figure 5.7), 
indicating that, although CHCHD2 is consistently detected at higher levels in nuclei of 
U87vIII cells, it does not transactivate expression of itself.  
 
Figure 5.7. Ectopic overexpression of CHCHD2 in U87vIII cells. (A) Representative western blot of U87vIII cells 
transfected to express CHCHD2 3x-FLAG and pCI-Neo empty expression vector. (B) Quantification of relative 
endogenous CHCHD2 band intensity (16 kDa) in WT, CHCHD2 3x-FLAG, and pCI-Neo empty vector expressing 
cells. Data are presented as mean ± SE. n = 2. 
87 
 
5.4. DISCUSSION 
The dual localization of CHCHD2 in mitochondria and the nucleus implicates CHCHD2 
as a protein involved in mitonuclear communication and signaling. The ability of 
mitochondria to communicate their status to the nucleus under stressful conditions 
represents a key signaling axis in tumor cell plasticity and adaptive capabilities. The 
current work investigated the dynamics of CHCHD2 in U87 and U87vIII cells as a function 
of metabolic stressors including chronic hypoxia and acute serum deprivation, as well as 
chronic redox stress imposed by chemical oxidation or reduction induced by BSO or NAC, 
respectively. It was found that, under normoxic oxygen tensions, U87vIII cells displayed 
a greater propensity to harbor nuclear CHCHD2. Chronic hypoxia, acute serum 
deprivation, chronic oxidative stress with BSO, and reductive unfolding with DTT were all 
able to induce nuclear accumulation of CHCHD2 in both cell lines. Given the striking 
increases in nuclear CHCHD2 under acute treatment conditions (30 min) relative to the 
half-life and turnover rate for a pool of cellular CHCHD2 (3 h and 15 h, respectively), as 
well as the lack of an increase in total CHCHD2 protein levels in hypoxia, the observed 
subcellular redistribution most likely arises due to direct translocation of a reduced form 
of CHCHD2 from mitochondria to the nucleus. 
 The CHCHD2 protein harbors a number of motifs directing its localization to the 
mitochondria, including: 1) a putative N-terminal mitochondrial targeting sequence; 2) a 
MISS motif required for interaction with the CHCHD4 import machinery into the 
mitochondrial IMS; and 3) a CHCH domain required for oxidative folding, import, and 
trapping in the IMS. However, a putative nuclear localization sequence is not present 
within the 151 amino acid sequence of CHCHD2. Shuttling of proteins between the 
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nucleus and cytoplasm is mediated by nuclear pore complexes (NPC), one of the largest 
macromolecular complexes in eurkaryotic cells at ~120 million Daltons (Timney et al., 
2016). Canonically, nuclear localization or export sequences present on proteins destined 
for nuclear import or export are recognized by importins, which chaperone proteins 
through the NPC via facilitated diffusion in a GTP-dependent manner (Wente & Rout, 
2010). However, passive diffusion of proteins through the NPC has also been described, 
limited by a molecular mass size threshold of 30-60 kDa (Timney et al., 2016). Notably, 
at only 16 kDa, CHCHD2 may well passively permeate into the nucleus under certain 
favorable conditions, such as those described in this study. 
 Although real-time monitoring of CHCHD2 shuttling in live cells using GFP-fused 
CHCHD2 may have directly demonstrated direct translocation in response to various 
stressors, use of a CHCHD2-GFP fusion expression vector did not yield appropriate 
controls. Specifically, U87vIII cells transfected with a pEGFP CHCHD2 expression vector 
displayed cytosolic localization of CHCHD2 (not shown). It is likely that the addition of the 
globular, 27 kDa GFP protein to the C-terminus of CHCHD2 interfered with its ability to 
be appropriately imported into mitochondria, precluding the ability to observe its 
subcellular dynamics. 
 Nevertheless, acute treatments to model the relationship between CHCHD2 protein 
folding and subcellular localization in U87 and U87vIII cells provide indirect evidence 
supportive of direct translocation. This conclusion is supported by various lines of 
evidence. First, neither U87 nor U87vIII cells increased their expression of total CHCHD2 
protein under decreasing oxygen tensions (Figure 5.2), indicating that increased total 
CHCHD2 expression was not responsible for increased nuclear CHCHD2 observed in 
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hypoxia. Notably, in U87vIII cells, incubation in 1% O2 decreased total CHCHD2 levels in 
conjunction with increased CHCHD2 detected in nuclei (Figure 5.2). Second, acute 
treatment for 30 min with serum-free media, as well as 30 and 15 min application of 
various concentrations of the thiol-reducing agent DTT to model protein reductive 
unfolding (1, 5, and 10 mM), resulted in significant increases in nuclear CHCHD2 (Figure 
5.4, 5.5). The possibility that this is explained by preferential shuttling of newly translated 
CHCHD2 is unlikely, given i) the short time frame of subcellular redistribution (15-30 min) 
relative to the 3 hour half-life of CHCHD2, as well as ii) the likely disruption of protein 
translation machinery resulting from DTT treatment. Furthermore, environmental stresses 
such as nutrient starvation (simulated by serum-deprivation) generally reduce rates of 
protein translation (B. Liu & Qian, 2014).  
 Because import of CHCHD2 into the mitochondrial IMS depends upon oxidation of its 
twin CX9C motifs (resulting in formation of disulfide bonds that stabilize the helix-turn-
helix fold of the CHCH domain and trap CHCHD2 within the IMS), it was hypothesized 
that reduction of these disulfide bonds, modeled via treatment with the disulfide-reducing 
agent DTT, would induce reductive unfolding and retro-translocation out of the 
mitochondrial IMS. The observation that reduced CHCHD2 localized rapidly to the 
nucleus is consistent with mechanisms of redox regulation of nuclear transcription factors. 
Redox-dependent modulation of DNA binding has been described for a number of 
transcription factors, including NF-kB, p53, and Nrf-2, all of which contain at least one 
critical cysteine residue that must be reduced in nuclei for DNA binding, a function 
inhibited by oxidation (Go & Jones, 2010). Functional domain analysis of CHCHD2 
demonstrated that the amino acids immediately upstream of Cys114 (aa 101-113) are 
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required for CHCHD2 interaction with RBPJ and transactivation of a COX4I2 luciferase 
reporter (Aras et al., 2015). Notably, site-directed mutagenesis of all four cysteine 
residues, which would preclude proper oxidative folding of CHCHD2 and inhibit its import 
into the IMS, did not inhibit its ability to transactivate the COX4I2 luciferase reporter (Aras 
et al., 2015), indicating that CHCHD2 could perform its gene transactivation function in a 
reduced, unfolded state. 
 Notably, other than the reductive protein unfolding modeled using DTT, stimulants of 
CHCHD2 nuclear accumulation, such as serum deprivation, treatment with BSO, and 
hypoxia, are conventionally regarded as oxidative stressors. Additionally, U87 GBM cells 
expressing EGFRvIII have been reported to exhibit greater levels of reactive oxygen 
species (Nitta et al., 2010; Sangar et al., 2014), and CHCHD2 was consistently detected 
at greater levels in resting U87vIII versus U87 cells (Figure 5.1). It should be noted that 
redox poise across organelles is independently maintained and compartmentalized, and 
distinctly altered by environmental insults. For instance, hypoxia induces oxidation of the 
cytosolic and IMS glutathione pools, yet reduces the mitochondrial matrix glutathione pool 
(Byrne, Leslie, Patel, Gaskins, & Kenis, 2017; Waypa et al., 2010). It is possible that IMS 
glutathione oxidation in hypoxia could lead to glutathionylation of CHCHD2 thiol(s). 
Alternatively, redox stress could also potentially perturb interactions between CHCHD2 
and its mitochondrial binding partners CHCHD10 and p32 (Imai, Meng, Shiba-Fukushima, 
& Hattori, 2019; Purandare, Somayajulu, Huttemann, Grossman, & Aras, 2018), 
facilitating disulfide modification of its CHCH domain and translocation. However, the 
binding mode of IMS-resident CHCHD2 with matrix-resident p32 and the orientation of 
CHCHD2 within the IMS (soluble or membrane-embedded) remains unclear. Future 
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studies are warranted to dissect these, or other, possibilities, to obtain a clearer picture 
of CHCHD2’s apparent redox-sensitive translocation activity. 
It was further demonstrated that CHCHD2 did not transactivate expression of itself in 
U87vIII cells. Despite displaying increased nuclear localization in hypoxia, gene 
expression of CHCHD2 was unaltered and protein levels were decreased in hypoxic 
U87vIII cells (Figure 5.2). Additionally, ectopic expression of CHCHD2 with the pCI-Neo 
CHCHD2 3x-FLAG expression vector in U87vIII cells did not result in increased levels of 
endogenous CHCHD2 (Figure 5.7). These data contrast with previous studies 
demonstrating transcription factor activity of CHCHD2 inducing expression of itself 
maximally at 4% O2 via luciferase reporter assays in HEK293 and rat pulmonary cells, as 
well as increased protein levels of endogenous CHCHD2 in HEK293 cells ectopically 
overexpressing CHCHD2 with a 3x-FLAG epitope (Aras et al., 2013). Aras et al. 
previously demonstrated that CHCHD2 enhances gene expression via interactions with 
RBPJ, the main downstream effector of the Notch signaling pathway. Notably, recent 
work by Xie et al. has implicated RBPJ as critical for maintenance of brain tumor initiating 
cell viability and stemness (Q. Xie et al., 2016). Given the studies implicating CHCHD2 in 
neuroectodermal differentiation capacities of human embryonic stem cells (Zhu et al., 
2016), its association with the migratory capabilities of neural stem cells in patients with 
lissencephaly (Shimojima et al., 2015), as well as recent work highlighting neural stem 
cells as a GBM cell of origin (J. H. Lee et al., 2018), it is tempting to speculate that the 
CHCHD2-RBPJ interaction may play a role in maintaining glioma stem cells and tumor 
progression. Future studies should investigate the extent to which CHCHD2 interacts with 
RBPJ in GBM cells, as well as determine the suite of genes CHCHD2 may regulate, which 
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could reveal novel gene targets to further explain the contribution of nuclear CHCHD2 to 
GBM malignancy. 
 
5.5. CONCLUSIONS 
These data indicate that CHCHD2 accumulates in the nucleus of U87 and U87vIII GBM 
cells in response to metabolic and redox stress, and that reductive unfolding drives rapid 
nuclear localization of CHCHD2. This is the first work to provide evidence that this 
subcellular redistribution from mitochondria to the nucleus is likely driven by translocation 
of reduced mitochondrial CHCHD2, versus other potential mechanisms. 
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CHAPTER 6: CHARACTERIZING MICROGLIA-GLIOBLASTOMA CROSSTALK 
ABSTRACT 
INTRODUCTION 
Glioblastoma (GBM) is the most common and deadly form of primary malignant brain 
tumor in adults. Microglia, the primary resident immune cells in the brain, represent a 
substantial portion of GBM tumors, and paracrine signaling networks between microglia 
and GBM play a critical role in cultivating a microenvironment that facilitates 
angiogenesis, cell invasion, immunosuppression, and tumor expansion. Additionally, 
glutamate, the main excitatory neurotransmitter in the central nervous system, is released 
in excess by GBM tumors and promotes cell proliferation and invasion. Export of 
glutamate and import of cystine through system xc- serves to both remodel the 
extracellular environment and preserve intracellular glutathione redox status. The 
objective of the current study was to characterize the potential impact of the tumor-
specific antigen, EGFRvIII, on immunologic and angiogenic crosstalk between GBM cells 
and microglia, as well as the impact of microglia on system xc--mediated glutathione redox 
status in GBM cells. We hypothesized that GBM-microglia crosstalk would facilitate 
secretion of soluble factors that promote angiogenesis and extracellular matrix 
remodeling, as well as alter GBM cell glutathione redox balance. 
METHODS 
The U87 parental GBM cell line, U87 cells transduced to stably express EGFRvIII 
(U87vIII), patient-derived EGFRvIII-expressing GBM6 short-term explants, HMC3 
microglia cell line, and primary neonatal murine microglia were employed to model tumor-
microglia crosstalk. The influence of tumor-microglia crosstalk on secretion of soluble 
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factors related to angiogenesis and matrix remodeling was assessed using the R&D 
Systems Proteome Profiler Angiogenesis Cytokine Array. Cell proliferation in response to 
incubation in conditioned-media was analyzed via Iba1 and Ki-67 staining. 2D cell 
migration in response to tumor-microglia crosstalk was characterized using GBM:HMC3 
co-culture conditions in 2-well adhesive cell culture inserts. Mitochondrial GSH:GSSG 
status in U87 and U87vIII cells was determined using fluorescent redox biosensors 
targeted to the mitochondrial matrix (mito-Grx1-roGFP2). Expression of the system xc- 
glutamate-cystine antiporter was analyzed using western blot of xCT, as well as RT-qPCR 
of the SLC7A11 gene.  
RESULTS 
The expression of EGFRvIII on U87 cells resulted in an altered profile of secreted 
angiogenesis-related factors under basal culture conditions. Similarly, primary neonatal 
murine microglia, but not HMC3 cells, exhibited differential angiogenesis-related 
secretomes when cultured in U87 or U87vIII conditioned media. Primary murine microglia 
additionally displayed increased cell proliferation when cultured in U87 and U87vIII 
conditioned media, while HMC3 cells did not. Cell migration of U87 and U87vIII cells was 
not increased in the presence of HMC3 co-culture, although differences in cellular spatial 
organization and adhesion were observed. GBM6 conditioned medium led to a striking 
increase in HMC3 secretion of angiogenesis-related factors, inducing the greatest 
secretion of CCL2, IGFBP-2, TIMP-4, angiogenin, and IGFBP-3. HMC3 conditioned 
medium decreased expression of the system xc- antiporter and increased glutathione 
oxidation in mitochondria of U87 cells, while its xCT expression and mitochondrial 
glutathione redox status in U87vIII cells remained stable. 
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CONCLUSIONS 
GBM cells stimulate the secretion of cytokines, chemokines, and soluble factors by 
microglia to cultivate an immunosuppressive microenvironment promoting angiogenesis 
and cell invasion. Additionally, system xc- expression and, consequently, intracellular 
glutathione redox balance remain stable in U87vIII cells exposed to HMC3 conditioned 
media. 
 
6.1. INTRODUCTION 
Glioblastoma (WHO grade IV glioma) is the most common and malignant primary brain 
tumor in adults and represents approximately 50% of all gliomas diagnosed each year 
(Barnholtz-Sloan et al., 2018). Median survival for patients with GBM is only 14.6 months, 
with less than 5% of patients surviving after 5 years (Stupp et al., 2005). The current 
standard of care, which is multimodal and consists of surgical resection, radiotherapy, 
and chemotherapy with temozolomide, is only palliative and does little to prevent tumor 
dissemination into surrounding brain parenchyma and, eventually, inevitable tumor 
relapse. Numerous features of the surrounding tumor microenvironment, such as tumor-
associated microglia, play a dynamic role in modulating cell behavior and thus selecting 
for more malignant cell populations. 
Microglia are the primary resident immune cells of the brain and spinal cord and 
account for 5-12% of cells in the brain (Alliot et al., 1999; Hickman et al., 2013; 
Nimmerjahn et al., 2005). As sentinels of baseline immunity in the brain, microglia exhibit 
profound plasticity which allows them to assume neurotoxic or neuroprotective states that 
determine their responses to changes in the surrounding microenvironment, invading 
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pathogens and toxins, neurodegenerative diseases and traumatic brain injury, and 
cellular debris (Hickman et al., 2013; Nimmerjahn et al., 2005). Seminal work conducted 
by Nimmerjahn et al. (2005) revealed that, in the healthy brain, microglia continuously 
and dynamically surveil their surroundings via continuous cycles of de novo formation 
and withdrawal of cellular processes, which interact with cortical elements such as 
astrocytes, neurons, and blood vessels (Nimmerjahn et al., 2005). Further facilitating 
microglial monitoring of brain parenchyma is a repertoire of cell surface proteins and 
receptors including chemoattractant and chemokine receptors, cytokine receptors, 
receptors involved in cell-cell interaction, and receptors for extracellular matrix proteins, 
collectively termed the microglial sensome (Hickman et al., 2013). 
Previous studies have demonstrated various avenues of synergistic crosstalk 
between GBM tumors and tumor associated microglia and macrophages (TAMs). 
Notably, TAMs constitute up to 30% of the GBM tumor bulk, promoting tumor progression, 
angiogenesis, and invasion (Coniglio et al., 2012). Intratumoral microglia density is higher 
than in surrounding normal brain and increases with tumor grade (Bettinger, Thanos, & 
Paulus, 2002). TAMs are not merely a nonspecific reaction to tissue injury, but rather are 
actively recruited to GBMs via tumor secretion of chemotactic factors such as 
granulocyte-macrophage stimulating factor (GM-CSF), monocyte chemoattractant 
protein-1 (MCP-1 aka CCL2), glial cell-derived neurotrophic factor (GDNF), and 
hepatocyte growth factor (HGF) (Bettinger et al., 2002; Hambardzumyan et al., 2016). In 
turn, recruited microglia release several anti-inflammatory (e.g. TGF-β, IL-10), pro-
inflammatory (e.g. TNF-α, IL-1β), and extracellular matrix remodeling, invasion promoting 
factors (e.g. EGF, MMP-9, VEGF). 
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Glutamate, the main excitatory neurotransmitter in the central nervous system, is 
released in excess by GBM tumors and promotes cell proliferation and invasion (de Groot 
& Sontheimer, 2011). System xc- is a sodium-independent membrane transporter which 
couples the influx of extracellular cystine to the efflux of glutamate (Robert et al., 2015). 
Previous studies have reported upregulation of system xc- expression conferring 
chemoresistance and stem-like properties in glioma cells (Polewski, Reveron-Thornton, 
Cherryholmes, Marinov, & Aboody, 2017; Polewski et al., 2016). Upregulation of xCT 
confers a tumor growth advantage by 1) increased import of cystine, which is rapidly 
reduced within the cell to cysteine, the rate-limiting substrate for synthesis of glutathione 
(GSH), the main intracellular redox buffer; and 2) increased efflux of glutamate, which 
can result in excitotoxic damage to neurons, thus clearing room for tumor growth and 
resulting in tumor-associated seizures (Robert et al., 2015). 
The objective of the current study was to exsamine inter-cellular crosstalk between 
microglia and GBM cells, and to profile its effects on cell proliferation, invasion, and 
glutathione redox status. Conditioned-media and co-culture experiments were conducted 
to interrogate the impact of GBM-microglia crosstalk on cell proliferation, cell migration, 
and microglia secretion of a repertoire of angiogenesis-related factors. A variety of models 
were employed, including the human HMC3 microglia cell line, primary neonatal murine 
microglia, U87 and U87vIII GBM cells, and primary EGFRvIII-expressing GBM6 patient-
derived cells. 
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6.2. METHODS 
Cell culture 
The human U87 parental GBM cell line, as well as U87 GBM cells transduced to stably 
express the constitutively active EGFRvIII mutant (U87vIII) were generously provided by 
Dr. Nathan Price (Institute for Systems Biology, Seattle, WA). Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 1 mM sodium pyruvate, 15 mM 
HEPES, non-essential amino acids, 10% fetal bovine serum (FBS), and 1% 
penicillin/streptomycin. 
 GBM6 (EGFRvIII/PTEN-wt, highly invasive) primary patient-derived cells obtained 
from Dr. Jann Sarkaria (Mayo Clinic) were cultured as spheroids in methacrylated gelatin 
(GelMA) hydrogels. Spheroids were generated by seeding cells in equal densities (5,000 
cells/well) in a low-adhesion, round-bottom 96-well plate, followed by shaking at 60 rpm 
for 48 h. Resultant spheroids were cultured in GelMA hydrogels photopolymerized under 
UV light (AccuCure LED 365 nm, 7.1 mW cm-2 for 30 s) in the presence of a lithium 
acylphophinate photoinitiator. 
 The human microglia cell line HMC3 was obtained from American Type Culture 
Collection (ATCC, CRL-3304) and cultured in DMEM containing 1 mM sodium pyruvate, 
15 mM HEPES, non-essential amino acids, 10% FBS, and 1% penicillin/streptomycin. 
Primary murine microglia were isolated from neonatal mice and generously provided 
by Dr. Andrew Steelman and cultured in DMEM/F12. Briefly, brains from neonatal 
C57BL/6 pups (1-3 d old) were harvested, meninges removed, and tissue incubated in 
Accutase for 30 min at 37 °C. Tissue was then homogenized using a 70 µm filter and 3 
mL syringe, and the filter washed with 5 mL DMEM containing 10% FBS. Cell suspension 
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was then centrifuged at 300 x g for 5 min, and cells resuspended in fresh media, counted, 
and plated in a T-75 flask at a concentration of 1 x 106 cells/mL. Medium was changed 
every other day until cells reached confluency, at which point the flask was shaken at 170 
rpm for 1 h at 37 °C. Microglia were isolated as floating cells in media. All cells were 
maintained at 37 °C and 5% CO2. 
 
Cytokine array  
U87 and U87vIII cells were seeded at equal densities (150,000 cells/well) in two 6-well 
plates and allowed to condition media for 72 h. The resulting conditioned media (CM) 
from each cell line was centrifuged for 5 min at 267 x g, and supernatant directly applied 
to HMC3 cells seeded at equal densities (100,000 cells/well) in a 12-well plate. HMC3 
cells were incubated in either U87 or U87vIII CM for 48 h. Media from untreated HMC3 
cells, HMC3 cells incubated in U87 or U87vIII CM, as well as U87 and U87vIII CM was 
profiled for the presence of secreted angiogenesis-related factors using the R&D Systems 
Proteome Profiler Angiogenesis Cytokine Array according to the manufacturer’s 
instructions (R&D Systems, Minneapolis, MN). Similarly, U87 and U87vIII cells were 
cultured for 72 h before application of conditioned media from each cell line to primary 
neonatal murine microglia plated in a 24-well culture plate. Additionally, the influence of 
GBM6-conditioned media (GBM6 CM) on HMC3 secretion of angiogenesis-related 
factors was examined. Conditioned media were collected directly from the culture flask in 
which GBM6 cells were plated and shipped from Mayo Clinic. 
 
Cell proliferation 
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Cell proliferation of HMC3 cells in response to U87 and U87vIII CM was assessed using 
Ki-67 staining and analysis. U87 and U87vIII cells were seeded at equal densities 
(150,000 cells/well) in a 6-well plate and allowed to condition media for 72 h. Afterwards, 
conditioned media was centrifuged at 267 x g for 5 min, and applied to HMC3 cells seeded 
at equal densities in an µ-Slide eight-well ibiTreat microscopy chambers (Ibidi, Munich, 
Germany). Cells were incubated in either control DMEM or GBM-conditioned media for 
48 h before fixation and staining for Ki-67 (1:400, D3B5, Cell Signaling Technology, 
Danvers, MA). Stained samples were imaged using the tile scan function at 20x on a 
Zeiss LSM 700 confocal fluorescence microscope (Carl Zeiss, Oberkochen, Germany), 
and Ki-67+ cells manually counted. To assess U87 and U87vIII cell proliferation in 
response to HMC3 CM, the cell culture workflow above was conducted in reverse.  
Proliferation of primary neonatal murine microglia in response to U87 and U87vIII CM 
was observed. Microglia treated with U87 and U87vIII CM for 48 h were fixed and stained 
with anti-Iba1 antibody and Hoechst. Iba-1+ cells were counted in three 20x fields per 
well, and averages of each well and condition were calculated.  
 
Cell migration 
Cell migration of U87 and U87vIII cells in response to co-culture with HMC3 cells was 
assessed using wound-healing assays. U87 and U87vIII cells expressing the fluorescent 
mitochondrial marker pDsRed2-Mito were seeded at equal densities in each well of iBidi 
2-well silicone adhesive culture inserts (iBidi) placed in a 12-well plate. Use of these 
inserts allows for a reproducible, defined 500 µm cell-free gap to assess cell migration. 
U87 and U87vIII cells were seeded either independently or co-cultured 2:1 with HMC3 
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cells (2 GBM:1 HMC3), and time-lapse images of three 4x fields per well were acquired. 
Percent of initial wound closure was tracked over time in each condition. 
 
RT-qPCR 
Expression of SLC7A11 in U87 and U87vIII cells incubated for 48 h in 72 h HMC3 CM 
was measured using TaqMan gene expression probes (Hs00921938_m1, Thermo 
Fisher, Waltham, MA). Total cellular RNA was isolated from cells using the RNeasy Mini 
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. Complementary 
DNA (cDNA) was generated by reverse transcriptase polymerase chain reaction using 
the High Capacity cDNA Reverse Transcription Kit (Applied BiosystemsTM, Foster City, 
CA). Transcript levels were measured by real-time PCR using an Applied Biosystems 
7900HT Fast Real-Time PCR System. Analysis was performed using the ΔΔCt method. 
Gene expression was normalized to GAPDH (Hs02786624_g1). 
 
Western blot 
Total protein levels of the glutamate-cystine antiporter xCT (1:500, ab37185, Abcam, 
Cambridge, UK) were compared in U87 and U87vIII cells incubated for 48 h in 72 h HMC3 
CM using western blot. β-actin (1:1000, #4967, Cell Signaling Technology, Danvers, MA) 
was used as loading control. Total protein concentrations were determined using the 
Pierce BCA assay (Thermo Fisher). Protein lysates were mixed 1:1 with 2X Laemmli 
Sample Buffer (Bio-Rad, Hercules, CA) (5% β-mercaptoethanol) and heated at 95 °C for 
5-10 min. Denatured lysates were loaded into 4-20% Mini-Protean ® TGXTM 
electrophoresis gels (Bio-Rad, Hercules, CA), and SDS-PAGE was run at 150 V for 1-1.5 
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h. Proteins were transferred to a nitrocellulose membrane (Amersham, Little Chalfont, 
UK) at 300 mA for 2 h at 4⁰ C. Membranes were then blocked with 5% BSA for 1 h at RT, 
then incubated in primary antibody at designated concentrations overnight at 4⁰ C. 
Membranes were washed in TBS-T for 5 min 3x, then incubated in HRP-linked goat anti-
rabbit secondary antibody (1:2500, #7074, Cell Signaling Technology) at RT for 1.5 h. 
Following TBS-T washes (3x 5 min each), membranes were imaged using the 
SuperSignalTM West Femto Maximum Sensitivity Substrate (Thermo Fisher) in an 
ImageQuant LAS 4010 (GE Life Sciences, Pittsburgh, PA). Band densitometry analysis 
was performed using ImageJ. 
 
Measurement of mitochondrial glutathione redox poise 
U87 and U87vIII cells were transfected with genetically encoded, fluorescent redox 
biosensors targeted to the mitochondrial matrix (mito-Grx1-roGFP2), previously 
described by our lab (Kolossov et al. 2015). Cells expressing mitochondrial Grx1-roGFP2 
were seeded at equal densities in standard culture medium without phenol red in µ-Slide 
eight-well ibiTreat microscopy chambers (Ibidi). Time-lapse images were collected with a 
fluorescence-enabled inverted microscope (Axiovert 200 M, Carl Zeiss, Feldbach, 
Switzerland). Dual-excitation imaging of live cells used 395 and 494 nm excitation cubes, 
and an emission filter at 527 nm was used for both cubes. Exposure times were set to 
100-200 ms, and images were taken every 15 s. To assess the effect of 72 h HMC3 
conditioned media on mitochondrial GSH:GSSG status, U87 and U87vIII cells were pre-
treated with conditioned media 48 h before time-lapse image acquisition. Acquired 
images were processed with Zeiss Axiovision SE64 Rel6.8 software, via manual selection 
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of three to five individual cells to obtain multiple regions of interest in each time lapse. 
The means of emission intensities at 527 nm were exported to Excel files and corrected 
by background subtraction. 
 
Statistical analysis 
Differences among means were tested for using Student’s t-test or one-way ANOVA, 
followed by post-hoc Student-Newman-Keuls analysis where appropriate. Statistical 
significance was set at p < 0.05. Variance is reported as standard error of the mean. 
 
6.3. RESULTS 
EGFRvIII expression influences the secretion of pro-angiogenic and ECM remodeling 
factors by U87 cells and primary murine microglia 
The milieu of 
angiogenesis-related 
factors secreted by 
U87 and isogenic 
U87vIII cells under 
standard basal culture 
conditions was 
profiled via cytokine 
array. Proteins 
secreted greater than 
1.5 fold by U87 versus 
Figure 6.1. Effect of EGFRvIII on U87 and microglia secretion of 
angiogenesis-related factors. Secreted chemokines, cytokines, and soluble 
factors related to angiogenesis were profiled in culture media using a R&D 
Systems Cytokine Array. (A) Angiogenesis-related factors secreted > 1.5 fold by 
U87 vs U87vIII cells. (B) Heatmap of angiogenesis-related factors secreted > 1.5 
fold by U87vIII cells vs U87 cells. (C) Angiogenesis-related factors secreted > 2 
fold by primary neonatal murine microglia incubated in U87 and U87vIII CM for 48 
h.  
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U87vIII cells included coagulation factor III (F3), endoglin (ENG), GM-CSF, angiopoietin-
2 (ANGPT2), amphiregulin (AREG), IL-1β, thrombospondin-2 (THBS2), IL-8, GDNF, 
activin A, and CXCL16 (Figure 6.1A). Conversely, proteins secreted greater than 1.5 fold 
by U87vIII cells included insulin growth factor binding proteins 2 and 3 (IGFBP-3, IGFBP-
2), endocrine gland derived vascular endothelial growth factor (EG-VEGF), platelet-
derived endothelial cell growth factor (PD-ECGF), vasohibin, angiogenin, MMP-8, and 
TGFβ-1 (Figure 6.1B). 
 The effect of EGFRvIII expression 
extended beyond secretion patterns of 
U87 cells. Primary murine microglia 
exhibited differential secretion patterns of 
angiogenesis-related factors in response 
to incubation in U87 or U87vIII conditioned 
media (CM). Compared to U87 CM, 
U87vIII CM induced greater microglia 
secretion of various factors including 
MMP-3, CXCL1, CCL2, IGFBP-3, and IL-
10 (Figure 6.1C). However, this effect was 
not observed by HMC3 cells incubated in 
U87 or U87vIII CM (Figure 6.2A-B). No 
factors were secreted greater than two-fold 
by HMC3 cells in response to incubation in 
U87 or U87vIII CM. Only secretion of angiogenin in response to U87 CM and FGF-7 in 
Figure 6.2. Effect of U87 and U87vIII conditioned 
media on angiogenesis-related factors released by 
HMC3. Secreted chemokines, cytokines, and soluble 
factors related to angiogenesis were profiled in culture 
media using a R&D Systems Cytokine Array. (A) 
Heatmap of secreted factors detected in HMC3 culture 
media, U87 culture media, and HMC3 culture media 
after incubation in U87 conditioned media. (B) Heatmap 
of secreted factors detected in HMC3 culture media, 
U87vIII culture media, and HMC3 culture media after 
incubation in U87vIII conditioned media. 
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response to U87vIII CM exceeded a fold change greater than 1.5 (1.85 and 1.88 fold, 
respectively). Collectively, these data indicate differential protein secretion by U87 GBM 
cells, as well as primary murine microglia, as a result of GBM EGFRvIII expression.  
 
U87 and U87vIII conditioned media increase proliferation of primary neonatal murine 
microglia 
Proliferation of microglia is key in 
their response to damage in the 
brain and central nervous system 
pathologies. The number of Iba1+ 
primary murine microglia in vitro 
was significantly increased when 
cells were incubated in U87 CM 
compared to basal control 
conditions, and more so when 
incubated in U87vIII CM (Figure 
6.3A-B). Additionally, microglia treated with U87vIII CM exhibited apparent morphological 
changes over the 48 h incubation period. These data indicate the presence of soluble 
factors constitutively released by U87 and U87vIII cells under basal culture conditions 
that stimulate microglia proliferation.  
 Similarly, the impact of U87 and U87vIII conditioned media on HMC3 proliferation was 
assessed via staining for Ki-67, a nuclear protein and marker of actively proliferating cells 
whose expression markedly increases during progression through S phase of the cell 
Figure 6.3. Effect of conditioned media on cell proliferation. 
(A) Representative 20x field images of primary neonatal murine 
microglia incubated in U87 or U87vIII conditioned media for 48 h 
and stained for Iba1 and Hoechst. (B) Average Iba1+ cell counts 
in wells treated with CTL media, U87 CM, or U87vIII CM for 48 h. 
(C) Average fold change in Ki-67+ HMC3 cells incubated in CTL 
media, U87 CM, or U87vIII CM for 48 h. (C) Average fold change 
in Ki-67+ U87 and U87vIII cells incubated in CTL media or HMC3 
CM. Data are presented as mean ± SE, n = 3-4. n.s.: not 
significant. * p < 0.05 
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cycle. An apparent pattern of increased HMC3 proliferation in response to U87 and 
U87vIII CM occurred similar to murine microglia; however, this was not statistically 
significant over multiple experiments (Figure 6.3C). Similarly, U87 and U87vIII cells 
displayed a non-statistically significant pattern of increased proliferation in response to 
HMC3 CM (Figure 6.3D). 
 
Cell migration of U87 and U87vIII cells is not enhanced by co-culture with HMC3 cells 
The influence of U87 and 
U87vIII co-culture with 
HMC3 cells on cell migration 
was investigated using 
wound healing assays. As 
tumor-associated microglia 
and macrophages can 
constitute 30-50% of GBM 
tumors (Hambardzumyan et 
al., 2016), U87 and U87vIII 
cells were co-cultured 2:1 
with HMC3 microglia. 
Representative images of 
U87 and U87vIII cells seeded independently or co-cultured with HMC3 cells are displayed 
in Figure 6.4A. U87vIII cells display a propensity to participate in spontaneous spheroid 
formation and adhesion-independent growth, which resulted in gradual increases in 
Figure 6.4. Effect of HMC3 co-culture on cell migration. (A) 
Representative images of U87 and U87vIII cells seeded independently or 
co-cultured 2:1 with HMC3 cells at 0 h and 12 h timepoints of cell migration 
wound healing assay. The propensity for U87vIII cells to participate in 
spontaneous spheroid formation and anchorage-independent growth 
precluded the ability to observe efficient wound closure. However, co-
culture with HMC3 cells, while not limiting spheroid formation, improved 
cell adhesion throughout the assay. (B) Representative images of U87 
cells expressing the pDsRed2-Mito marker highlight a patterned re-
organization during co-culture with HMC3 cells. This was not observed in 
U87vIII cells. (C) Quantification of wound area percent decrease 
normalized to 0 h. Note y-axis lower bound. (D) Quantification of wound 
area change for U87vIII cells. Note y-axis lower bound. Data are presented 
as mean ± SE, n = 3. * p < 0.05 between independent and co-culture 
conditions at given time point. Scale bar = 0.5 mm. 
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wound area over time and precluded the ability to observe efficient wound closure (Figure 
6.4A, D). Notably, however, when cultured with HMC3 cells, U87vIII maintained adhesion 
throughout the assay, although wound closure was not altered (Figure 6.4D). U87 cells, 
which do not readily form spheroids in traditional cell culture, maintained adhesion 
throughout the assay, though wound closure over 12 h was marginal (5-6%) and not 
significantly improved by co-culture with HMC3 (Figure 6.4A, C). However, co-culture 
with HMC3 appeared to induce a spatial re-organization of U87 cells, an observation not 
seen with U87vIII cells (Figure 6.4B). 
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HMC3 cells exhibit a striking secretory response when stimulated with primary patient-
derived GBM cell conditioned media 
The GBM6 patient-derived xenograft is characterized by expression of the EGFRvIII 
mutant, a highly invasive phenotype, significant resistance to the receptor tyrosine kinase 
inhibitor erlotinib, expression of the MGMT DNA repair enzyme, and classical GBM 
subtype (Figure 6.5A). Compared to U87vIII CM, HMC3 cells responded strikingly to 
GBM6 CM (Figure 6.5B), producing and secreting significantly increased amounts of 
factors including CCL2, IGFBPs 1, 2, and 3, TIMP-4, angiogenin, TGFβ-1, and others 
(Figure 6.5C). Protein interaction networks among upregulated secreted proteins 
clustered around VEGF (Figure 6.5D), with gene ontology analysis revealed the most 
Figure 6.5. Effect of GBM6-conditioned media on HMC3 secretion of angiogenesis-related factors. (A) 
Descriptive table of patient-derived xenograft (PDX) GBM6, with descriptors including EGFR/PTEN status, patient 
status, invasion in mouse orthotopic xenografts, erlotinib sensitivity, MGMT methylation status, and subtype. (B) 
Heatmap of secreted factors detected in GBM6 culture media, HMC3 culture media, and HMC3 culture media after 
incubation in GBM6 conditioned media. (C) Angiogenesis-related factors secreted > 2 fold (> 1 log2 fold change, 
blue), or downregulated (< -1 log2 fold change, grey) by HMC3 cells treated with GBM6 CM vs resting HMC3 cells. 
(D) STRING protein-protein interaction map of angiogenesis-related factors secreted > 2 fold by HMC3 cells in 
response to GBM6 CM. (E) Gene ontology biological processes associated with upregulated secreted factors. 
109 
 
enriched biological functions of upregulated secreted factors being related to regulation 
of cell proliferation, migration, and endothelial cell proliferation (Figure 6.5E). 
 
HMC3 conditioned media decreases expression of xCT in U87, but not U87vIII cells 
Tumor cells display an increased 
demand for amino acids to meet the 
biosynthetic demands of rapidly 
proliferating cells and often upregulate 
expression of cell surface amino acid 
transporters, such as the system xc- 
glutamate-cystine antiporter, to meet 
this need (Bhutia, Babu, 
Ramachandran, & Ganapathy, 2015; 
Pavlova & Thompson, 2016). Both U87 
and U87vIII cells displayed baseline 
expression of the SLC7A11 gene, which 
encodes the system xc- catalytic subunit xCT. When incubated in HMC3 CM, U87 cells 
displayed decreased expression of SLC7A11 with a concomitant decrease in xCT protein 
levels (Figure 6.6A, C, D). In contrast, expression of SLC7A11 and xCT in U87vIII cells 
was not significantly altered (Figure 6.6B, C, E). These data indicate that HMC3 cells 
induce downregulation of system xc- in U87 cells, and that xCT expression displays 
greater stability in U87 cells expressing EGFRvIII.  
 
Figure 6.6. Expression of the glutamate-cystine 
antiporter in U87 and U87vIII cells exposed to HMC3-
conditioned media. RT-qPCR of SLC7A11 in (A) U87 and 
(B) U87vIII cells incubated in control or HMC3-conditioned 
media for 48 h. (C) Representative western blot of xCT in 
U87 and U87vIII cells incubated in control or 72 h HMC3-
conditioned media for 48 h. Quantification of xCT relative 
band intensity in (D) U87 and (E) U87vIII cells. β-actin was 
used as loading control. Data are presented as mean ± SE, 
n = 2. n.s.: not significant. * p < 0.05. 
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HMC3 conditioned medium oxidizes the mitochondrial glutathione pool in U87, but not 
U87vIII cells 
The system xc- transporter 
mediates the import of 
extracellular cystine, the rapid 
reduction of which into cysteine 
provides the rate-limiting 
precursor for the synthesis of 
reduced glutathione (GSH); 
thus, system xc- expression is 
an important determinant of 
intracellular redox balance. 
Using genetically encoded 
fluorescent redox biosensors 
targeted to the mitochondrial 
matrix (Figure 6.7A-B), HMC3 
conditioned media increased 
mitochondrial glutathione oxidation in U87 cells (Figure 6.7B’-C). In contrast, glutathione 
oxidation in U87vIII mitochondrial matrix was unaltered by incubation in HMC3 CM 
(Figure 6.7D).  
 
 
 
Figure 6.7. Mitochondrial matrix glutathione redox status in U87 
and U87vIII cells incubated in HMC3 conditioned media. (A) 
Schematic of the molecular mechanism of the Grx1-roGFP2 sensor 
and redox response of the compartmentalized probe to exogenous 
oxidant and reductant. Superoxide (•O2−) is rapidly converted by 
superoxide dismutase (SOD) into H2O2, which is then reduced by 
glutathione peroxidase (GPx) to water. Glutaredoxin (Grx) fused to 
roGFP2 efficiently and rapidly equilibrates the probe with alterations in 
the local GSH:GSSG ratio. Additionally, thiol-disulfide equilibration is 
reversible, as GSH reductase (GR) catalyzes reduction of GSSG to 
GSH. (B) Representative fluorescence images demonstrate the 
sensor targeted to mitochondria of U87 cells incubated in CTL (left) or 
HMC3 conditioned media (right). (B’) Corresponding time-lapse 
responses of the 395/494 nm ratio to treatment with 1 mM diamide 
(vertical solid line) to the fully oxidized state and 10 mM DTT (vertical 
dashed line) to the fully reduced state. Each trace designates a 
separate cell. Arrows represent basal oxidation level of probe. Percent 
oxidized mito-Grx1-roGFP2 in (C) U87 and (D) U87vIII cells incubated 
in CTL or HMC3 conditioned media. Data are presented as mean ± 
SE, n = 5. n.s.: not significant. * p < 0.05. 
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6.4. DISCUSSION 
Tumor-associated microglia and macrophages represent a key component of the GBM 
tumor microenvironment, which promotes glioma cell proliferation and invasion, 
angiogenesis, extracellular matrix degradation, and immunosuppression 
(Hambardzumyan et al., 2016). The current work examined crosstalk between EGFRvIII-
expressing GBM cells and microglia by profiling secreted chemokines, cytokines, and 
soluble factors related to angiogenesis, as well as examining system xc- expression and 
compartmentalized glutathione redox balance of U87 GBM cells incubated in HMC3 
conditioned media. 
Notably, the expression of EGFRvIII influenced secretion patterns of U87 GBM cells 
(Figure 6.1A-B). U87vIII cells secreted greater levels of insulin-like growth factor-binding 
proteins 2 and 3. Canonically, IGFBPs bind to IGF in the extracellular compartment and 
can both enhance as well as hamper IGF binding to its receptor (Chesik, De Keyser, & 
Wilczak, 2004). IGFBP-2 was demonstrated recently to stimulate vasculogenic mimicry 
of glioma cells, i.e. the construction of fluid-conducting channels formed by aggressive 
tumor cells rather than endothelial cells, both in vitro and in vivo (Y. Liu et al., 2018). 
IGFBP-2 also enhanced expression of MMP-2 to promote cell invasion, promote self-
renewal of neural stem cells during CNS development in mice, and regulate expression 
of Notch pathway and neural stemness genes including Nestin, OLIG2, and SOX2 (Shen, 
Song, Liu, Zhang, & Wei Song, 2018; H. Wang et al., 2003). Similarly, IGFBP-3 
expression correlated with glioma grade and tumor histology, with siRNA-mediated 
IGFBP-3 knockdown suppressing tumor growth and longer survival of tumor-bearing mice 
(C. H. Chen et al., 2019). Notably, the secreted factors profiled in the current work are 
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limited in scope to those available for analysis by the angiogenesis array. U87, U87vIII, 
and GBM6 cells likely secrete a milieu of other proteins stimulating cell invasion and 
extracellular matrix remodeling. Indeed, Sangar et al. previously demonstrated the 
striking effect of EGFRvIII expression in U87 GBM cell secretion of pro-invasion proteins, 
observing that EGFRvIII-expressing cells secreted a profile of proteins enriched in the 
promotion of epithelial-mesenchymal transition (e.g. CD44), angiogenesis (e.g. TIMP1), 
proteolysis (e.g. cathepsins, MMPs), and oxidative stress (Sangar et al., 2014).  
The presence of EGFRvIII on U87 cells additionally influenced differential protein 
secretion of ECM-remodeling proteins by murine microglia (Figure 6.1C), leading to 
greater microglia secretion of (among others) MMP-3, MMP-9, IGFBP-2, and CCL2. 
Although HMC3 cells did not respond significantly in their secretion of soluble factors in 
response to U87 or U87vIII CM (Figure 6.2), they exhibited a striking response to 
incubation in GBM6 CM (Figure 6.4). Secretion of all IGFBPs analyzed was significantly 
upregulated, as were chemotactic factors including HGF, ECM-remodeling proteins 
including MMP-9 and VEGF, and proteins implicated in cell growth and invasion such as 
EGF and TGF-β1. Of note, the most highly induced protein secreted was CCL2. Levels 
of the C-C chemokine CCL2, also known as monocyte chemoattractant protein-1 (MCP-
1), are elevated in GBM and drive macrophage infiltration as well as recruitment of 
regulatory T cells to promote immunosuppression (Chang et al., 2016). Recent work 
demonstrated that EGFR and EGFRvIII cooperatively induce tumor macrophage 
infiltration via upregulation of GBM cell CCL2 expression (An et al., 2018). Receptor 
tyrosine kinase inhibition with lapatinib decreased CCL2 expression in GBM6 and GBM39 
EGFRvIII-expressing patient-derived xenografts. Notably, CCL2 expression and 
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macrophage infiltration were both significantly enhanced by co-expression of both EGFR 
and EGFRvIII in U87 cells, compared to when EGFR or EGFRvIII were expressed 
independently, indicating a synergistic signaling effect between wild-type and mutant 
receptors. 
 The presence of EGFRvIII additionally led to differential responses in intracellular 
glutathione redox balance in U87 cells incubated in HMC3 CM, as the mitochondrial 
glutathione pool became more oxidized in U87, but not U87vIII cells (Figure 6.6). It is 
conceivable that this oxidation of glutathione in U87 cells resulted from decreased 
expression of system xc- (Figure 6.5), which in turn would hamper cellular uptake of 
cystine and thus lead to decreased rates of glutathione synthesis. Notably, U87vIII cells 
did not display an increase in oxidized glutathione, coinciding with stable expression of 
system xc- in HMC3 CM (Figure 6.5-6.6). Previous work has elegantly demonstrated that 
EGFR and EGFRvIII stabilize xCT cell surface expression on GBM cells via a kinase-
independent, physical interaction between the EGFR intracellular domain and 
transmembrane domains of xCT (Tsuchihashi et al., 2016). Our results are also 
corroborated by evidence that ectopic overexpression of EGFR in U87 cells increases 
surface xCT expression and total glutathione content (Tsuchihashi et al., 2016). 
Numerous studies have detailed the stimulatory effect of microglia on GBM cell 
proliferation and invasion (Bettinger et al., 2002; Coniglio et al., 2012; Coniglio & Segall, 
2013; Hambardzumyan et al., 2016; Poon, Sarkar, Yong, & Kelly, 2017; Ye et al., 2012); 
however, experiments described here making use of the HMC3 human microglia cell line 
were unable to detect significant differences in these outcomes. Compared to primary 
neonatal murine microglia, immortalized HMC3 cells constitutively proliferate, which may 
114 
 
have confounded the ability to detect changes in proliferative index in response to U87 or 
U87vIII CM. However, in a broader sense, microglia harbor distinctive ontogeny, 
morphology, gene expression patterns, and functional characteristics that can vary widely 
depending on cellular context and upon the model of microglia used (Butovsky et al., 
2014; Gosselin et al., 2017). Previous studies demonstrate disparities between 
expression of microglia signature genes among primary microglia and immortalized 
microglia cell lines, including HMC3, on which there are conflicting reports regarding its 
expression of microglia signature genes such as C1Q, P2RY12, and TMEM119 (Butovsky 
et al., 2014; Dello Russo et al., 2018; Rawat & Spector, 2017). HMC3 cells used in this 
study stained strongly for IBA1 but weakly for TMEM119 (not shown), yet also exhibited 
a strong secretory response when stimulated with primary GBM patient-derived cells 
(Figure 6.5). Future work may benefit from incorporating more representative, primary 
models of disease, such as the primary murine microglia and GBM6 samples this study 
benefitted from. 
 Interfering with microglia activation, attempting to inhibit the tumor-promoting effects 
of TAMs, and depleting the TAM compartments within GBM tumor microenvironments 
have received attention as potential strategies to decrease tumor burden. While therapies 
such as PLX3397 and BLZ945 (CSF-1R inhibitors) targeting the TAM compartments of 
the GBM tumor microenvironment show promising preclinical results, long-term 
regression remains a challenge as a subset of tumors invariably acquires resistance to 
CSF-1R inhibition in a manner that is dependent upon the tumor microenvironment itself 
(Quail et al., 2016). A phase II multicenter study demonstrated limited efficacy of PLX3397 
as a single agent in increasing progression-free survival of patients with recurrent GBM 
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(Butowski et al., 2016). A phase I clinical trial using the antibiotic minocycline to impair 
microglia activation as an adjuvant therapy alongside chemoradiation in patients with 
newly diagnosed GBM is currently underway (NCT02272270). Enhancing our 
understanding of the complex milieu of signals tumor cells receive from neighboring 
malignant, cancer-associated, and co-opted endothelial and tissue-resident cells, as well 
as how they sense and respond to gradients in extracellular metabolic and biophysical 
cues, may reveal new approaches to managing tumor burden and improving patient care. 
 
6.5 CONCLUSIONS 
The current work demonstrated a modulatory effect of EGFRvIII on i) U87 GBM cell 
secretion of pro-angiogenic soluble factors, ii) microglia secretion of ECM-remodeling 
chemokines and cytokines, and iii) subcellular glutathione redox balance in U87 cells 
exposed to HMC3 secreted factors. Incorporation of additional patient-derived GBM cell 
specimens in addition to GBM6, developing culture platforms including endothelial cells 
to more truly measure angiogenesis as a result of GBM-microglia paracrine signaling, as 
well as exploring the mechanism by which microglia-secreted factors modulate system 
xc- expression, will add to the current understanding of microglia-GBM crosstalk. 
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CHAPTER 7: OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
The work described herein provides evidence supporting the relevance and functional 
capacity of the mitochondrial protein CHCHD2 in mediating GBM cell malignant 
characteristics as they navigate transitions in the tumor microenvironment. Previous 
studies have ascribed a variety of functions to CHCHD2, including regulation of 
mitochondrial respiration and redox status (Aras et al., 2015; Baughman et al., 2009), cell 
migration (Seo et al., 2010), regulation of pluripotent stem cell differentiation into 
neuroectoderm (Zhu et al., 2016), negative regulation of apoptosis (Y. Liu et al., 2015), 
and hypoxia-sensitive transcription factor activity (Aras et al., 2013). Inspired by these 
findings, the current work is the first to describe the role of CHCHD2 in GBM cells. 
Leveraging CRISPR-Cas9 techniques, the work described demonstrates a role for 
CHCHD2 in mediating mitochondrial respiration and glutathione redox status, cell 
sensitivity to select cytotoxic agents, and cell proliferation and invasion in both standard 
culture conditions and in response to hypoxia, highlighting CHCHD2 as a functional node 
in GBM cells expressing the frequently observed mutant EGFRvIII. It should be noted that 
GBM tumors of various subtypes indeed consist of a heterogenous cell population, which 
harbor a variety of cell surface receptor tyrosine kinases with various intra-tumor 
expression patterns, and are not limited by EGFR or EGFRvIII expression. Profiling of 
total CHCHD2 protein levels in a panel of patient-derived GBM specimens, which 
themselves are comprised of both tumor and parenchymal cells, revealed that CHCHD2 
expression was generally greatest in GBM6, which expresses EGFRvIII, is defined as a 
classical subtype tumor, and is the most invasive specimen analyzed. A contextualized 
analysis of CHCHD2 function in an in vivo setting will be critical to understanding how 
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tumor phenotype is mediated by CHCHD2 in the context of other GBM hallmarks, such 
as angiogenesis and suppression of anti-tumor immunity, particularly in light of the paucity 
of effective immunotherapies against gliomas to date. 
 Previous studies had demonstrated the ability of CHCHD2 to act as a hypoxia-
sensitive transcription factor (Aras et al., 2013). Plasticity in the face of hypoxia provides 
a key growth advantage to GBM tumors. Indeed, CHCHD2 KO U87vIII cells displayed a 
diminished ability to proliferate and invade in hypoxic conditions. Motivated by the 
literature and results from Chapter 4, Chapter 5 provides an analysis of CHCHD2 
subcellular distribution, specifically between mitochondria and the nucleus, as a function 
of a variety of imposed stressors. Chronic hypoxia, chronic glutathione redox stress, and 
acute serum starvation all resulted in nuclear accumulation of CHCHD2. Furthermore, it 
is likely that reductive unfolding and translocation of mitochondrially localized CHCHD2 
is the mechanism by which immediate nuclear accumulation of CHCHD2 occurs in the 
face of imposed stress. Such a mechanism wound underscore the importance of intra-
molecular disulfide bonds which perform not just structural, but also regulatory roles in 
protein function. Subcellular fractionation followed by CHCHD2 redox western blots of 
CHCHD2 in mitochondrial and nuclear fractions in response to imposed stressors would 
provide an additional level of mechanistic understanding. However, It is still possible that, 
over longer periods of metabolic stress (e.g. chronic hypoxia), newly translated CHCHD2 
is preferentially shuttled to the nucleus versus mitochondria. Additionally, discrete details 
of CHCHD2 protein interactions in various subcellular compartments in GBM cells during 
its translocation remain to be described. Previous literature has highlighted the ability of 
CHCHD2 to physically interact with CHCHD10 and p32 in mitochondria, and bind to RBPJ 
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to transactivate expression of nuclear target genes (Aras et al., 2013; Imai et al., 2019; 
Purandare et al., 2018). Notably, work by Xie et al. has implicated RBPJ as critical for 
maintenance of brain tumor initiating cell viability and stemness (Q. Xie et al., 2016). 
Given the studies implicating CHCHD2 in neuroectodermal differentiation capacities of 
human embryonic stem cells (Zhu et al., 2016), its association with the migratory 
capabilities of neural stem cells in patients with lissencephaly (Shimojima et al., 2015), as 
well as recent work highlighting neural stem cells as a GBM cell of origin (J. H. Lee et al., 
2018), it is tempting to speculate that the CHCHD2-RBPJ interaction may play a central 
role in maintaining glioma stem cells and tumor progression. Future studies should 
investigate whether CHCHD2 interacts with RBPJ in GBM cells, as well as determine the 
suite of genes CHCHD2 may regulate, which could reveal novel gene targets to further 
explain the contribution of nuclear CHCHD2 to GBM malignancy. 
 Tumor-associated microglia represent another key component of the GBM tumor 
microenvironment. Chapter 6 explored GBM-microglia crosstalk by employing a variety 
of cell models, including U87 and U87vIII GBM cell lines, GBM6 primary patient-derived 
specimens, the HMC3 microglia cell line, and primary neonatal murine microglia. Overall, 
it was found that the expression of EGFRvIII on GBM cells influenced the secretion of 
chemokines, cytokines, and soluble factors involved in angiogenesis released by 
microglia activated by GBM-conditioned media. Additionally, EGFRvIII expression 
stabilized the glutamate-cystine antiporter xCT on U87 cells incubated in HMC3-
conditioned media, likely contributing to enhanced defense against oxidative stress 
suffered by U87 cells lacking EGFRvIII. Future work would largely benefit from 
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incorporating more representative, primary models of disease, as well as translating work 
to an in vivo setting. 
 Collectively, the studies conducted herein are all motivated by the understanding that 
GBM tumors (and truly, all tumors) are shaped by dynamic crosstalk with their 
surrounding microenvironment. Indeed, tumor progression can be considered an 
accelerated microcosm of Darwinian evolution, in which cues from the tumor 
microenvironment inform the selection of increasingly malignant cell populations that 
compete, survive, and reproduce, altogether contributing to disease progression. 
Advancing our understanding of the unique aspects of the GBM tumor microenvironment, 
as well as how tumors sense and respond to these microenvironmental cues, will be key 
in combatting a disease marked by highly plastic and adaptive cells. In turn, the tumor 
microenvironment itself is influenced by patient physiology. For instance, a number of 
studies have demonstrated the impact of chronic psychological distress on 
immunosuppression and anti-tumor immunity (Appendix A). Therefore, an appreciation 
for, and continued understanding of the tight, dynamic relationships between tumor and 
its surrounding microenvironment will be crucial in identifying aspects of tumor biology 
that may be leveraged to improve patient well-being and prognosis. 
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APPENDIX A 
THE INTERPLAY AMONG PSYCHOLOGICAL DISTRESS, THE IMMUNE SYSTEM, 
AND BRAIN TUMOR PATIENT OUTCOMES1 
Sebastian Otto-Meyer1, Jan Lumibao, Eugene Kim, Erik Ladomersky1, Lijie Zhai1, Kristen 
L. Lauing1, Denise M. Scholtens2, Frank Penedo6,7,8, Christina Amidei1, Rimas V. 
Lukas1,3,4,5, Derek A. Wainwright1 
1Department of Neurological Surgery, 2Department of Preventative Medicine-
Biostatistics, 3Department of Molecular Genetics, 4Department of Medicine-Division of 
Hematology and Oncology, 5Robert H. Lurie Comprehensive Cancer Center of 
Northwestern University, 6Department of Biochemistry and Molecular Genetics, 
7Department of Neurology, 8Department of Microbiology-Immunology, Northwestern 
University Feinberg School of Medicine, Chicago, IL 60611 
ABSTRACT 
A malignant brain tumor diagnosis is often accompanied with intense feelings and 
can be associated with psychosocial conditions including depression, anxiety, and/or 
increased distress levels. Previous work has highlighted the impact of uncontrolled 
psychological distress among brain tumor patients. Given the negative impact of 
maladaptive psychosocial and biobehavioral factors on normal immune system functions, 
the question remains as to how psychological conditions potentially affect the brain tumor 
patient antitumor immune response. Since immunotherapy has yet to show efficacy at 
increasing malignant glioma patient survival in all randomized, phase III clinical trials to-
                                                 
1 Otto-Meyer S, Lumibao J, Kim E, Ladomersky E, Zhai L, Lauing KL, Scholtens DM, Penedo F, Amidei 
C, Lukas RV, Wainwright DA. The interplay among psychological distress, the immune system, and brain 
tumor patient outcomes. Current Opinion in Behavioral Sciences. 2019;28:44-50. doi: 
10.1016/j.cobeha.2019.01.009. 
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date, this review provides new insights into the potential negative effects of chronic 
distress on brain tumor patient immune functions and outcomes. 
 
Challenges of immunotherapy for malignant glioma 
Brain tumors are a relatively rare but potentially life-threatening diagnosis, 
accounting for approximately 1-2% of cancers in the United States ("United States Cancer 
Statistics: 1999–2011 Incidence, WONDER Online Database.," 2015). Nearly 80% of 
primary malignant brain tumors are a form of glioma, with glioblastoma (GBM, WHO grade 
IV) representing the most common, deadly subtype, and accounting for over half of all 
malignant glioma cases (Ostrom et al., 2017). Despite the current standard of care, GBM 
remains incurable with a median overall survival (OS) ranging from 9 to 21 months, and 
a five-year survival of only 5% to 14% (Darefsky, King, & Dubrow, 2012; Dubrow et al., 
2013; Stupp et al., 2017). Standard of care for GBM patients consists of surgical 
resection, radiation, chemotherapy, and tumor treating fields, which prolongs survival and 
may transiently reduce symptom burden. However, these treatments also impair the 
quality of life since patients are presented by a diagnosis that induces significant 
psychological distress (R. Liu, Page, Solheim, Fox, & Chang, 2009).  
Recent research efforts aimed at enhancing treatment efficacy for GBM, have 
focused on immunotherapy, which is an effective treatment strategy for a subset of cancer 
patients diagnosed with melanoma (Larkin et al., 2015), non-small cell lung (S. J. Antonia 
et al., 2016), and renal cell (Motzer et al., 2015) malignancies, as well as many others 
that originate outside of the central nervous system (CNS) (Bellmunt et al., 2017; R. Chen 
et al., 2017; Frenel et al., 2017; Muro et al., 2016; Zinzani et al., 2017). In contrast, high-
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grade glioma patients treated with immunotherapy have not demonstrated an OS benefit 
in all phase III clinical trials to-date (Reardon et al., 2017b; M. Weller et al., 2017). Several 
immunotherapeutic strategies have been investigated, including: (i) vaccines (ie. 
rindopepimut, HSPPC96, or dendritic cells); (ii) checkpoint inhibitors [ie. nivolumab (anti-
PD-1 mAb)]; and (iii) chimeric antigen receptor (CAR) T cells. However, despite the 
excitement from early phase trials, immunotherapy has yet to translate into an effective 
clinical solution for patients, as demonstrated in late phase, randomized, multi-site clinical 
evaluation (Bloch et al., 2017; Sampson et al., 2010; Schuster et al., 2015; M. Weller et 
al., 2017).   
Additional challenges likely contributing to the effective application of 
immunotherapy for treating GBM include the: (i) highly infiltrating nature of the disease, 
which prevents surgical resection from completely removing all associated tumor burden; 
(ii) potently immunosuppressive microenvironment, characterized by a relatively low level 
of tumor-infiltrating effector T cells, combined with an accumulation of 
immunosuppressive regulatory T cells (Tregs; CD4+CD25+FoxP3+) and myeloid derived 
suppressor cells; (iii) older age of the patient; and (iv) anatomical location that impedes a 
routine use of tumor biopsies for monitoring the response to therapy. A critical factor that 
may be overlooked during immunotherapeutic treatment considerations is the impact of 
high psychosocial and biobehavioral levels of distress. The subject of distress, specifically 
its prevalence and influence on the immune system and outcomes in patients with a 
malignant brain tumor, forms the basis of our review. Research in the past two years will 
be emphasized, with attention to the associations between increased distress levels, the 
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negative impact of systemic immune/neuroendocrine functions, and preclinical and 
clinical outcomes in the setting of primary brain cancer.  
 
Psychological distress in patients with brain tumors 
Depression and anxiety are common in patients with a terminal illness (Mitchell et 
al., 2011).Meta-analyses have found that, cancer patients in the palliative care setting 
have a rate of mood disorders, including depression, anxiety, and adjustment disorder, of 
29%  (Mitchell et al., 2011). Notably, this rate of psychosocial conditions is likely 
underappreciated and/or underreported, as cancer patients can experience chronic 
distress and demoralization without the presence of a psychiatric diagnosis (Philip et al.; 
Sterckx et al., 2015; Vehling et al., 2017).  
Psychological distress, depression, and anxiety may be particularly enhanced in 
patients with primary brain tumors. A recent analysis found that 24% of a 4,000 mixed-
cancer patient cohort, possessed clinical signs of depression, significantly higher than the 
general population (Hartung et al., 2017). Strikingly, the rate among patients with primary 
brain cancer was markedly higher, with 36% showing signs of depression. In contrast, 
patients diagnosed with malignant melanoma and prostate cancer, had reduced rates of 
depression, at 16% and 10%, respectively. Additional meta-analyses and prospective 
studies have discovered an increased rate of psychological conditions and distress 
among brain tumor patients as compared to the general population (J. Huang et al., 2017; 
F. Liu et al., 2018) and as compared to patients diagnosed with non-CNS tumors 
(Edelstein et al., 2016).  
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Furthermore, psychological distress in brain tumor patients is not always 
appropriately acknowledged or well-managed. Although attention to the mental health 
care of malignant brain tumor patients has increased (Catt, Chalmers, & Fallowfield, 
2008; Randazzo & Peters, 2016; Rooney, Carson, & Grant, 2011), a recent review by the 
European Association of Neuro-Oncology emphasized the lack of evidence for 
appropriately treating depression and anxiety in glioma patients and, as such, was unable 
to provide strong recommendations on the subject (Pace et al., 2017). The direct 
neurological involvement of primary brain tumors further complicates management 
guidance from psychosocial standard of care for the treatment of non-CNS cancers. 
Recent studies have found that psychological needs are highly unmet among brain tumor 
patients (Langbecker & Yates, 2016; Renovanz et al., 2017). A longitudinal investigation 
of mostly high grade glioma patients found that, despite increased distress in 
approximately half of the patients during various time points, only 14% of the distressed 
patients received psychological care as an in-patient, and less than half of the distressed 
patients received psychological care in an outpatient setting (Singer et al., 2018). 
Collectively, the above studies indicate psychological distress and depression as 
common concerns for patients with primary brain cancer. 
The etiology of distress among primary brain cancer patients may be related to the 
inherently high load of stressors accompanying their diagnosis. However, neurological 
insult, regardless of tumor burden, has been shown to be correlated with increased 
depression and distress. Patients who present with a stroke have an increased rate of 
depression as compared to those with a myocardial infarction (Ladwig et al., 2018), and 
the prevalence of depression is also higher for individuals diagnosed with the CNS 
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autoimmune disease, multiple sclerosis (MS), as well as for traumatic brain injury (TBI) 
patients (Feinstein, Magalhaes, Richard, Audet, & Moore, 2014; Osborn, Mathias, & 
Fairweather-Schmidt, 2014). Although potentially resulting from the reduced quality of life 
suffered by patients with neurological insult(s), increased depression may be the direct 
result of enhanced inflammation. There is a well-established link between the 
development of depression and stressors that trigger inflammatory phenotypes and 
increased immune activity through the sympathetic nervous system (SNS) (Miller & 
Raison, 2016; Slavich & Irwin, 2014). Indeed, inflammation resulting from stroke, MS, and 
TBI is associated with depression, further supporting a role for generalized inflammation 
in in the pathogenesis of depression (Bodnar, Morganti, & Bachstetter, 2018; Fenn et al., 
2014; Levada & Troyan, 2018; Morris et al., 2018). The connection between inflammation 
and depression is not well-characterized for patients with primary brain cancer. However, 
levels of inflammatory cytokines are significantly increased in GBM patients and may play 
a role in outcomes dependent on levels of depression, anxiety, and distress (Chiorean et 
al., 2014; Kore & Abraham, 2014; Yeung, McDonald, Grewal, & Munoz, 2013) (Fig. A.1). 
Additional work is necessary to comprehensively profile the incidence of psychosocial 
conditions in brain tumor patients and its effects on OS outcomes and responses to 
therapy.  
Interactions between distress, immunosuppression, and cancer 
Untreated distress may affect brain tumor patient outcomes through the 
interactions between psychosocial distress and the immune system. The relationship 
between excess adrenergic signaling and immune dysregulation, inflammation, and 
tumor growth is well- established (Partecke et al., 2016; Powell, Tarr, & Sheridan, 2013; 
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Qiao, Chen, Bucsek, Repasky, & Hylander, 2018). Increased distress promotes the 
release of stress hormones, primarily in the form of catecholamines including epinephrine 
and norepinephrine via the sympathetic nervous system (SNS), as well as glucocorticoids 
via the hypothalamic-pituitary-adrenal axis. Chronic release of these molecules, in turn, 
increases immunosuppression that facilitates uncontrolled tumor growth by inhibiting the 
anti-tumor immune response as demonstrated in preclinical models of lymphoma and 
fibrosarcoma (Nissen, Sloan, & Mattarollo, 2018; Schmidt, Peterlik, Reber, Lechner, & 
Männel, 2016). Interestingly, beta blockers, which inhibit catecholamine-induced β-
adrenergic receptor signaling, inhibit proliferation and tumor growth in models of liver 
cancer, early stage breast cancer, and melanoma (Kokolus et al., 2018; Montoya et al., 
2017; F. Wang et al., 2018); although this effect is not universal (Cardwell et al., 2016). 
Additionally, recent studies found that the inhibition of β-adrenergic signaling with the pan-
beta blocker, propranolol, enhances PD-1 checkpoint inhibitor efficacy in preclinical, 
syngeneic, mouse melanoma models (Bucsek et al., 2017; Kokolus et al., 2018). Notably, 
β-adrenergic blockade increased the frequency of CD8+ tumor infiltrating lymphocytes, 
as well as the ratio of CD8+ effector T cells to Tregs in B16-OVA tumors (Bucsek et al., 
2017). Altogether, these studies suggest a potential role for targeting β-adrenergic 
signaling to decrease tumor cell proliferation and enhance synergy with immunotherapy.  
Although once thought to be an immuno-privileged site, it’s now well-established 
that leukocytes infiltrate the brain upon appropriate activation signals (Kmiecik et al., 
2013; Lohr et al., 2011; Zhai et al., 2017). However, potent immunosuppressive factors 
are normally present in the brain, including TGF-β, IL-10, and VEGF, which dampen 
cytotoxic T lymphocyte migration while enhancing Treg accumulation (Dutoit et al., 2016). 
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Parenchymal cells of the CNS also express FasL, which can facilitate brain-infiltrating 
Fas+ T cell apoptosis. Collectively, these characteristics contribute to the profoundly 
immunosuppressive environment under normal circumstances that likely further 
contribute to the poor immune response against malignant glioma. Increased β-
adrenergic signaling in response to psychosocial distress would only exacerbate the 
profoundly immunosuppressive microenvironment and facilitate immune escape of GBM 
cells.  
To counteract immunosuppressive β-adrenergic signaling, propranolol has been 
considered for adjuvant therapy in patients diagnosed with malignant glioma. However, 
this consideration is primarily based on the results observed in other cancers, or as direct 
evidence in GBM cells (Rundle‐Thiele, Head, Cosgrove, & Martin, 2016). Accordingly, 
isoproterenol, a β-adrenergic receptor agonist, enhances GBM U251 cell proliferation and 
metalloproteinase expression – an effect inhibited by propranolol treatment (He et al., 
2017). In contrast, β-adrenergic receptor blockade with prazosin, inhibits glioblastoma 
tumor growth in an orthotopic, immunocompetent, syngeneic mouse model, highlighting 
the potential for an immunosuppressive contribution by β-adrenergic signaling 
mechanisms (Assad Kahn et al., 2016). Beyond adult brain tumors, β-adrenergic 
receptors are expressed by malignant pediatric brain tumor cells (Sardi et al., 2013), 
raising the possible generalizability of targeting the β-adrenergic signaling axis in both the 
pediatric and adult brain tumor settings.  
Cortisol, a glucocorticoid released during periods of distress, participates in the 
neuroendocrine signaling axis and is associated with suppression of immune cell effector 
functions, may also play a role (Silverman & Sternberg, 2012). The chronic release of 
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glucocorticoids, as mediated by mechanisms associated with chronically high levels of 
distress, may promote tumor progression by suppressing the anti-GBM immune response 
(Dhabhar & McEwen, 1997; Eng et al., 2014). While the impact of endogenous 
glucocorticoid signaling has not been characterized among brain tumor patients and their 
associated outcomes, a large body of evidence suggests that the use of exogenously-
administered dexamethasone (trade name, Decadron), is potently immunosuppressive 
(Giles et al., 2018). Dexamethasone is a corticosteroid commonly used to relieve 
symptomatic effects and intracranial edema during therapy for high-grade glioma. 
Treatment with dexamethasone is associated with a worse prognosis of patients with 
GBM (Pitter et al., 2016; Shields et al., 2015). In contrast, the fast tapering of 
dexamethasone is associated with significantly better outcomes (Diez Valle et al., 2018). 
Furthermore, phase I trial evaluation of GBM patients treated with the  immune checkpoint 
inhibitor, atezolizumab, had a decreased level of circulating lymphocytes and a trend 
toward decreased OS, when concurrently treated with corticosteroids (Rimas V. Lukas et 
al., 2018). Strikingly, long-term survivors in the trial were not treated with corticosteroids. 
While it’s inappropriate to assume that the effects of synthetic steroids are directly 
comparable to endogenous glucocorticoid signaling, it is possible that the consistent 
release of cortisol, due to high distress levels, suppress leukocyte functions and result in 
a worse patient prognosis, similar to those effects associated with dexamethasone 
treatment.  
Impact of distress on outcomes in brain cancer patients 
Psychological distress has been linked to a reduced quality of life among 
individuals diagnosed with glioma and in other brain tumor patients (Hartung et al., 2017; 
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Hoffmann, Kamp, Steiger, Sabel, & Rapp, 2017). A recent meta-analysis found a 
decrease in glioma patient OS when also diagnosed with depression (Shi et al., 2018). 
Similarly, a retrospective analysis of 1,003 patients undergoing surgical management of 
high-grade glioma found that, a clinical diagnosis of depression, prior to surgical 
intervention, was associated with a decreased landmark rate of survival (Gathinji et al., 
2009). Although there was significant heterogeneity within the studies, these collective 
results suggest a potential for depression to negatively impact the physical health of 
glioma patients. In contrast, demographic factors associated with the potential 
strengthening of a glioma patient’s support system, including marriage, are predictors for 
improved GBM patient OS (J. C. Xie, Yang, Liu, & Zhao, 2018). Exercise also improves 
glioma outcomes (Levin, Greenwood, Singh, Tsoi, & Newton, 2016; Ruden et al., 2011) 
potentially by decreasing the effects of inflammation and/or inflammatory mediator-
induced depression (Gourgouvelis, Yielder, Clarke, Behbahani, & Murphy, 2018; Woods, 
Wilund, Martin, & Kistler, 2012). Therefore, interventions that decrease the level of 
psychological distress may improve future prognoses among patient with malignant 
glioma (Fig. A.2). 
Standardized surveys have been proposed as mechanisms to better assess 
psychological distress levels in patients with brain cancer (Hickmann et al., 2017; 
Renovanz, Hickmann, et al., 2018; Renovanz, Tsakmaklis, et al., 2018). Reducing the 
stigma, to better increase the participation in psychosocial assistance programs, is also 
necessary to properly care for patients with elevated distress levels (Langbecker, Ekberg, 
& Yates, 2017; Tondorf et al., 2018). After identification and connection with psychosocial 
services, proper treatment can be initiated. Currently, home-based psychosocial 
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interventions and other therapies have been shown to address distress in brain cancer 
patients (Amidei, 2018; Ownsworth et al., 2015). 
Few studies have previously evaluated the role of medications in addressing 
psychosocial distress in malignant brain tumor patients. Although beta blockers may help 
improve survival in distressed glioma patients, based on evidence from the treatment of 
patients diagnosed with non-CNS cancers, the use of selective serotonin reuptake 
inhibitors (SSRIs) or tricyclic antidepressants (TCAs) may be another beneficial option. 
Exposure of tumor cells to SSRIs causes anti-proliferative effects in vitro, and in mouse 
models of GBM. Theoretically, SSRIs would also decrease distress levels in glioma 
patients (V. C. H. Chen, Hsieh, Chen, Hsu, & Tzang, 2018; K.-H. Liu et al., 2015; Then et 
al., 2017). A study of 160 individuals diagnosed with glioma showed an OS benefit for 35 
patients treated with an SSRI, while several reports have advocated for their use as 
potential adjunct therapy during standard of care (Caudill, Brown, Cerhan, & Rummans, 
2011; S. K. Tan et al., 2018). Ultimately, more investigation is needed to objectively 
evaluate the efficacy of psychosocial modifiers in patients with malignant brain cancer. 
Conclusions 
Malignant brain tumors are a profoundly devastating disease associated with 
significant increases in depression, anxiety, and distress among patients. We propose a 
direct biological link between psychosocial stressors and poor outcomes in malignant 
glioma patients. High adrenergic signaling and endogenous steroid activity may impair 
immune system functions, resulting in the uncontrolled proliferation of tumor cells, as 
observed in non-CNS cancer patients. Notably, high levels of distress are not always 
appropriately identified or managed among brain tumor patients. Therefore, additional 
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work is required for understanding the role of distress on prognosis, immune suppression, 
tumor growth, and clinical care. Ultimately, this future work may substantially improve the 
quality, and potentially, quantity of life.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.1: Proposed interactions between inflammation, depression, and immune cell dysfunction in 
subjects with brain cancer. Brain tumors and psychosocial stress independently contribute to brain inflammation, 
which provide favorable conditions for the development of depression. High distress levels lead to a cycle of 
increased sympathetic signaling and dysfunctional HPA signaling. Together, signaling due to the sympathetic and 
HPA axes, decrease immune effector control of tumor cell proliferation, resulting in worse outcomes for patients. 
Breaking these cycles and addressing increased distress / depression in brain cancer patients may improve survival 
outcomes. 
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Figure A.2: Proposed interactions between inflammation, 
depression, and immune cell dysfunction in subjects with brain 
cancer. Brain tumors and psychosocial stress independently contribute to 
brain inflammation, which provide favorable conditions for the 
development of depression. High distress levels lead to a cycle of 
increased sympathetic signaling and dysfunctional HPA signaling. 
Together, signaling due to the sympathetic and HPA axes, decrease 
immune effector control of tumor cell proliferation, resulting in worse 
outcomes for patients. Breaking these cycles and addressing increased 
distress/depression in brain cancer patients may improve survival 
outcomes.  
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